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REAGENTS 
1. lMTris(l liter) 
Dissolve 121.14 gm. of Trizma base in 800 niL. of distilled water. 
Adjust the pH to the desired value by adding cone. HCl. 
pH 
7.4 
7.5 
8.0 
Comments: 
HCl 
70mL. 
60mL. 
42mL. 
• If IM solution has a yellow color, discard it and obtain better 
quality Trizma base. 
• The pH of Tris solution is temperature dependent and decreases 
approximately 0.03 pH unit for each 1 C increase in temperature. 
E.g. a 0.05M solution has pH values of 9.5, 8.9 and 8.6 at 5"C, 
25"C and 37V respectively. 
• Sterilize by autoclaving. 
2. 5M NaCI (1 liter) 
Dissolve 292.2 gm. of NaCl in 800mL of distilled water. Adjust the 
\olume to 1 liter and sterilize by autoclaving. 
3. 0.5M EDTA [pH 8.01 (100 mL.) 
Add 18.61 gm. of EDTA to 80mL. of distilled water, stir vigorously 
on a magnetic stirrer. Adjust the pH to 8.0 with NaOH (approx. 2 
gm. of NaOH pellets). Sterilize by autoclaving. 
Kcci^eiii\ 
Comments: 
• The disodium salt of EDTA will not go into solution until the pH 
of the solution is not adjusted to approx. 8.0 by the addition of 
NaOH. 
4. 10% SDS (1 liter) 
Dissolve 100 gm. of electrophoresis grade SDS in 900 niL. of 
distilled water. Heat to assist dissolution. Adjust the pH to 7.2 by 
adding a few drops of cone. HCl. Adjust the volume to 1 liter. Do not 
autoclave. 
5. Digestion buffer (for DNA extraction from cervical scrape) 
(100 mL.) 
SMNaCl 2mL. (lOOmM) 
IMTris (pH8.0) ImL. (lOmM) 
0.5M EDTA (pH 8.0) 5mL. (25mM) 
10% SDS 5mL. (0.5%) 
Adjust the volume to lOOmL. by adding distilled water. 
6. lOOX TE (pH 8.1) (1 liter) 
IMTris 121.14 gm. 
O.IMEDTA 37.22 gm. 
Dissolve in 800mL. autoclaved distilled water. Mix it properly and 
adjust pH 8.1 with cone. HCl. Make up the volume to 1 liter by 
autoclaved distilled water. 
7. IX TE IpH 8.1] (1 liter) 
IMTris lOmL. (lOmM) 
0.5M EDTA 2mL. (ImM) 
Adjust the volume to 1 liter by adding distilled water. 
8. Lysis Buffer [for DNA isolation from biopsy] (lOOmL.) 
3 % S D S i n 2 X T E ( p H 8 . 1 ) 
1OOX TE 2mL. 
!()%SDS 30mL. 
Make up the volume to lOOmL. by adding distilled water. 
9. Proteinase K 
Stock solution is 20nig./mL. of distilled water. 
Storage temperature is -20 C. 
Concentration in reaction is 100 microgram per mL. 
Reaction buffer is 0.01 M Tris (pH 7.8) 
0.005 M EDTA 
0.5% SDS 
Reaction temperature is 37-56 C. 
Comments: 
Proteinase K (pK) is a highly active protease of the subtilisin type that 
is purified from the mold Tritirachium album Limber. The enzyme has 
two binding sites for Ca++, which lie some distance from the active 
site and are not directly involved in the catalytic mechanism. However, 
when Ca-H- is removed from enzyme, approx. 80% of the catalytic 
activity is lost because of long range structural change^Bajorath et al. 
1989). Because the residual activity is usually sufficient to degrade 
proteins that commonly contaminate preparations of nucleic acids 
digestion with pK is usually carried out in the presence of EDT^^to Jif 
inhibit the action of Mg++ dependent nucleases). 
10. PhenoI(Mol.Wt. 94.11) 
• Put the bottle at 65°C in water bath for overnight. 
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• To 2()0mL. of phenol add 0.2 gm. of 8-Hydroxyquinoline (Mol. 
Wl. 145.16)1.6.0.1% 
• AddZOOmL. IX TE. 
• Add 200|iL p- mercaptoethanol 
• Incubate at 37V overnight. 
11. 3M Sodium Acetate (Anhydrous) pH 5.2 and 7.0 
Sodium acetate 246.09 gm. 
Add 800mL. of distilled water and adjust the pH to 5.2 with Glacial 
acetic acid or the pH to 7.0 with dilute acetic acid. Adjust the 
volume to lliter with distilled water and sterilize by autoclaving. 
12. IMNH4CI 
53.5gm. of NH4C1 in 1 liter of distilled water and sterilize by 
autoclavmg. 
13. IMKHCO3 
100.1 gm of KHC03 in 1 liter of distilled water and sterilize by 
autoclaving. 
14. Lysis Solution [for DNA isolation from blood| (lOOmL.) 
155mMNH4Cl 15.5mL. of IM NH4CI 
1 OniM KHCO3 1 mL. of 1M KHCO3 
0.1 niM EDTA 20nL of 0.5M EDTA 
Adjust the volume to lOOmL with autoclaved distilled water 
Reciffc'iits 
15. SE solution [for DNA isolation from blood] (200mL.) 
75mM Nacl 3mL of 5M NaCl 
20mM EDTA 8mL of 0.5M EDTA 
make up the volume to 200mL with autoclaved distilled water 
16. Ethidium Bromide (lOmg/mL) 
Add Igm of EtBr to lOOmL of autoclaved distilled water. Stir on 
magnetic stirrer for several hours top ensure that the dye has 
dissolved. Wrap the container in aluminium foil or transfer the 
solution to a dark bottle and store at room temperature. 
Comments: 
• EtBr is powerful mutagen and is a moderately toxic. Gloves should 
be worn when working with solutions that contain this dye and a 
mask should be worn by weighing it out. After use, these solutions 
should be decontaminated by method (Appendix E "Molecular 
Cloning" Maniatis Volume III). 
• Quantity to be used in agarose gel is 0.5|jg/mL. 
17. 10 X PBS (I liter) 
NaCl 80g 
KCl 2g 
Na2HP04 14.4g 
KH2PO4 2.4g 
Reageiil\ 
Dissolve the above in 800mL of distilled water. Adjust the pH to 7.4 
with HCi. Make up the volume to 1 liter and sterilize by autoclaving. 
Store at room temperature. 
18.10XTBE(1 liter) 
Tris Base lOSg 
Boric Acid 55g 
0.5MEDTA (pH 8.0) 40mL 
dHjO 800mL 
Finally make the volume to I liter. Sterilize by autoclaving. 
Comment: 
A precipitate fomis when concentrated solutions of THE are stored for 
long period of time. To avoid problem, store the solution in glass bottles at 
room temperature and discard any batches that develop a precipitate. TBE 
was originally used in the working strength of IX (1:10 dilution of the 
concentrated stock) for agarose gel electrophoresis. However, a working 
solution of 0.5X provides more than enough buffering power, and almost 
all agarose gel electrophoresis is now carried out with a 1:20 dilution of 
the concentrated stock. TBE is used at a working strength of IX for 
PAGE twice the strength usually used for agarose gel electrophoresis. The 
buffer reservoirs of the vertical tanks used foi PAGE are fairly small, and 
the amount of electric current passed through them is often considerable. 
IX TBE is required to provide adequate buffering power. 
19. 50 X TAE (1 liter) 
Tris Base 
Glacial acetic acid 
0.5M EDTA (pH 8.0) 
242gm. 
57.1mL 
lOOmL 
Adjust the volume to 1 liter with distilled water and sterilize by 
autoclavuiy. 
Reii^enls 
20. O.IM DTT 
Dissolve 3.09g of DTT in 20mL of 0.01 Sodium acetate (pH 5.2) 
Sterilize by filtration. Store at -20V. 
Comment: 
Do not autoclave DTT or solutions containing DTT 
21. TTB (DNA isolation from cervical scrape) 
lOmMTris ImL of IM Tns (pH 8.0) 
1 OmM MgClz 1 mL of 1M MgC12 
300mM Sucrose 30mL of IM Sucrose 
0.8% of Triton X 100 800^1 
Make up the volume to lOOmL by adding autoclaved distilled water. 
22. TEB (DNA isolation from cervical scrape) 
1 OmM Tris 1 mL ofl Mtris (pH 8.0) 
1 OmM EDTA 2mL of 0.5M EDTA 
1 OmM NaCl 200)al of 5M NaCl 
Make up the volume to lOOmL by adding autoclaved distilled water. 
23. BPB (Gel loading dye) 
0.25% Bromophenol Blue 
40% (w/v) Sucrose in water 
(Store at 4"C) 
Comment: 
• The gel loading dye increases the density of the sample ensuring 
that the DNA drops evenly into the well. 
• They contain dyes that, in an electric field, move toward the anode 
at predictable rates. 
Reagenis 
• They add colour to the sample, thereby simplifying the loading 
process. 
• BPB migrates through agarose gels approx. 2.2 fold faster than 
Xylene cyanol FF, independent of agarose concentration. 
• BPB migrates through agarose gels run in 0.5XTBE at approx the 
same rate as linear double stranded DNAOQbp in length. These 
relationships are not significantly affected by the concentration of 
agarose gel over the range of 0.5% to 1 A%.[Courtsey ManiatisJ 
24. Sequencing Mix 
Acrylamide 28.5gm 
Bis-acryl amide 1.5gm 
Urea 210 gm 
lOXTBE 50mL 
Formamide 75mL 
Make up the volume to 500mL y auioclaved distilled water. Store 
in amber colour bottle. Sterilize by filtering through 3MM 
Whatman. Keep at 4'*C. 
25. 10%APS(10mL) 
APS Ig 
dH20 lOmL 
A small amount of 10% (w/v) stock solution should be prepared 
in deionized water and stored at 4^C. APS decomposes slowly, 
and fresh solution should be prepared weekly. 
26. Preparation of 6% Denaturing sequencing gel 
Sequencing Mix 120mL 
10% APS 700|il 
TEMED 150^1 
Pour gel immediately after adding TEMED. 
^^ Reagents 
26. Sequencing Dye (50mL) 
95% Formamide 47.5mL 
20mM EDTA 2mL of 0.5M EDTA 
0 05% BPB 0.025gm 
0.05% Xylene Cyanol 0.025gms 
20iTiMNaOH 500^1 of 2M NaOH 
Store at room temperature. 
27. Dilution Buffer (50mL) 
0.1% SDS 0.5mLof 10%SDS 
lOmM EDTA ImL of 0.5MEDTA 
Make up the volume by adding autoclaved distilled water and 
store at room temperature. 
28. 30% Acrylamide 
Acrylamide 29gm 
Bisacrylamide Igm 
Heat the solution to 37V to dissolve the chemicals. Make up the 
volume to lOOmL by adding autoclaved distilled water and 
sterilize by filtering through 3MM Whatman. 
29. Preparation of 10% non denaturing gel (for tlie analysis of 
CYP2D6 polymorphism) 
30% Acrylamide 16.6mL 
10 X THE 5mL 
10% APS 700|al 
TEMED 35|al 
xii Kecifieiil.', 
Make up the volume to 5ofnL by adding autoclaved distilled 
water and pour solution immediately into the sealed glass plates 
after adding TEMED. 
Reagents for immunohistochemistry 
0.05 M Tris-HCI Buffer (For washing) 
pH 7.4-7.6 
Tris hydroxymethyl Methylamine 6.1gm 
NaCl 8.7gm 
HCl 3.7mL 
Double distilled water Utr 
Endogenous Peroxidase Bloclcing Solution 
(To be prepared immediately before use) 
Absolute Methanol 96mL 
H202 (30%) 4mL 
DAB Solution 
(Must be prepared immediately before use) 
Combine 1-2 drops (40-lOOL) of DAB Chromogen with each ImL of 
DAB substrate. 
Apply mixture to tissue section 
Incubate tissue section for 5-15 minutes 
Rinse tissue, counterstain, dehydrate, clear in Xylene and coverslip 
Reagents 
lOmM Citrate Buffer pH 6.0 
(For Microwave antigen retrieval) 
Citric acid anhydrous 2.1gm 
Double distilled water 1 liter 
(Adjust pH with NaOH pellets) 
Poly- L-Lysine 
(For coating the glass slides) 
Poly-L-Lysine (Sigma) 
Double distilled water 
lOmL 
90mL 
Migration Rates of Marker Dyes Through Denaturing 
Polyacrylamide Gels 
% Polyacrylamide Bromophenol 
Blue' 
15 
26 
19 
12 
Xylene 
Cyanol FF 
106 
76 
55 10 
20 
Superscript a, denotes the numbers that are the approximate sizes of 
DNA (in nucleotides) with which the marker dyes will co migrate. 
Reagents 
Migration Rates of Marker Dyes Through Non-Denaturing 
Polyacrylamide Gels 
% Polyacrylamide Bromophenol Xylene 
Blue" Cyanol FF' 
8 45 160 
12 20 70 
15 15 60 
20 12 45 
Superscript b, denotes the numbers that are the approximate sizes (in 
nucleotide pairs) of fragments of double stranded DNA with which the 
dye CO migrates. 
[Courtesy Mamatis] 
Reagents 
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1. INTRODUCTION 
Cancer is a disease involving dynamic changes in the genome. 
Several lines of evidence indicate that tumorigenesis in humans is a 
multistep process and that these steps reflect genetic alterations that 
drive the progressive transformation of normal cells into highly 
malignant derivatives. Genomes of tumor cells must acquire increased 
mutability in order for the process of tumor progression to reach 
completion in several decades (Loeb, 1991). This increased mutability 
could be a result of malfunctioning of genomic "caretaker" systems, 
which are responsible for the maintenance of genomic integrity by a 
complex array of DNA monitoring and repair enzymes (Lengauer et al., 
1998). Tumor suppressor genes fall into this category, which, in 
response to DNA damage, elicits either cell cycle arrest or to allow 
DNA repair to take place or apoptosis, if damage is excessive. The type 
of genetic damage might take different forms such as gene 
amplification, loss of heterozygosity, point mutations and viral DNA 
integration (Lazo et al., 1999). It is eminently plausible, indeed likely, 
that the enzymes which guard us against the systemic entry of toxic 
exogenous chemicals sbeal4-play some-part-in the etiology of human 
cancers caused by chemicals. 
Introduction 
Cancer of the uterine cervix is the second most common cancer 
among women worldwide The estimated new cancer cervix cases per 
year are 5,00,000, of which 79% occur in the developing countries 
(lARC Scientific Publication, 1997) Precursors of cervical cancer 
traditionally occur at least a decade earlier than does the invasive cancer, 
supporting the temporal evolution of cervical cancer from its precursors 
(Koss et al, 1963; Richart 1973; Hellberg et al , 1993) These 
precursors, or precancerous lesions are known as dysplasia The term 
"dysplasia" which literally means bad molding was introduced in the 
late 1950s (Reagan et al., 1953). A spectrum of pathological lesions 
between normal epithelium to cancer occurs as mild, moderate, severe 
dysplastic and carcinoma in-situ, before developing uterine cervical 
cancer Extensive viral carcinogenesis studies the world over point to 
human papillomavirus as an important factor in cervical carcinogenesis 
(zur Hansen, 1991, 1996, Munoz et al 1992, Schiffman et al 1993, 1995. 
Bosch et al 1995, Franco et al 1995) However, experimental evidences 
suggest infection of HPV alone is not sufficient for transforming a 
normal cell into malignant one, indicating involvement of additional 
genetic alterations in the progression of cen'ical cancer, either 
independently or in conjunction with other etiological factors including 
HPV infection These genetic factors could be a cascade of genetic 
alterations involving either inactivation of tumor suppressor genes 
2 /ntioductioii 
(Mitra et al., 1994a; Mullokandov et al., 1996) or activation of 
oncogenes (Bishop and Weinberg, 1996; Peifer et al., 1997), or both. 
Recently, differential amplification as well as expression of erbB-2 and 
bcta-catenin was reported in cervical cancer (Mitra et al., 1994b; 
Sharma et al., 1999; Pinion et al., 1991). 
Among other environmental factors tobacco smoking is an 
important and frequent cause of cervical cancer. The link between 
cervical cancer and cigarette smoke which contain carcinogenic 
substrates for phase 1 cytochrome P450 (CYP) and phase 2 detoxifying 
enzymes suggests susceptibility to this cancer may be linked to allelic 
variation at these loci. Individuals differ in their susceptibility to cancer, 
and identification of predisposing genes could allow identification of 
women that are at risk of cervical cancer. 
In view of the above, the aim of the present study was to 
m investigate the status of genetic alterations including loss of 
2 \ 
heterozygosity and microsatellite instability, expression of erbB-2 and 
beta catenin, CYP2D6 polymorphism and HPV infection in cancer of 
the uterine cervix in order to understand the possible molecular events 
involved in the development of cervical cancer. 
Introduction 
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2. AIMS AND OBJECTIVES 
The aims of the present study are: 
1. Analysis of microsatelhte instability (MSI), using reference panel 
of five markers, Bat-25, BAT-26, D2S123 (AFM093xh3), 
D5S346 (APC) and D17S250 (Mfd215 CA) including both mono 
and dinucleotide repeats and their correlation with HPV infection 
in cancer of the uterine cervix. 
2. To determine the prevalence of loss of heterozygosity (LOH) on 
chromosomes 3p and 5p in the cancerous lesions. 
3. Detection of human papillomavirus infection (HPV) among 
different grades of cancerous lesions, and/typing ot prevalent 
HPV types (6, 11, 16, 18) 
4. Genetic polymorphism of cytochrome P450 2D6 (CYP2D6) and 
susceptibility to cervical cancer in Indian population. 
5. Analysis of expression of the oncogene erbB-2/Her2neu and beta 
catenin in squamous cell carcinoma and adenocarcinoma of 
cervix uteri, by immunohistochemistry. 
Aims and Objectives 
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3. REVIEW OF LITERATURE 
Cancer of the uterine cervix is a leading cause of morbidity and 
mortality among women worldwide. It is the eighth commonest cancers 
in the world and the second most common cause of cancer-related 
mortality in women worldwide. The estimated new cancer cervix cases 
per year are about 500,000 of which 79% occur in tiie developing 
countries (lARC Scientific Publication, 1997), with an estimated death 
of around 203,000 annually (Van Ranst et al., 1992). The higher rates of 
cervical cancer in developing countries especially in South East Asian 
regions are generally associated with poor hygiene and economic 
condition. The age adjusted incidence rate (AAR) of cancer cervix of 
different countries is seen in Graphs. 1. 
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Graph 3.1 Incidence of Cervical cancer in different countries 
ONewzealand 
O Australia 
• UK England 
• Switzerland 
• Germany 
•Thailand 
• Korea 
• Japan 
• China 
• India (Madras 
• USA HSP White 
a Peru 
' D Brazil m I I 20 40 60 
Incidence (%) 
^ % Uganda 
•Zimbabve 
Review of Literature 
India alone contributes about 100,000, i.e. 1/5 of this world 
disease burden. The truncated rate (TR) in the age group 35-64 years in 
Chennai, India, is even higher (99.1/100,000; 1982-95) than rate reported 
from Cali, Colombia (77.4/100,000, 1987-91). The cervical cancer 
burden in India alone is estimated as 100.000 (Shanta et al., 2000). 
Cancer of the cervix is the number one cancer in females in 
Bangalore, Barshi, Bhopal and Chennai. While over 50% of cancers in 
females in Barshi were cancers of the cervix, Chennai had the highest 
AAR of 30.7 per 100,000. Cancers of the cervix and breast together 
"T 
account for over40% of cancers in urban women and 65% of cancers in 
rural registry in Barshi. Incidence rate begins to rise in the early twenties 
in all registries and reach a peak in the 50-54 age group and only slowly 
If ' 
thereafter. In all the registries over 90% of cases of cancer of cervix were 
A 
squamous cell carcinomas. Adenocarcinoma constituted 2-4% of all 
cerx'ical cancers. According to PBCR report (1990-96) cancer of the 
cen'ix was the leading site in Bangalore, Barshi, Chennai and second in 
Delhi and Mumbai after the cancer of breast (Graph 3.2). Most of the 
National Cancer Registries have been showing a declining or stationery 
trends since 1988. It has been estimated that every year 0.15 million new 
cervical cancer arise annually in India. The precancerous lesions (low 
grade and high grade squamous intra-epithelial lesions) account for 6 
million cases prevalent in the country. 
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Graph 3.2 The bar chart shows the five leading sites of cancer in the five 
registries in females. The leading sites of cancer were decided on the basis 
of crude incidence rates [PBCR consolidated report 1990-1996]. 
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Two sites, cervix and breast together constituted over 40% of cancer of 
all sites in females in urban registries and over 65% of cancers in the 
rural registry at Barshi (Consolidated report of PBCRs: 1990-1996). 
Cervical cancer mortality trends in a nimiber of countries have 
been reported by Cuzick an Boyle, (1988); Beral et al., (1994) and others. 
The higher rates are found in South America, Asia and Africa (Coleman 
et al., 1993) on the other hand, very low rates are seen in Israel and the 
Middle East. The rates appear to be fairly stable in these areas and this is 
also true for Southern and Eastern Europe. However, marked declines 
have been observed in both incidence and mortality of cervical cancer in 
North America, Western Europe and Japan. Much of the reduction has 
been attributed to an effect of screening (Hakama et al., 1991; Aareleid et 
al., 1993). However, an exception is the recent increase in rates among 
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young women in the United Kingdom, Australia and New Zealand 
(Cuzick and Boyle 1988). Even more recently, increases in cervical 
cancer rates among young women have been reported in Scandinavia and 
Eastern Europe (Beral et al., 1994). In the USA, blacks have 
approximately twice the cervical cancer rate than that of whites. But a 
recent study in Detroit of women aged 15 to 39 (Weiss et al., 1994) 
found that the rates were decreasing more rapidly in blacks and was 
nearly equal to those of whites by 1991. In United States, the incidence 
of mortality rates dropped to about 50% over the last 30 years due to 
effective cancer screening and control programs. On the other hand, 
cancer surveys in United Kingdom (Cook and Draper, 1984) have 
suggested an increase in incidence and mortality rates among young 
women. 
Although most National Cancer Registries have been showing 
declining or stationary trends, however, changes in sexual behavior 
among adolescents, increase in oral contraceptive use, built-up of HIV 
epidemic, lack of infrastructure to screen, early detection and treatment 
of pre-cancerous lesions may reverse these trends in years to come. 
Cancer of the uterine cervix shows an interestingly, highly 
variable and well characterized but an unpredictable developmental 
pattern. Cervical cancer does not arise de-novo; it involves a cascade of 
events and begins with the development of precancerous lesions spanning 
10-15 years. These lesions may regress to normalcy, persist, and if left 
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untreated may culminate to invasive cancers. The precancerous lesions 
include a spectrum of epithelial changes, termed as cervical dysplasia, 
which may invade basal membranes and progress to advanced stages. 
It has been shown in one of the long term prospective study that 
the natural history of the disease is the same as that reported in the West 
and every year more than 100,000 women develop this cancer in India 
(Luthra et al 1987) and that every alternate severe dysplasia would 
progress to carcinoma-in-situ, every 4"^  moderate dysplasia and every 
lO"^  mild dysplasia will show progression (Murthy, et al 1990). 
RISK FACTORS 
Epidemiological studies have identified a number of risk factors 
that contribute to the development of cervical cancer precursors and 
cerx'ical cancer. These include infection with certain oncogenic types of 
human papillomaviruses (HPVs), and other socio-economic factors 
(lARC, 1995; Bosch et al., 1995; Schiffman, 1994; Walboomers et al., 
1999; Franco et al., 1999; Frenczy and Franco, 2002). 
Socio-economic factors 
The exact cause of cervical cancer is still unknown. However, a 
number of predisposing factors have been identified. Major risk-factors 
for cervical cancer in India are considered to be socio-economic status 
(related to education, low income, multiple sexual partners and sexual 
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exposure prior to age of 18). Within the country, the highest incidence 
of cervical cancer is found in Chennai and Barshi, rural Maharashtra. In 
urban areas where the level of education is comparative high females are 
at reduced risk of cervical abnormalities (Graph 3.2, Consolidated 
report of PBCR: 1990-96). Age at first intercourse, age at first child 
birth, high parity, number of sexual partners, promiscuity these all have 
been identified as possible risk factors. Progression to malignancy was 
found to be influenced by age at consummation of marriage (ACM). 
Women with consummation of marriage under 18 years of age had a 
2.8-fold higher progression than those with ACM over 18 years. This 
may be possibly duejexual insult to the younger cervix. Earlier ACM 
increases the susceptibility of the cervix to the further action of 
carcinogenesis (Brinton and Fraument, 1986b; Luthra et al., 1987). But 
none of these factors attained independent significance. Sexual activity 
and the number of male sex partners have been identified as specific risk 
factors for cervical carcinogenesis. The married women of rural India 
are most at risk for cervical cancer. The disease has been less commonly 
found in the nun population and high among sex workers indicating that 
the partner also may play role as a possible risk factor. Studies suggest 
that females with history of sexually transmitted disease are more prone 
to cervical cancer. High parity is also associated with increased risk of 
developing cervical abnormalities. Regular PAP tests have dramatically 
reduced the risk of developing cervical cancer in developed countries. 
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Education and income have been accepted as major indicators of socio-
economic status. The distribution of cervical cancer by educational level 
and income level in the hospital registry and demographic registry 
highlights the inverse relationship of income group and educational 
level 
Besides other factors, females not maintaining proper hygiene after 
urination and intercourse are found to be at increased risk of cervical 
cancer. Proper washing of genitalia of both partners reduces the risk. 
The Indian registries show significantly lower incidence of cervical 
cancer in the Muslim women compared to other religious groups (Wahi 
et al., 1972; Jussawala et al., 1971). The religion specific incidence rate 
(RSI) of cancer cervix in Hindu is 24.1, Christian 21.0 and Muslim 11.2. 
The religious difference is strikingly marked in penile cancer incidence 
also. The high incidence of cancer cervix among Hindu women has been 
attributed to early age at coitus and poor penile hygiene on the part of 
male partner. The low frequency among Muslim women was attributed 
to the practice of ritual circumcision in Muslim men. 
Human Papillomaviruses and the Development of Cervical 
Carcinoma 
The infection of HPVs is considered to be the principal 
etiological agent responsible for cervical cancer (zur Hansen 1996; Das 
et al., 2000). More than 98% of the invasive cervical cancer shows 
presence of HPV. Papillomavirus viruses were first recognized many 
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years ago as the cause of warts on the hands and feet or condyloma 
accuminata on the pubic area (penis and urethra in males or vulva and 
vagina in females). Papillomaviruses are small non-enveloped virions 
with icosahedral capsid composed of 72 capsomeres (Klug and Finch 
1965: Pfister. 1987; Baker et al.,1991; Pfister & Fuchs, 1994) measuring 
55nm in diameter. Viruses classified in Papillomaviridae family. 
Cervical intraepithelial neoplasia and cervical cancer both are strongly 
associated with HPVs. Extensive viral carcinogenesis studies world over 
point to Human papillomavirus as an important etiological factor. The 
first lARC-sponsored case control study on HPV and cervical cancer in 
India carried out at Cancer Institute, Chennai documented 99% of 
uterine cervix were HPV positive compared to 22% in the controls. Over 
90% of the cervical carcinoma has been shown to contain HPV infection 
(Bosch et al., 1995). Human papillomaviruses have two possible roles in 
malignant lesions, either due to the presence of vial early gene 
expression or due to the genetic damage caused by viral DNA 
integration (Clavel et al., 1998). After infection there is an incubation of 
6-8 weeks, certain types of HPV are now officially declared to be human 
carcinogens (lARC 1995) representing the most important etiological 
agents of cervical squamous cell carcinoma and many other cancers 
related to squamous epithelium (zur Hausen 1996). Like any other viral 
infections HPV infection also remain asymptomatic or mildly 
symptomatic. 
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The circular DNA genome of all papillomaviruses can be divided 
into three segments of unequal size. The long control region (LCR), also 
called the upstream regulatory region (URR) or noncoding region, 
represents about 10% of the genome. The early (E) and late (L) genes 
are coded by about 50% and 40% of the genome respectively. 
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Fig.3.1 simplified organization (linearized) of human papillomavirus type 
16 genome 
HPV infection may be categorized into clinical and sub clinical 
infection. Clinical infection may be expressed in the form of condyloma 
accuminata. The subclinical infection is usually associated with 
oncogenic potential. The latent infection is usually associated wim 
histological cervical lesion with HPV DNA. More than 70 types of HPV 
types have been characterized so far on the basis of differences in their 
DNA sequences (Favre et al., 1989a,b,c and d; Heilman et al., 1980; 
Danos et al., 1982; Kremsdorf et al., 1980, 1984; Gismann et al., 1977; 
Diirst et al., 1983., Boshart et al., 1984; Cole 1986; Beaudenon et al., 
1986; Lorincz et al., 1987, 1989; Muller et al., 1987, Nuovo et al., 1988 
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etc.). Type specific prevalence is presented for the eighteen most 
common HPV types as identified by Clifford et al., 2003; Lechner et al., 
(1992) in meta-analysis of HPV types in invasive cervical cancers are: 
HPV types 6, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 70, 73 
and 82 in order of descending prevalence for each subgroup analysis. 
Two third of invasive cervical cancer cases included in the meta-
analysis were associated with HPV 16 (51.0%) or 18 (16.2%) infection. 
Nubia Munoz et al., (2003) in their epidemiologic classification of 
human papillomavirus types grouped fifteen HPVs as high-risk types 
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82); three as 
probable high-risk types (26, 53 and 660 and 12 were classified as low-
risk types (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108). During 
the normal HPV cycle, viral DNA is maintained episomally in the 
nucleus of the infected cell. The detection of integrated viral DNA 
sequences in cervical neoplasia (Schwarz et al., 1985) is frequently 
associated with malignant progression, integration being more common 
in carcinomas than in cervical intraepithelial neoplasia (Cullen et al., 
1991), with some studies reporting integration in high-grade dysplasia 
(Lehn et al., 1988; Fukushima et al., 1990). The persistence of both 
episomal and integrated copies of the HPV genome in some cervical 
cancers has been reported (Kristiansen et al., 1994) and most studies 
identify at least some carcinomas with only episomal form (Das et al., 
1992). 
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HPV Detection 
Digene Hybrid Capture Assay -II 
Digene Diagnostics (Bellsville, MD) have developed HPV tests 
for clinical routine. This test has been recently approved in the USA, by 
the Food and Drug Administration (FDA). The Digene HPV test using 
Hybrid Capture -II technology is a signal amplified hybridization 
antibody capture microplate assay that utilizes chemiluminiscent 
detection. Specimens containing the target DNA hybridize with a 
specific HPV RNA probe cocktail. The resultant RNA: DNA hybrids are 
captured onto the surface of a microplate well coated with antibodies 
specific for RNA: DNA hybrids. Immobilized hybrids are then reacted 
with alkaline phosphatase conjugated antibodies specific for RNA: DNA 
hybrids and detected with a chemiluminiscent substrate, several alkaline 
phosphatase molecules are conjugated to each antibody. Multiple 
conjugated antibodies bind to each captured hybrids resulting in 
substantial signal amplification. As the substrate is cleaved by the bound 
alkaline phosphatase, light is emitted which is measured. It is a simple 
technique that could be readily automated for large-scale use if required. 
Polymerase chain reaction 
PCR is currently the most sensitive method to detect human 
papillomavirus DNA in cervical scrapes.(Walboomer et al., 1997) It is 
based on in-vitro enzymatic DNA amplification and in principle detects 
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one copy of a target sequence in a given sample. To date at least 30 
different HPV genotypes have been isolated from anogenital tract 
among which 14 are HR-HPV genotypes (16, 18, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66 and 68) have been defined on the basis of their isolation 
from cei-vical carcinomas (Bosch et al.,1995; Chaouki et al., 1998). 
Different primers have been used for the detection of wide range of 
HPVs e.g. General primers -mediated (GP) PCR based amplification, 
selected from highly conserved region L1 and E1 of HPV genome. This 
assay is based on three different approaches viz.: 
a). Use of degenerate primers (mixture of oligonucleotides showing 
nucleotide differences at several intervals) 
b). Degenerate primers in addition contain inosine residues at certain 
ambiguous base positions, 
c). Acceptance of certain degree of mismatch between primers and 
target DNA accomplished by reducing the stringency of primer 
annealing (Snijders et al., 1990) Recently a new method was introduced 
using GP+/GP6+ PCR based procedure which included Southern Blot 
hybridization of PCR products with cocktails of radioactively labeled 
HPV type-specific internal oligonucleotides. There are several reports 
on the efficacy of the two most commonly used primer sets (MY09/11 
and GP5+/GP6+) used for the detection of HPV. Both primer sets 
amplify a wide spectrum of HPV genotypes. There was differential 
amplification sensitivity of HPV types between the MY-PCR and GP+-
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PCR primer systems (Qu et al., 1997). It was shown that MY-PCR 
primer set was more robust than GP+-PCR primer set in the 
ampHfication of multiple HPV DNA types within a given sample. The 
GP--PCR primers were relatively inefficient in the amplification of 
HPV types 53 and 61 compared to MY-PCR, whereas MY-PCR was 
inefficient in the amplification of HPV 35. 
Detection of different HPV types 
Cervical intraepithelial neoplasia and cervical cancer both are 
strongly associated with persistence presence of some types of human 
papillomavirus. Over 90% of the cervical carcinoma have been shown to 
contain some high-risk HPV types (Nieminen et al, 1991). The genital 
HPVs are classified into two groups high and low risk based on whether 
or not the lesions with which they are associated are at significant risk 
for malignant progression. The low risk HPVs such as HPV-6 and 11 
are generally associated with genital warts (condyloma accuminata and 
flat genital warts), lesions that only rarely progress to cervical cancer. 
The high-risk viruses, such as HPV-16 (Favre et al, 1989; Seedorf et al, 
1985), HPV 18 (Cole ST et al, 1987) and HPV 33 (Beaudenon et al, 
1986; Cole et al 1986), and few other are associated with CIN and 
cervical cancer. HPV 16, 18, 33 and 45 accounts for more than 90% of 
the high risk types. The MY09/MY11 primer set mediated PCR (MY-
PCR) (Hildesheim et al., 1994; Manos., et al., 1989) and the 
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GP5+/GP6+ primer set mediated PCR (GP+-PCR) (de Roda et al., 
1995) are the most frequently used amplification systems for the 
detection of HPV DNA in clinical samples and genotyping by type 
specific primers (Van Den Brule et al., 1989). There was differential 
amplification sensitivity of HPV types between the two systems. MY-
primer set was found to be inefficient for HPV type 35 detection but was 
proved to be more sensitive than GP+-PCR primer set in the 
amplification of multiple HPV DNA types within a given sample (Qu et 
al., 1997). According to a recent meta-analysis (Clifford et al., 2003), it 
was found that HPV prevalence vary little between geographical 
regions. The most common high-risk HPV types in cervical squamous 
cell carcinoma was HPV 16 whereas, HPV 18 was predominant in 
adenocarcinomas and adenosquamous carcinomas followed by HPV 16. 
The MY09/11 primer set has been used predominantly in epidemiologic 
studies in North and South America and Asia (Bosch et al., 1995; Liaw 
et al., 1995) whereas the GP5+/GP6+ has been used primarily in Europe 
(de Rod Husman et al., 1995). Furthermore, various studies indicated 
frequent co-infections of HPV 16 and HPV6, suggesting interaction 
between different HPV types in multiple infections. HPV 16 and 6 
appeared to have antagonistic interference in cervical carcinogenesis. 
Serological evidences indicate protection by HPV type 6 infection 
against HPV type 16 cervical carcinogenesis (Sillins et al., 1999), 
whereas in co-infections the E6 protein of low-risk HPV (type 6) 
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augments the ability of E7 of HPV type 16 or E7 of HPV type 6 coupled 
with E6 of type 16 increases the potency and ability to immortalize cells 
(Halbert et al., 1992). These studies suggest the detection of low-risk 
HPV types and their co-infections alongwith HR-HPVs to be important 
for understanding the pathogenesis of the disease and the biological 
behavior of HPVs during cervical carcinogenesis. Infection of multiple 
HPV DNA types is a risk factor for cervical intraepithelial neoplasia 
(Liaw et al., 1995). These observations demand for an early detection of 
virus types, especially those associated with cervical dysplasia and 
cancers, with an easy, cost-effective and simple diagnostic procedure. 
We. developed a new rapid and cost-effective PCR- RPLP technique, 
n 
using restriction digestion with Rsa 1, of the amplified products of LI fi"^-** 
region (by MY09/11 consensus primers) (Naqvi et al., 2004). It detects 'y.>\y 
five different HPV types and their co-infections simultaneously 
Comparing the two techniques, RFLP with restriction enzyme Rsa 1 and 
PCR with type specific primers, we found that RFLP using Rsa-lean 
detect co-infections simultaneously and more consistently than 
individual typing with type specific primers and was cost effective as it 
saves the total cost of second PCR for HPV typing with type specific 
primers (Aadrian et al., 1990). Use of nested PCR with degenerate 
primers has been described by various workers to be extremely sensitive 
means of detecting a wide range of HPV types (Broker et al., 2001; 
Harwood et al., 1999; Pizzighella et al., 1995). RFLP of the inner nested 
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PCR product of MY09/11 primers using Bst Ell and a double digest of 
Pst I and Bgll (Patti et al., 2002) detected ten high-risk anogenital HPV 
types. Both the methods were able to detect broad range of HPV types. 
Most of the PCR-RFLP studies show either use of multiple restriction 
enzymes with two rounds of amplification. Whereas, method described 
in this paper, was found to be precise, with only one round 
amplification, followed by RFLP using single restriction enzyme, 
detected the five most prevalent HPV types commonly associated with 
cer\'ical abnomialities and cancer. In conclusion, this method was less 
cumbersome, low-cost and user-friendly for the detection of HPV DNA 
from cervical swabs, both at clinical and research level. 
CYP2D6 polymorphism in cervical cancer 
Among other environmental factors tobacco smoking is an 
important and frequent cause of cervical cancer. Data of cancer registry 
reveals a positive correlation between cervical cancer and tobacco 
related cancers (Winkelstein, 1977). Tobacco smoke contains many 
potential carcinogens including polycyclic aromatics hydrocarbons, N-
nitrosamines, aromatic amines, aldehydes and halomethanes. The 
importance of tobacco derived compounds as local carcinogens is shown 
by the findings that nicotine cotinine are concentrated in cervical mucus 
which can be mutagenic (Winkelstein, 1990; Gram et al., 1992; Burger 
et al., 1993), and DNA from cervical epithelial cells of smokers contains 
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adducts of the type expected from reaction with polycyclic aromatic 
hydrocarbons and aromatic amines (Simons et al., 1993). This may 
explain the biological plausibility of the association between smoking 
and cervical cancer. Cytochrome P450s constitute superfamily of 
enzymes cmcial for the oxidative, peroxidative and reductive 
metabolism of a diverse group of compounds, including endobiotics, 
such as steroids, bile acids, fatty acids, prostaglandins and leukotrienes 
and xenobiotics including most of the therapeutic drugs and 
environmental pollutants (Nelson et al., 1996; Bertz and Granneman, 
1997). The first report on existence of cyp enzyme or a "microsomal 
carbon mono oxide binding pigment", as it was called at that time, was 
published in 1958 by Klingenberg et al. This enzyme gave a unique 
450nm optical absorption peak, and when its hemoprotein nature was 
recognized, it was given the name cytochrome P450 (Omura 1999). In 
several instances, striking differences in the activities of these enzymes 
among human subpopulations can be explained by allelic differences in 
a single gene (Nebert et al., 1990; Meyer et al , 1990). Therefore, it is 
likely that an understanding of these allelic differences will be important 
for detennining an individual's risk of cancer and susceptibility to 
potentially toxic agents. CYP enzymes are expressed ubiquitously in 
different life forms: they have been found in animals, plants, fungi and 
bacteria (Nelson et al., 1996). They seem to be indispensable for 
eukaryotic species but not for prokaryotes, since some bacteria lack cyp 
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enzymes (Nelson, 1999). Eukaryotes need CYPs for the biosynthesis of 
sterols, which are constituents of plasma membrane (Omura, 1999). 
Eukaryotic cyp enzymes are membrane bound mostly localized to the 
endoplasmic reticulum, but some CYPs are also present in 
mitochondrial inner membranes. In order to function, cytochrome P450s 
require an electron transfer chain. In the endoplasmic reticulum this 
source is NADPH-cytochrome P450 reductase, previously called 
NADPH - cytochrome c reductase (Omura 1999). In mitochondria, 
electrons are transferred from NADPH by redoxin reductase to redoxin 
and then to CYP (Gonzalez, 1990). Despite their occasionally minimal 
sequence similarity, all CYPs have a similar structural fold with a highly 
conserve core (Graham and Peterson, 1999). Most biotransformation of 
xenobiotics is done by enzymes from the families CYPl, CYP2 and 
CYP3. The CYP2 family has been under intensive study using the rat, 
mouse and rabbit as model system. The CYP2 family includes seven 
subfamilies in mammals. In the human, the most important CYPs from 
the viewpoint of drug metabolism are CYP2A6, CYP2C9, CYP2C19, 
CYP2D6 and CYP2E1. The expression of CYP enzymes varies between 
individuals due to genetic and environmental factors and some diseases. 
These factors produce inter-individual variation in the rate and 
metabolic pathways of xenobiotics. One example of genetic factors 
influencing the inter-individual variation is the polymorphic expression 
of at least CYP2A6, CYP2C9, CYP2C19 and CYP2D6 among the 
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population. The frequency of poor metabolizers (PMs) varies between 
races and ethnic groups. Some dietary compound, cigarette smoking, 
alcohol and drugs may cause induction or diminution of the expression 
of certain CYPs (Pelkonen and Breimer, 1994; Pelkonen et al., 1998). 
The human genome includes only one functional gene in CYP2D 
subfamily, namely CYP2D6 (Nelson et al, 1996). Cigarette smoking is a 
risk-factor, suggesting polymorphism at loci that encode carcinogen-
metabolizing enzyme such as cytochrome P450 (CYP2D6) and 
glutathione S transferase (GSTTl, GSTMl) may determine 
susceptibility to cervical cancer. 
Genetic Alterations In Cervical Cancer 
Although specific human papillomavirus types appear to be 
necessary etiological factors for most cervical cancers, HPV infection 
alone is not sufficient for transforming a normal cell to malignant one 
(zur Hausen 1994; Nishimura et al., 2000), additional genetic alterations 
seem to be required for their development and progression 
(Mullokandov, et al., 1996). These genetic changes include activation of 
proto-oncogenes and inactivation of tumor suppressor genes (TSGs). 
Knowledge of these genetic changes, in conjunction with the viral status 
of these cancers, might lead to improved methods of prognosis and the 
development of more effective therapeutic strategies. It is widely 
accepted that there are multistep molecular changes leading to malignant 
transformation from preneoplastic lesions to invasive tumors. Genetic 
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alterations in a tumor are important determinants for the behavior of the 
tumor cells. Proto-oncogenes are normal cellular genes, when 
inappropriately activated as oncogenes by molecular and chromosomal 
rearrangements in coordination with cellular transcription factors, cause 
dysregulation of growth and differentiation pathways and enhance the 
probability of neoplastic transformation. In contrast to proto-oncogenes, 
tumor suppressor genes are normal cellular genes that, when 
inappropriately inactivated or interaction of tumor suppressor gene 
products with viral oncoproteins, cause dysregulation of growth and 
differentiation pathways and may contribute to the development of 
cer\'ical cancer. Non-lethal genetic damage lies at the heart of 
carcinogenesis. Carcinogenesis is a multi-step process at both the 
genetic and phenotypic level that results in tumor progression. The 
targets of the mutations are either the proto-oncogenes, tumor 
suppressor genes where both normal alleles must be damaged to develop 
cancer, or the genes that regulate cell death or apoptosis, which may be 
dominant or recessive, or the DNA repair genes. 
Cancer related genes fall into two categories: tumor suppressor genes 
with a recessive phenotype and oncogenes that have a dominant effect. 
Tumor suppressor genes: 
Certain functions of putative tumor suppressor genes 
• Induce terminal differentiation 
• Maintain genomic stability 
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• Trigger senescence 
• Induce programmed cell death 
• Regulate cell growth 
Signal transducers of negative growth factors 
Regulators, e.g.PTPase y, of tyrosine kinases 
• Inhibit proteases 
• Alter DNA methylase activity 
• Modulate histocompatibility antigens 
• Regulate angiogenesis 
• Facilitate cell to cell communication 
Major cellular oncogenes (c-onc) and their functions 
Localization and Function Oncogenes 
Growth factor related : sis, hst/int-2 
Receptor-related : erbB-1 (EGFR). erbB-2 (HER-2/neu) erbB-3 
Ros, blyn,fms, trk. kit, sea. LA-1 
Signal transducers : ras. N-ras, K-ras. Ha-ras, src, fes. raf, abl, 
yes.fgr, Ick, uck, fin. gsp. gip. iiios.fps. Crh-
2. mos, SOS 
Nuclear oncogenes 
Tumor suppressor 
Regulators of cell death 
myc, myh.fos.jun. erb A, ets. rel, ski 
Rb, p53. WT, NF-1. FAR. DCC. PRAD-1 
bcl-2 
Cytogenetic Studies 
Cytogenetic analyses of tumors have revealed the association of 
specific chromosomal alterations with particular types of cancer, 
resulting in identification of the specific chromosomal regions involved 
in a number of cancers. The cytogenetic analyses of cervical carcinomas 
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have demonstrated non-random alterations of several chromosomes. A 
specific chromosomal abnormality associated with the condition may 
indicate potential candidate regions in which gene(s) affected by the 
predisposing lesion reside. The Knudson two-hit model of 
carcinogenesis (Knudson, 1971) proposed that a mutation transmitted as 
a dominant trait might be recessive at the cellular level and lead to 
cancer when the normal allele is lost or inactivated. The chromosomal 
mechanisms which can lead to somatic inactivation of loci in tumors 
suggest another method of determining the location of genes whose 
function must be lost for malignancy to develop: assay for tumor 
specific loss of genetic material. Studies of chromosome specific loss of 
heterozygosity (LOH) in tumor cells affecting a limited genomic region 
have supported gene localizations suggested by constitutional and tumor 
specific deletion or linkage analysis. LOH has been used to suggest the 
presence of tumor suppressor genes in a wide variety of tumors. 
Cytogenetic studies, although limited, have revealed non-random 
chromosomal changes such as i(5p), deletion at 3p, 6q and 17p (Mitra et 
al., 1994b; Atkin 1997), also a correlation between the common fragile 
sites and integration of HPV DNA (Cannizzaro et al., 1988). Mutations 
or deletions of a tumor suppressor gene have been shown to be 
frequently accompanied by loss of the remaining allele, leading to 
homozygous inactivation of the gene (Marshall, 1991). Several 
molecular studies (Mitra et al., 1994a; Mullokandov et al., 1996; 
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Kersemaekers et al., 1998) have identified a few frequent losses of 
heterozygosity (LOH) sites, suggesting possible involvement of the 
TSGs in the development of cervical cancer. Another common region of 
loss of heterozygosity is the short arm of chromosome 3 identified as 
3pl4 and 3p25 (Chung et al., 1992), 3p21-22 (Karlsen et al., 1994) or 
3pl4-or 3p 14-21 and 3p22-24.1 (Yokota et al., 1989), loss of genetic 
material at these loci was seen in both HPV positive and HPV negative 
women. There was no correlation between HPV infection and 3p 
deletion. Loss of heterozygosity on chromosome 3 was found in both 
invasive cancers and cervical premalignancies, suggesting that these 
alterations play a role in tumor development. 
Loss of Heterozygosity 
Recently, with the availability of molecular cytogenetic 
techniques some frequent genetic abnormalities like losses of 
heterozygosity (LOH) consistent with the data of comparative genome 
hybridization (CGH), have been detected. The term 'loss of 
heterozygosity' was first used by Dracopoli and Fogh, (1983) to 
describe a reduced level of heterozygosity. Further it was noted that loss 
of functional gene expression was predicted by models of carcinogenesis 
involving the accumulation of recessive somatic mutations (Dracopoli 
and Fogh, 1983). Allelic loss and deletion mapping using microsatellite 
markers and the detection of homozygous deletions represented until 
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now the most powerful method to localize potential tumor suppressor 
genes. Frequent LOH at a given locus implies the existence of a 
candidate tumor suppressor gene that is important in the pathogenesis of 
the particular cancer under study. Currently, the consistent observation 
of LOH for markers at a specific location in a series of tumors of a 
particular histological type is considered to be a marker for loss of 
function of one or more tumor suppressor genes in the marked genomic 
region. LOH is being detected with increasing frequency in a wide 
variety of human tumors (Meltzer et al., 1987; Kovacs et al., 1988; 
Yokota et al., 1989; Vogelstein et al., 1988; Fey et al., 1989; Vogelstein 
et al., 1989; Lee et al., 1990; Simon et al., 1991; Wagata et al., 1991; 
Khoslaetal., 1991). 
Various tunior suppressing pathways and cancer-causing genes have 
been extensively studied over the past decade ((Evan et al., 2001). The 
clearest example of the use of LOH analysis to gain insight into tumor 
progression is in colorectal cancer, which offers a prototype approach to 
delineating the sequence of functional loss of tumor progression of 
malignancy. Several regions of the short arm of chromosome 3 are 
commonly affected in different epithelial tumors, and chromosome 3p 
contain several tumor suppressor genes. Frequent deletions with 
complicated profiles have been revealed in 3p by cytogenetic and 
allelotypiiig studies (Kok et al., 1997; Lerman et al., 2000). Frequent 
deletions with complicated profiles have been revealed in 3p by 
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cytogenetic and allelotyping studies (Kok et al., 1997; Mertens F., 
1997). High frequency of LOH on chromosome 3p (47%) was reported 
(El-Naggar et al., 1995) in invasive HNPCC but no significant 3p loss 
(0.5%) in pre-invasive lesions while Mao et al., (1996) reported allelic 
loss (36%) for 3p in oral leukoplakia. Studies in breast cancer have 
revealed several regions where LOH is predictive of outcome 
independent of standard clinicopathological classification. LOH is 
believed to represent inactivation of one allele of a tumor suppressor 
gene by chromosomal or subchromosomal deletion (Mitra et al., 1994a). 
LOH studies through Southern Blotting require large quantities of intact, 
high molecular weight DNA and sensitivity of These LOH were 
detected in both SCC (68%) and AC (42%) (Larson et al., 1997) as 
frequent LOH at a given chromosomal locus implies the existence of a 
TSG that is important in the pathogenesis of the particular cancer study. 
LOK analysis has been done with a panel of probes for chromosomal 
arms 3p and 5p. LOH at 3p might be an indicator of progression since 
its frequency increases from 25% in FIGO stage I to 100% in stage IV 
cases (Larson et al., 1997). Several studies agree that within the region 
3p 14-22 there are two sub regions where the LOH are concentrated and 
frequently both are altered in the same tumor. These two regions are 
3pl4.2 and 3p21(Kohno et al., 1993; Chu et al., 1998). The data suggest 
that two TSGs are located in this chromosomal region (Huettner et al., 
1998). Recently the FHIT gene has been identified within the 
29 Review of Literature 
chromosoma! region 3pl4.2 which is altered in several types of tumors 
such as lung (Sozzi et.al.,1996), breast (Hayashi et al. 1997), esophagus 
(Zou et.al.,1997), cervical (Pierre et al., 1998). Another study with 75 
highly polymoiphic loci located on major autosome arms was used to 
estimate the incidence of LOH in 38 cervical cancers. LOH was found to 
involve 19 chromosome arms in 20-30% of the tumors. High frequency 
of allelic loss was found on 6p, 3p and 18q. Frequent deletions on 3p 
have been confimied by many other studies. LOH at 3p were shown not 
only in cervical cancers but also in cervical intra-epithelial neoplasia. 
Mutation or deletion in a TSG is fi-equently accompanied by loss of the 
remaining allele, leading to homozygous inactivation of the gene 
(Marshal 1991). Chromosome deletions and loss of heterozygosity 
studies from a variety of neoplasms have identified the short arm of 
chromosome 3 (3p25 -3pl4) as the location of genes involved in tumor 
suppression. Tumors with evidence of recurring chromosome 
abnomialities and high frequency allelic loss of 3p include: small cell 
lung cancer (SCLC)(3p22-p21) (Killary et al., 1992; Brauch et al., 
1987), non small cell lung carcinoma (3p23-p21) (Kok et al., 1987), 
renal cell carcinoma (3pl4.3-pl3) (Kovacs et al., 1988), breast, ovarian 
and testicular cancer (3p23-p21) (Devilee et al., 1989; Trent et al., 1985; 
Lothe et al., 1989), squamous cell carcinoma (3p24-pl2) (Gollin et al., 
1994) and cervical carcinoma (Mitra et al., 1994a; Mullokandov et al., 
1996). LOH studies using molecular genetic tools provided a powerful 
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approach to identify the minute genetic losses. In an analysis of 38 cases 
of cervical carcinoma, twenty one pefcent (8/38) of which were HPV 
negative, Muilokandov et al.(1996), noted that the spectrum of allelic 
losses observed in both HPV positive and HPV negative tumors was 
similar to that observed in other tumors of epithelial origin suggesting 
that, in general, the origin and progression of cervical cancer shares 
many features with other epithelial tumors. The expected exception was 
LOH on chromosome 17p. LOH for I7p, a presumed marker for loss of 
function of p53 is observed in 50-90% (Kern et al., 1989; Huang et al., 
1992) of most tumors of epithelial origin but was seen in only 15% of 
HPV positive cervical cancer. Thus, while viral inactivation of p53 is a 
vital step in HPV mediated cervical carcinogenesis, other genetic 
changes leading malignancy in HPV positive tumors appear to be 
similar to those occurring in HPV negative tumors. Mitra et al. (1994a), 
obtained similar results. To identify the genetic events that may play a 
role in the development of cervical carcinoma detailed allelotype 
analysis was performed by Mitra et al., 1994a, LOH was observed more 
than 25% at sites on eleven chromosomal arms. In order to further 
understand the role of genetic alterations that effect in cervical 
carcinogenesis, status of microsatellite instability in precancerous 
lesions has been investigated on 5p 14-ter (Mitra et al., 1995). LOH was 
observed in the allelotype analysis at eleven chromosomal sites which 
included Iq (26%), 3p (35%), 3q (31%), 4q (46%), 5p (53%), 5q (38%), 
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6p (28%), lOq (28%), l ip (24%), 18p (38%) and Xq (26%) the most 
frequent being 4q and 5p where 5p (53%) and Xq (26%) were the two 
novel sites that are not reported in any other cancers (Mitra et al., 1994a) 
suggesting that candidate TSG may be present on these arms playing a 
role in the development of cervical carcinoma. Study dealing with 
frequent deletion sites in relation to HPV infection was also conducted. 
LOH on 3p revealed significant association with HPV-16/18 infection, 
64% of LOH at 3p was in HPV-16/18 positive tumors. On the other 
hand 78.6% of LOH at 5p which was most frequent (56.3%) was in 
tumors without HPV-16/18 infection vs. 43.7% in tumors that had 
infection. In another study of 38 cases of cervical carcinoma 21% were 
HPV negative (MuUokandov et al., 1996) noted that the spectrum of 
allelic losses observed in both HPV positive and negative tumors was 
similar to that observed in other tumors of epithelial origin suggesting 
the similar origin and progression of cervical cancer as that of other 
epithelial tumors. LOH analysis has been extensively applied to cervical 
cancer leading to the identification of several chromosomal regions that 
are recurrently affected in this cancer. LOH analysis has been 
extensively applied to cervical cancer leading to the identification of 
several chromosomal regions that are recurrently affected in this tumor. 
The 3p region has been implicated in ovarian, breast, testis, lung and 
renal carcinoma. In cervical cancer a broad region (3p 12-24) was 
identified as a target for LOH. The data shows that LOH occurs at an 
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average frequency of 48% depending on the number of marker used 
(Mitra et al. 1994; Mullokandov et al., 1996; Jones et al., 1992; Kohno 
et al., 1993; Ku et al., 1997; Karlsen et al., 1994; Huettner et al., 1998). 
These LOH were detected in squamous cell carcinoma and 
adenocarcinomas. 
Table 2.1 Recurrent LOH in cervical cancer 
Chromosomal "/..age References 
Region 
3pl4.1-22 48 Yokota e ta l . l 989, Nakamura, 1992, 
Mitra et al, 1994, Kersaemaeker, 1998b 
Mullokandov et al, 1996. 
4p 16 40 Hampton et al, 1996, Kersaemaeker 1998b. 
Mullokandov etal 1996 
4q21 -31 32 Mitra etal 1994, Kersaemaeker etal 1998b 
Mullokandov et al 1996 
5pl3-15 17 Mitra etal 1994, Kersaemaeker 1998b, 
Mullokandov etal 1996. 
6p21.3-22 41 Mitra et al 1994, Kersaemaeker 1998b, 
Mullokandov etal 1996. 
I lpl5 28 Mitra et al 1994, Kersaemaeker 1998b, 
Mullokandov etal 1996. 
II q23 38 Hampton et al 1994, Kersaemaeker 1998b. 
Mullokandov etal 1996 
17pl3.3 24 Fujita et al 1992, Kersaemaeker 1998b, 
Mitra et al. 1994, Mullokandov etal 1996. 
18q 12.2-22 24 Mitra et al 1994, Mullokandov etal 1996. 
Kersaemaeker et al 1998b . 
[Courtesy Lazo, P.A.. The molecular genetics of cervical carcinoma. 
British J. Can. (1999)] 
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Microsatellite Instability 
Microsatellite instability (MSI) is characterized by small 
deletions or expansions within these short tandem repeats in tumor DNA 
as compared with matching normal DNA. Repetitive sequences arc 
common in eiikaryotic genomes and vary in length of repeat unit from 
one to several thousand base pairs. Repeated sequences can occur in 
tandem array, such sequences are unique to each person. One such class 
of sequences in humans consists of simple tandem repeats, often a 
mono-di or tri-nucleotide repeat. Such repeats of 2-5 nucleotide 
segments are known as microsatellite DNA. Abnormalities of such 
repeats have been implicated in the genesis of a number of human 
genetic conditions. 
DNA repair enzymes, "Nucleotide Excision Repair" recognize 
and repair large, bulky lesions in DNA. The "Mismatch Repair" 
pathway, in contrast, is responsible for detecting and repairing short 
segments of mismatched base pairs. Since microsatellite repeats fall into 
this category, disorders of the mismatch repair pathway lead to errors in 
these polymorphic segments. MSI was discovered to be the result of 
germline mutations in the genes that encode the components of the DNA 
proofreading complex. These genes are hMSH2, hMLHl, hPMSl and 
hPMS2, and these are the human homologues of the bacterial inutHLS 
system. Mismatch repair may be altered by mutations in any of these 
genes whose product is required for functional DNA mismatch repair. 
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Microsatellite Instability and Development of Neoplasia 
It was recently discovered that mutations in the mismatch repair 
genes are responsible for hereditary nonpolyposis colon cancer 
(HNPCC). These tumors demonstrated new microsatellite alleles in 
tumor DNA compared to non-neoplastic normal DNA. Greater than 
80% of HNPCC tumors demonstrate microsatellite instability. (Aaltonen 
et al., 1994) and approximately 30% of the families with HNPCC have 
germline mutations in hMSH2, while another 30% mutations in hMLHl 
(Lui et al.,1994; Papadopoulos. et al., 1997; Peltomaki et al., 1997). 
Microsatellite instability is not unique to tumors of the colon. The 
presence of MSI has been reported in a variety of human malignancies. 
(Arzimanoglou et al., 1998), including cancer of endometrium 
(Peltomaki et al., 1993;Risinger et al., 1993; Lim et al., 1996; Caduff et 
al., 1996; Kobayashi et al., 1996; Katabuchi et al., 1995; Duggan et al., 
1994; Burks et al., 1994), stomach (Han et al., 1993; Aaltonen et al., 
1994; Dos et al., 1996; Strickler et al., 1994; Hayden et a;.1997; 
Mironov et al., 1994; Keller et al., 1995; Chong et al., 1994; Semba et al 
1996; Rhyu et al., 1994; Seruca et al., 1994; Wu et al., 1997; Battista et 
al ., 1997), bladder (Gonzalez-Zulueta et al., 1993), renal, (Uchida et al., 
1994) cervical (Mitra et al, 1995; Chung et al., 2001;), ovary (Fujita et 
al., 1995; Sood et al., 1997; Wooster et al., 1994; Arzimanoglou et al., 
1996; Phillips et al., 1996; King et al., 1995; Risinger et al., 1995; Han 
et al., 1993) and pancreas (Han et al., 1993; Kimura et al., 1996; 
35 Review of Lileraliiix' 
Brentnall et al.,1995), prostate (Watanabe et al., 1996; Gao et al., 1994), 
breast (Paulson et al., 1996; Yee et al., 1994)), cervical (Han et al., 
1993), glioma (Izumoto et al., 1997), leukemia (Ohyashiki et al., 1996), 
testis (Peltomaki et a!., 1993), esophageal (Meitzer et al., 1994) 
Microsatellite instability is thought to represent a type of genomic 
instability, which, in turn, may predispose cells to the accumulation of 
other genetic alterations necessary to attain a malignant phenotype. 
Microsatellite is often observed in microsatellite polymorphisms 
because the short repeat units in these polymorphisms are susceptible to 
replication errors. Microsatellite instability has been reported in 35% 
(7/20) of invasive cervical cancers. Instability was assayed on PCR 
based assay by comparing the tumor DNA to that with DNA derived 
from normal tissue of the same patient. Although dinucleotide repeats 
have been used most frequently for these studies, instability has also 
been observed in mono, di, tri, and tetra-nucleotide repeats (Hoang et 
al., 1997; Zhou et al., 1997). Selection of markers as well as the number 
of markers used in the study, for the detection of microsatellite 
instability has a significant effect on the determination of MIN status. It 
has been recommended that for the best results it is best to utilize a 
combination of mono and di-nucleotide repeats. Because of differences 
in marker selection and total number of markers used a comparison 
between various studies is quite difficult. In the present study analysis 
of microsatellite instability was done using the Bethesda Consensus 
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Conference reference panel of five markers, Bat-25, BAT-26, D2S123, 
D5S346 and D17S250 (Boland et al., 1997). 
Oncogenes in cervical cancer 
Involvement of various oncogenes has been reported in several 
human cancers. About twenty such oncogenes were reported to be 
involved in cancers in human. These genes were first identified from 
oncogenic RNA viruses called retroviruses. These oncogenes are named 
after the viral strain from which they were isolated: e.g. rel, src, myb, 
erb-K erb-B, fps, yes, ros, mos, ras, abl, fes, fms and sis. Another agent 
that stimulates proliferation, epidermal growth factor, like src increases 
phosphorylation of membrane proteins at tyrosines, and so it is thought 
that this tyrosine phosphorylation somehow controls cell proliferation. 
Cancer cells contain ten times more phosphotyrosine than normal cells. 
Amplification of cellular proto-oncogenes has been associated with 
tumor progression (Bishop et al.,1991), e.g. ; MYCN in neuroblastomas 
(Brodeur et al., 1984), small cell lung cancer (Wong et al.,1986),and 
various other tumor types, and erbB-2 (HER-2/nue) in breast (Slamon et 
al., 1987; Skalova et al.2003) ovarian (Slamon et al., 1989; Tyson et al., 
1991; Hou et al., 1996), gastric (Houldsworth et al., 1990; Al-
Kasspooles et al., 1993) and bladder carcinomas (Coombs et. al., 1991) 
suggesting that this gene may play a role in tumorigenesis (Bishop et al., 
1991). Expression of oncogenes, including ras, inyc and erbB-2 has also 
fbeen reported in a high proportion of cholangiocarcinomas. 
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erbB-2 (HER-2/neu) 
The oncogene erbB-2 located on chromosome 17q has been 
reported to be frequently amplified and overcxpressed in many 
adenocarcinomas and carcinoma of breast (Slamon et al.. 1989), 
stomach (Yokota et al., 1988), renal (Freeman et al., 1989) and ovary 
(Slamon et al., 1989; Tyson, et al., 1991; Hou et al., 1996). 
It has recently been reported that erbB-2 oncogene is 
overcxpressed in adenocarcinomas of uterine cervix (Kihana., et al., 
1994) and in CIN and invasive cancer of the cervix (Mitra et al., 1994b; 
Soh et al., 2002). Earlier studies reported by Mitra et al (1994b) on 
frequent DNA amplification of erbB-2 in primary squamous cell 
carcinoma was done by Southern Blot where chances of false negativity 
could be high and cell to cell analysis of amplified cells and 
heterogeneity of amplification in tumor was not possible. erbB-2 
amplification was studied by same authors using non-fluorescence in-
situ hybridization on primary untreated squamous cell carcinoma. erbB-
2 amplification was observed in 36.6% tumors as compared to the study 
using Southern Blot (14%) i.e. 22% extra. However both the studies 
clearly indicate that erbB-2 amplification is common in cer\ical cancer 
and is considered to be one of the mechanisms of gene over expression 
and experimental evidences indicate that erbB-2 gene plays an important 
role in development of cancer (Zhang., et al., 1989). Gene amplification 
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is one of the mechanisms, besides transcriptional and translational 
controls or a single point mutation in the gene, which may cause an 
increase in tyrosine kinase activity. The erbB-2 gene encodes a 185 kDa 
protein, which is a member of the epidermal growth factor receptor 
(FGFR) subgroup of the protein tyrosine kinase superfamily. This group 
of kinases is involved in the regulation of a variety of vital functions 
including cell proliferation, cell differentiation, and stress response. 
Alteration in the expression of the kinases occurs in numerous tumor 
types and plays an important role in tumorigenesis, cancer progression, 
and susceptibility to cell killing by anticancer agents. Constitutive 
activation of the HER-2/neu gene has been detected in sub-populations 
of many types of human solid tumors. In general, tumor cells, which 
overexpress HER-2/nue, are intrinsically chemoresistant to DNA 
damaging agents. This may be a consequence of altered cell cycle 
checkpoint and DNA repair mechanisms and dysregulation of apoptotic 
pathways. HER-2/neu overexpression can also enhance metastatic 
potential by promoting multiple steps in the invasion and metastasis 
process. In general, HER-2/neu overexpression leads to a high degree of 
malignancy and may predict a poor prognosis and shorter survival of the 
patients. Because normal critical tissues show little or undetectable 
expression of the gene, the HER-2/neu gene and its protein product are 
attractive targets for therapeutic approach. The HER-2/neu oncogene 
was first identified as a dominant transforming gene in chemically 
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induced adrenal neuroblastomas of neonate mice and was refen-ed to as 
neu. Amplification of this gene occurs frequently in breast and ovarian 
cancer, and that it is associated with disease relapse and overall patient 
sur\'ival. Detection of overexpression can be performed by a variety of 
methods. Immunohistochemistry (IHC) is the most timesaving and cost-
effective way. In addition, it offers advantage of in situ analysis. It is the 
identification of tissue constituents in situ by means of a specific 
antigen-antibody reaction tagged by a visible label. We followed the 
indirect method, which was more sensitive than the direct method. The 
procedure involved antigen retrieval, blocking of endogenous 
peroxidase, application of primary and secondary antibodies, application 
of peroxidase conjugated streptavidin and visualizing by 
diaminobenzidine (DAB) reaction. The slides were counterstained by 
Harris'hematoxylin. 
P-Cateitin 
Cell-cell adhesion in tissue is mainly regulated by homotypic 
interaction of cadherin molecules, which are anchored to the 
cytoskeleton via cytoplasmic proteins, including a and P catenins. 
Normal epithelial cells tightly bind to each other, whereas cancer cells 
exhibit a looser association and invasive behavior. Cadherin, a cell-cell 
adhesion molecule, contains a transmembrane glycoprotein that 
accounts for its homotypic adhesion in the presence of calcium and 
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plays an important role in the organization and maintenance of tissue 
structure. Both P-catenin and y-catenin binds directly to E-cadherin in a 
mutually exclusive pattern while a-catenin binds through its amino-
terminal to P-catenin or y-catenin, and through its carboxy terminal to 
the actin cytoskeleton (Hinck et al., 1994). The catenins also associate 
and form E-cadherin independent complexes with other cellular proteins 
such as the epidermal growth factor receptor (Hoschuetzky et al., 1994) 
the adenomatous polyposis coli (APC) gene product (Rubinfeld et al., 
1993) and the proto-oncogenes erbB-2 (Ochiai et al., 1994). In invasion 
and metastasis of cancers the initial step is disruption of normal cell-ceil 
adhesion in the epithelial tissue. Coupling between adjacent cells by E-
cadherin bridges results in the transmission of antigrowth and other 
signals via cytoplasmic contacts with p-catenin to intracellular 
signalling circuits that include the Lef/Tcf transcription factor 
(Christofori and Semb, 1999). E-cadherin function is apparently lost in a 
majority of epithelial cancers, by mechanisms that include mutational 
inactivation of E-cadherin or P-catenin genes (Christofori and Semb. 
1999). 
The catenins (a,p and y) are ubiquitously expressed, cytoplasmic 
proteins associated with E-cadherin at cellular junctions, a-catenin can 
also bind P-cadherin and N-cadherin. a-catenin exhibits both actin 
binding and bundling activities. f3-catenin also binds to N-cadherin and 
co-immunoprecipitates with APC. Cadherin/ catenin complexes are 
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linked to the cytoskeleton via a direct association between a actinin and 
a-catenin. Increased tyrosine phosphorylation can disrupt catenin-
cadherin complexes, influencing cellular adhesion. (J-catenin, a central 
component of the cadherin adhesion system, binds to both the 
cytoplasmic domain of cadherin and the amino-terminai domain of a-
catenin and mediates cell adhesion. Mutated P-catenin does not link E-
cadherin and a-catenin in gastric cancer cell-lines (Oyama et al., 1994). 
Mutation in APC or (3-catenin are associated with carcinogenesis and 
accumulation of cytoplasmic (3-catenin. The role of cytoplasmic (3-
catenin has been revealed to be the formation of complexes with DNA 
binding proteins of the T-cell factor-lymphoid enhancer factor (Tcf-Lef) 
family and their translocation to the nucleus, where this complex may 
regulate cell proliferation and inhibition of apoptosis (Korinek et al., 
1997; Morin et al., 1997). Thus free cytoplasmic p-catenin behaves as 
an oncoprotein (Peifer et al., 1997). 
p-catenin has two distinct roles in E-cadherin-mediated cell 
adhesion and carcinogenesis through APC gene mutation. One occurs at 
cell-adhesion sites, where cadherin become linked to the actin-based 
cytoskeleton. The other occur in the cytoplasm and nuclei and are 
thought to regulate cell transformation, therefore, reduced P-catenin 
expression at the cell membrane are associated with cancer progression, 
on the other hand, P-catenin in the cytoplasm binds to the transcription 
factor Tcf/Lcf and is transferred to the nucleus where it upregulates 
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transcriplionai activity (Korinek et al., 1997). The accumulation of 
cytoplasmic P-catenin is reported to result from the genetic mutation of 
APC and Axin (Ikeda et al., 1998) or that of (i-catenin itself (Munemitsu 
et al., 1995) Thus overexpression of beta-catenin in the cytoplasm or 
nucleus is often found in cancers of various organs, including the large 
intestine (Takayama et al., 1998), endometrium, ovaries (Davies et al., 
1998), esophagus (Yutaka Kimura et al., 1999), thyroid (Huang et al., 
1998), soft tissue (Alman et al., 1997) and liver (Nhieu et al.,1999). 
Therefore the localization (cell membrane, nuclei or cytoplasm) of p-
catenin is of considerable importance. It has been reported by Yutaka 
Kimura et al., (1999) that accumulation of free soluble P-catenin in the 
cytoplasm and nuclei frequently occurs during carcinogenesis of 
squamous epithelium of esophagus. P- catenin was expressed on the cell 
membrane in non cancerous epithelial cells while it was frequently 
expressed in the cytoplasm and/or nucleus in cancer cells (Takehiro, et 
a! 2001). P-catenin is a structural component of the E-cadherin mediated 
cell-cell adhesion system as well as signaling molecule of the 
Wnt/wingless pathway (Miller, et al., 1999). In this signaling pathway 
(Behrens, et al., 1999; Morin, et al., 1999), P-catenin functions as an 
activator of T- Cell factor (Tcf)/ lymphoid enhance factor (Lef), and 
upregulates the transcription of downstream genes including c-myc (He, 
et al., 1998) and cyclin Dl (Tetsu, et al., 1999), which may be involved 
in human carcinogenesis. At present, /^catenin gene alterations and 
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abnonnally accumulated ^cafenin protein in tumor cell nuclei have 
been reported in variety of human malignancies, such colorectal 
carcinomas, hepatoblastomas, hepatocellular carcinomas, desmoid 
tumors, Wilm's tumor, melanomas, ovarian carcinomas, prostrate 
panc^rc rMiM-ito f»t al Onni- k'o-^^' ^t al IQQO- k'nnrlr. ^t al 1999" 
Miyoshi et al., 1998; Maiti et al., 2000; Omholt et al, 2001; Ueda et al., 
2001.. Voeller et al., 1998). Mutations of P-catenin and aberrant 
expression of its protein have been identified in a number of different 
types of human malignancies. Cell-cell adhesion in tissue is mainly 
regulated by homotypic interaction of cadherin molecules, which are 
anchored to the cytoskeleton via cytoplasmic proteins, including alpha-
and beta-catenin. Although Takayama et al., (1996) previously 
demonstrated that alpha-catenin is crucial for cadherin function in vivo; 
little is known about the role of beta-catenin. From an 
immunoprecipitation study, further Takayama et al., (1996) found that 
j3-carenin fomis a complex with E-cadherin not only in the nornial 
epithelium but also in cancerous tissues. Their findings suggested that P-
catenin fonns a complex with E-cadherin in vivo and down-regulation of 
beta-catenin expression is associated with malignant transformation. 
Perturbation in the expression or function of the E-cadherin-catenin 
complex results in loss of intercellular adhesion, with possible 
consequent cell transformation and tumor progression (Huiping et al., 
2001). 
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In view of the above review, it was noted that LOH at 3p was 
reported in many human cancers including cervical cancer. However, 
LOH at 5p was found to be a novel one and not reported in any other 
cancer. This study attempts to present further data on various genetic 
alterations and HPV infection prevalent in the cancerous lesions of 
uterine cervix, to have a comprehensive view. 
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4. MATERIALS AND METHODS 
Collection of samples: 
Biopsy and blood specimens 
Tumor samples from 83 cervical carcinomas were collected between the year 2000 
and 2003 from four major hospitals in Delhi. Clinically majority of the tissues of 
cancer patients belonged to stage II or III (FIGO classification) and histologically 
all the tumors were well to moderately differentiated squamous cell carcinoma. 
Corresponding blood samples were also obtained from the same patients after 
taking proper consent 
Cervical smear for HPV testing 
Cervical smears of the women who visited cancer clinics were collected in 
IX PBS (Phosphate buffer saline) and transported to the laboratory for HPV 
testing. A detailed questionnaire with proper consent of the patient was also filled 
by the trained social workers, keeping in view the privacy and secrecy of the 
patient as per the ethical guidelines. All the samples were transported in ice at 4°C 
and, stored at -20 C till further processing. Cervical scrapes were vortexed along 
with the wooden spatula, and poured in 1.5ml eppendorf tubes after removing the 
spatula. Then the eppendorfs were centrifuged at 2000 rpm for 2 minutes at 4°C. 
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Paraffin embedded tissue sections 
Paraffin embedded tissue sections were obtained from the biopsy specimens of 
cervical carcinoma, on Poly-L-Lysine coated slides for immunohistochemistry. 
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to Stop further tissue changes after removal from body and subsequently 
embedded in supporting material such as paraffin allowing sections (usually lOfi 
thickness) to be cut for examination by microscopy. The sections were 
histologically graded by experienced cytopathologists. 
Preparation of Genomic DNA 
DNA Extraction from tissue biopsies 
1. Frozen tissue was taken out from -70°C deep freezer and allowed to thaw. 
2. Tissue IS transferred to a disposable petridish, containing small amount of dry 
ice, and tissue was minced with the help of sterilized sharp surgical blade 
3. 2 5ml of Ix TE was added to the petridish and the tissue homogenate was 
transferred to the falcon tube (50ml) by the help of 1ml pipette man. The 
petridish was rinsed with 1.5ml Ix TE. 
4. Lysis buffer was added in the ratio of 1:2 i.e. 50% of the total volume i.e. 2ml 
in the present case. 
5. Proteinase K was added to a concentration of lOOp-g/ml. 
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6. The contents of falcon were mixed and incubated at 37 C for 1-2 hours or 50 C 
for overnight. 
7. Equal volume (6ml) of TE equilibrated phenol was added and mixed 
thoroughly on overhead shaker for 15-30 m.inutes. 
8. The mixture was centrifuged at 3000-4000 rpm for 15 minutes at 4°C. 
9. Supernatant was transferred to a fresh falcon tube with the help of Pasteur 
pipette. 
10. Equal volume of phenol + CIA (1:1) was added to the supernatant. (CIA = 
Chlorofomi: Isoamyl alcohol: : 24 : 1). 
11. The mixture was mixed thoroughly on overhead shaker for 15-30 minutes and 
centrifuged at 3000-4000 rpm for 15 minutes at 4°C. 
12. Supernatant was transferred to a fresh falcon tube. 
13. Equal volume of CIA was added and mixture was again mixed thoroughly on 
overhead shaker for 15-30 minutes and centrifuged at 3000-4000 rpm for 15 
minutes at 4 C and supernatant was transferred to a fresh falcon tube. 
14. To the supernatant thus obtained 1/10 volume of chilled 3M sodium acetate 
solution and 2.5 volume of absolute ethanol were added. 
15. The falcon was then shaken very gently and the spool of DNA was obtained. 
16. The spool of DNA was transferred very carefully to an 1.5 ml eppendorf by the 
help of pipette man with autoclaved tip. 
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17. The DNA was washed in 70% ethanol twice in order to remove salts that may 
interfere in the amplification reactions (washing done by centrifuging for 5-10 
minutes at 3000-4000 rpm). 
18.200^1 of IXTE was added to dissolve the pellet and the storage tube is left 
overnight at 37"C and afterwards is stored at 4 C. 
19. The amount of DNA was measured by running 1 or 2|j.l aliquot in a 1% 
minigel with Hind lll-digested Lambda DNA molecular weight marker. Using 
spectrophotometer did accurate measurement 
DNA Extraction from blood 
1. 2-5ml of heparinised blood is taken in 50ml falcon tube. 
2. 20ml of lysis solution (155mM NH4C1, lOmM KHC03 and O.ImM EDTA) 
was added to it. 
3. The falcon was kept at 4'^ C for one hour and then centrifuged at 4000rpm for 
10 minutes at 4"C. 
4. The supernatant was discarded and the pellet was resuspended in 20ml SE 
(75mM NaCl, 20mM EDTA pH 8.0). 
5. Proteinase K was added to a concentration of 100|ig/ml. 
6. 2ml of 10% SDS solution was added and the contents were mixed well in order 
to ensure that no cell clumps remain. 
7. The falcon was incubated at 37*^ C for overnight. 
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After this step protocol from DNA extraction from tissue biopsies was followed 
from step 7 to step 19. 
DNA extraction from cervical smear for HPV Testing 
The DNA isolation involves basically two steps first washing the pellet 
twice with Tris-Triton Buffer (TTB) and PK digestion in Tris-EDTA Buffer 
(TTB). 1.5ml of the sample containing scraped cervical cells was taken in 1.5ml 
Eppendorf tube and centrifuged at 5000 rpm for 5'. The pellet was again washed 
with chilled IXPBS and cold centrifugation was done for 2 min at 2000 rpm. The 
pellet was washed twice in 1ml chilled TTB containing lOmM Tris-HCI (pH 8.0), 
lOmM MgC12, 300mM Sucrose and 0.8% Triton-X 100. The pellet was collected 
and rewashed in 0.5ml Cold TE Buffer containing lOMM Tris-HCI (pH 8.0), 
lOmM EDTA and lOmM NaCl. Finally the pellet was resuspended in 200^1 TE 
buffer supplemented with 1.25mg/ml PK and incubated at 65 degrees Celsius for 
2.5hrs. The tubes were vigorously shaken every half-hour in order to allow 
uniform lysis of the pellet. When the solution became transparent it was assumed 
that extraction was completed was boiled at 95 degrees for 10 minutes for PK 
inactivation. Now the samples were ready for phenol chloroform extraction (if 
required). 
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Analysis of microsatellite instability 
Microsatellite instability was analyzed on 83 cervical carcinomas using the 
Bethesda Consensus Conference reference panel of five markers, Bat-25, BAT-26, 
D2S123 (AFM093xh3), B5S346 (APC) and D17S250 (Mfd215 CA) (Boland et 
al., 1998). 
Table: 4.1 Characteristics of the markers used for microsatellite instability 
analysis. 
Namt Clir Repeat Primer seq TmC'C) Size(bp) 
BAT 25 4q TTTT.T.TTTT(T)7A(Th5 TOG OCT CCA AGA ATG TAA GT 58 
TCT GCA TTT TAA CTA TGG CTC 
-90 
BAT 26 2p (T)5 (A)2, 
APC 5q21/22 (CA)26 
TGA CTA CTT TTG ACT TCA GCC 58 
AAC CAT TCA ACA TTT TTA ACC 
ACT CAC TCT AGT GAT AAA TCG' 55 
AGC AGA TAA GAC AGT ATT ACT AGTT 
-80-100 
96-122 
Mfcl15CA 17q11.2-12 (TA)7....(CA)24 GGA AGA ATC AAA TAG ACA AT 
GCT GGC CAT ATA TAT ATT TAA ACC 
52 -150 
AFM093xh 32p16 {CA),3TA(CA),5(T/G A)? AAA CAG GAT GCC GCC TGC CTT TA 60 
GGA CTT TCC ACC TAT GGG AC 
197-227 
One primer (usually the forward) was endlabelled with [y-^ ^P] ATP with a specific 
activity of greater than 500Ci/mmol (185 TBq/mmol), using Polynucleotide 
Kinase (PNK) and (O.IM) ditrio-threitol DTT at 37°C for one hour. 
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[y-'^P| ATP (LCP 101) 
(Board of Radiation and Isotope Technology, JONAKI Laboratory) 
Adenosine triphosphate labelled in the y-position prepared by enzymatic 
phosphorylation of the corresponding nucleoside 5' diphosphates with 
very high specific activity P orthophosphoric acid. The triphosphates 
are purified by HPLC using strong anion exchange column. 
End labelling Mix 
Primer (F) 2|iL 
T4 PNK 4|iL 
T4PNK buffer l^L 
DTT(O.IM) l^iL 
^¥ [YATP] 3HL 
Two reactions are set at 37°C for one hour in thermal cycler. 
Polymerase chain reaction 
After endlabelling the primer is added to the PCR mix and a 
standard polymerase chain reaction was carried out in a 25fiL reaction 
volume containing 30-50ng DNA, 20pmol of primers. Amplification 
reactions were carried out for 35 cycles at annealing temperatures 
ranging from 52°-56°C using 1 Unit of Taq DNA Polymerase {Roche, 
Applied Biosystems), 2.5mM MgC12 and 200|iM dNTPs {New England 
Biolab). The amplification was first checked on 2% agarose and finally 
resolved on 6% denaturing Polyacrylamide/ Urea gel (40cm x 20cm x 
0.5mm) i.e. slightly thicker than the usual sequencing gel. Gel was 
polymerized in the presence of urea and formamide that suppresses base 
52 
pairing of nucleic acids, alkali was not used as denaturing agent because 
it deaminates acrylamide. The DNA was denatured by heating the PCR 
products at 95°C and immediately placed in ice to prevent base pairing. 
Denatured DNA migrates through these gels at a rate that is completely 
independent of its base composition and sequence. In the presence of 
free radicals usually supplied by APS and stabilized by TEMED, a chain 
reaction is initiated in which monomers of acryl amide are polymerized 
into long chains whereas N,N' methylenebisacrylamide is included in 
the polymerization reaction, the chain becomes cross linked to form a 
gel. 
Preparation of glass plates 
• Plates were washed properly 
• Cleaned the plates first with distilled water then with alcohol 
• Applied siliconizing solution (Sigma Cote) on one of the plates 
• Sealed the glass plates with tapes placing appropriate spacers 
(0.5mm) 
• Placed the tabs on the two upper edges with clamps 
Preparation of the Sequencing mix 
• lOOmL of the Acryl amide stock was taken 
• To it was added 700|iL of 10% APS. Mixed well, taking care of the 
aeration of the sample. APS provides the free radicals that drive 
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polymerization of acryl amide and bisacrylamide. APS decomposes 
slowly, and fresh solutions should be prepared weekly. 
• 40|iL of TEMED (N,N,N', N ' - tetramethylethylenediamine) was 
added immediately before pouring, mixed the solution by swirling. 
TEMED accelerates the polymerization of acryl amide and 
bisacrylamide by catalizing the formation of free radicals from 
ammonium persulphate. 
• Gel was poured keeping the plates at an angle of 45° slowly, from 
the middle taking that care no air bubble is trapped inside 
• The comb was inserted and allowed the gel to polymerize for one 
hour at room temperature; additional acryl amide was added if the 
gel retracts significantly. When the gel was completely polymerized, 
a schieren pattern becomes visible just beneath the teeth of the comb. 
• After the polymerization was complete the comb and the tapes were 
removed carefully and the wells were rinsed with water immediately 
and the small amounts of acryl amide trapped in the wells are flushed 
out with IX TBE which if not cleansed create distorted bands which 
are difficult to interpret. 
• Plates were fixed on sequencing gel apparatus 
• Poured 0.5 X TBE in both the chambers of sequencing apparatus 
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Pre Heating of the gel 
• Gel was pre heated for about 10 minutes with loading dye in 2-3 
lanes prior to loading of the samples. 
Conditions for running the gel 
2000V, 170W, 90mA 
Preparation of samples 
• The samples were diluted with 50|iL dilution buffer 
• The samples are then mixed with 6X buffers (loading dyes), they 
increase the density of the sample ensuring that the DNA was 
dropped evenly into the well and they add color which make tracking 
easier and they contain dyes that move towards anode at predictable 
rates. 
• Denatured the samples at 95°C for 5 minutes and place immediately 
in ice. 
Loading of samples 
• The wells were gently cleaned by flushing out air bubbles from each 
well with the help of dropper 
• Samples were loaded (2-3|iL/well) immediately after taking out from 
ice; total time in loading should not exceed 20 minutes. 
• Electrophoresis was carried out by connecting the electrodes to the 
power pack. •* 
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• The gel was run (for 2.5 hrs) until the marker dyes have migrated to 
the desired distance. Electrophoresis buffer was discarded from the 
reservoirs after disconnecting the power supply and glass plates were 
detached. 
Removal of the glass plates 
• After disconnecting the power supply the buffer was drained 
carefully as it contained radioactivity. 
• The plates were rested on working table and allowed to cool (RT) 
• Placing a spatula in between lifted the smaller plate spacers were 
also separated. 
• A 3MM What man paper was placed over the gel, pressed gently and 
uniformly all over and lifted up along with the gel carefully taking 
care of the sequence of the wells by cutting a small comer at the site 
of the first well 
• Cellophane or saran wrap was wrapped over the gel, avoiding 
bubbles or folds in the Saran wrap. 
• The gel was placed on the gel drier (BioRad) 
• Dried the gel for one hour at 80"C 
Autoradiography was done by exposing the gel on X-ray film (Kodak) 
for 24 to 48 hours. 
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Autoradiography 
• The dried gel was placed in the cassette 
• Film (Kodak) was placed on to the gel in dark room making a mark 
(fold or cut) at the comer to indicate the start of loading 
« The cassette along with the film, was kept in -20°C for exposure 
• After 24-48 hours of exposure the film was developed and fixed in 
dark 
• The film was ready for analysis 
Autoradiography produces permanent images on photographic film. The 
two isotopes most commonly used for autoradiography are S and P, 
both of which emit f3-particles. The energies of these particles are very 
different. ^^ S emits a particle with a maximum energy of 0.167MeV that 
can penetrate film emulsion only to depth of 0.25mm (although 
sufficient for the interaction betsveen the emitted P-particle and the 
silver halide crystals in the film emulsions). ''^ P emits a particle with 
comparatively high energy (1.71 MeV) that can pass completely through 
an X-ray film. To increase the efficiency, an intensifying screen is 
applied below the film in the cassette and exposed at low temperatures 
(recommended = -70°C). 
Increase and decrease in the size of repeats as compared to their normal 
counterpart was considered evidence of instability. Two common band 
patterns were observed, either a novel discrete band in tumor DNA not 
observed in the corresponding normal DNA or as a marked alteration of 
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repeat length, often heterogeneous in nature and appeared as a ladder. 
RMA for individual primers were also calculated. [RMA = Number of 
cases with microsatellite instability/ total number of cases]. 
Analysis of loss of heterozygosity 
In addition to microsatellite instability, a detailed analysis of loss of 
heterozygosity was performed on the 83 cervical carcinomas cases with 
a panel of five different polymorphic markers of chromosomes 3p (3p 
14.2 to 5pl4.12) and 5p (5pl5.1-15.3). 
Table: 4.2 Characteristics of tlie markers used for LOH analysis. 
MARKERS AMPLIMER AMPLICON 
SIZE 
D3S1234 5'-CCTGTGAGACAAAGCAAGAC-3' lllbp 
5'-GAC ATT AGG CAC AGG GCT AA-3' 
D3S1300 5'-AGCTCACATTCTAGTCAGCCT-3' 236bp 
5'-GCC AAT TCC CCA GAT G-3' 
D3S1313 5'-CCCCTTGGAAAATCACTG-3' 233bp 
5'-CCA TGA ATA AGC CTT GCC-3' 
D5S208 5'-ACCTGA GTC TTC ATC AAT AC-3' 186bp 
5'-TCC AGA ATC ATC CAT GTT GT-3' 
D5S406 5'-CCTGCC AAT ACT TCA AGA AA-3' 185bp 
5'-GGG ATG CTA ACT GCT GAC TA-3' 
Tumor DNA was extracted from cervical biopsy and 
corresponding normal DNA (constitutional DNA) was extracted from 
blood. End labeling of one of the two (usually forward) primer was done 
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with [y-^ ^P] ATP using T4 Polynucleotide Kinase (PNK) and (O.IM) 
ditrio-threitol DTT at 37°C for one hour as described earlier. 
Amplification was done in the thermal cycler {Ependdorf/ Perkin Elmer) 
using 1 Unit of Taq DNA Polymerase with 95° of initial denaturation, 
52"-56°C annealing and a final extension of 72V. The amplified 
products were resolved on 6% Urea Polyacrylamide (denaturing) gel at 
2000 Volts, 170 W and 90mA for 2.5 hrs. Steps involving preparation of 
glass plates, sequencing mix, preparation and loading of samples and 
autoradiography were similar to that described in microsatellite 
instability analysis. 
Absence or decrease in signal intensity by more than 50% of one 
allele in tumor DNA compared with constitutional allele was considered 
evidence for LOH. The cases, which were homozygous for the allele, 
were taken as non-informative and were not included in the study. 
HPV Detection 
Detection of HPV was done by two methods: 
a) Polymerase chain reaction using consensus primers 
b) Digene Hybrid Capture Assay - II (DHCA-II) 
HPV Detection by PCR 
PCR is an in-vitro method for primer directed enzymatic 
amplification of specific target DNA sequences over a million times in a 
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few hours (Saiki et al 1985, Mullis et al 1987, Morris ct a! 1988). The 
detection level of PCR for HPV DNA has been estimated to be 10-100 
HPV DNA molecules among 5x 10'* cells. Several studies have been 
performed to assess the sensitivity of PCR to detect HPV in clinical 
samples. Dallas et al 1989 estimated the sensitivity of PCR to be 10 
copies of virus (0.08fg of DNA) in a 10,000-cell sample subjected tooL 
36 cycles with Taq Polymerase. Similar sensitivities have been reported 
by a number of subsequent studies. To exclude false positive results 
appropriate negative controls are mandatory. False negativity due to 
factors inhibiting polymerization can be avoided by proper DNA 
extraction. 
P-globin primers PC04 (5'-CAACTTCATCCACGTTCACC-3' )and 
GH20 (5'-GAAGAGCCAAGGACAGGTAC-3') (Saiki et al., 1988), 
which produces a 268bp PCR product, were used as the internal 
amplification control. Extra precautions were taken to avoid cross 
contamination of the amplified products. The samples were screened for 
the presence of HPV, with positive and negative controls, by amplifying 
them with consensus primers (MY09-
CGTCCMARRGGAWACTGATC and MYll-
GCMCAGGGWCATAAYAATGGj (Manos et al., 1989) from the LI 
region of HPV genome, which detects a broad spectrum of HPV types. 
[M= A/C; W=A/T; Y=C/T; R=A/G] 
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1 |al of the DNA was amplified in Thermal Cycler (Eppendorf), with 
MY09 and MY 11 consensus primers (Microsynth) of LI region of HPV 
genome, covering both low and high-risk HPV types. The amplification 
was done using Taq DNA Polymerase I OX Buffer with 2.5mM MgCla, 
and dNTPs (Bangalore Genci), at initial denaturation of 95^ for 5 
minutes following 35 cycles of; 
94" 30 sec 
56° 30 sec 
72° 30 sec each 
and a final extension of 72° for 10 minutes 
8|iL of the samples were loaded for resolution on 2% agarose and 
visualized after ethidium bromide staining. 
HPV Detection Using DHCA-II 
The HC-II test is a signal amplified hybridization antibody capture 
microplate assay for the chemiluminiscent detection of human 
papillomaviruses Types 6, 11, 16, 18, 31, 33, 35, 42, 43, 44, 45, 51, 52, 
56, 58, 59 and 68. We used Digene Hybrid Capture Assay for the 
detection of High Risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 55, 56, 
58, 59, 66 and 68) using single probe method. Specimens containing 
target DNA hybridize with a specific HPV RNA probe cocktail. The 
resultant RNA: DNA hybrids are captured onto the surface of a 
microplate well coated with antibodies specific for RNA: DNA hybrids. 
Immobilized hybrid cells are then reacted with alkaline phosphatase 
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conjugated antibodies specific for the RNA: DNA hybrids and detected 
with a chemiluminiscent substrate. 
Reagent Preparation 
All reagents supplied with the DHCA-II kit (Cat #: 5101-1096IVT) were 
ready to use except denaturation reagent, HPV probes and Wash buffer. 
Denaturation reagent 
5 drops of indicator dye (provided) was thoroughly mixed with 
denaturation reagent. 
HPV Probe A Cocktail 
For 96 wells we pipetted 140|iL of HPV Probe A into 3.5mL Probe 
dilutent. 
Wash Buffer 
lOmL of Wash Buffer concentrate was added to 2.9mL of distilled or 
deionized water. 
Steps: 
Deanaturation 
• The hybridization tubes were labeled and denaturation reagent was 
pipetted out (half the volume of the specimen) and added to Control, 
Calibrators and Specimens and the colour of the tubes become 
purple. 
• The tubes were incubated at 65°C for 45 minutes. In the mean time 
HPV Probe mix was prepared. 
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Hybridization 
• Pipetted 25|iL of Probe A into tubes labeled "A", and to each tube 
was added the denatured specimen (75}iL), the microtubes were 
covered by a plate sealer and after shaking on Rotary shaker at 1100 
i-pm for 3' the colour of the tubes became yellow then the tubes were 
incubated at 65°C for 5 minutes. 
Capture 
• The contents from the microtubes were transferred to he 
corresponding well in Capture Microplate, sealed with a plate sealer 
and again shook at 1100 rpm at 20-25°C for 65'. In the meantime 
wash buffer was prepared. 
• Decant and blot Capture Microplate. 
Conjugation 
• 75)iL of Detection Reagent 1 was added into each well of Capture 
Microplate covered with parafilm and incubated at 20-25*^ C for 30 
minutes. 
• Decant and blot Capture Microplate. 
Washing 
• The plate was washed three times, raining 5 minutes on absorbent 
paper each time and blotted. 
General Signal 
• 75|iL of Detection Reagent 2 was added to each well of Capture 
Microplate and incubated at 20-25"C for 15 minutes. 
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• The Capture Microplate was read on Luminometer. 
Detection of HPV types 
All the positive cases were amplified individually with type specific 
primers for each type viz. 6, 11, 16, and 18. 
Table 4.3 : Markers for detection of HPV types. 
HPV Type 
Type 6 (F) 
(R) 
Type 11 (F) 
(R) 
Type 16 (F) 
(R) 
Type 18 (F) 
(R) 
5' 
5' 
5' 
5' 
5' 
5' 
5' 
5' 
Primer Sequence 
-TAGTGGGCCTATGGCTCGTC-3' 
-TCCATTAGCCTCCACGGGTG-3' 
-GGAATACATGCGCCATGTGG-3' 
-CGAGC AGACGTCCGTCCTCG-3' 
- AAGGCCAACTAAATGTC AC-3' 
-CTGCTnTATACTAACCGG-3' 
- ACCTTAATGAAAAACCACGA-3' 
-CGTCGTTGGAGTCGTTCCTG-3' 
Ampiicon 
Size (bp) 
280 
360 
217 
100 
Each sample was amplified with every primer to detect the above five 
types using following cycles: Initial denaturation 95°C for 5 minutes 
followed by 35 cycles of 94°C for 30 sec, 56V for 30 sec and itC for 
30 sec each and a final extension of 72V for 7 minutes. The samples 
were then resolved on 3% agarose (2% agarose + 1% Nuisive) along 
with (t)X174 (Hae III) digested marker and stained with EtBr. The gel 
was visualized under UV. 
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Detection of HPV Types Using RFLP of LI Amplicon 
We developed a new rapid and cost-effective PCR- RFLP 
technique, using restriction digestion with Rsa 1, of the amplified 
products of Ll region (by MY09/11 consensus primers) (Naqvi et al., 
2004). Detection of human papillomavirus (HPV) types 6. 11, 16, 18 
and 33 including co-infections among females attending gynecological 
out patient department and cancer clinics, was done by restriction 
fragment length polymorphism (using Rsa-1), of approximately 450bp 
amplicon, obtained by the amplification of the Ll region of HPV 
genome with consensus primers MY09 /ll(Manos., et al., 1989). The 
degenerate primers MY09/11 used for amplifying Ll region, accepts 
certain degree of mismatch between primers and target DNA, 
accomplished by reducing the stringency of primer annealing, there 
being always a difference of few bases in the amplicon for different 
HPV types, which are not distinguishable in lower concentration of 
agarose gels. The product (amplicon) sizes amplified by MY09/11 
primers for HPV type 6 was 447bp; HPVll-449bp; HPV16-452bp, 
HPV18-455bp and for HPV33 was 449bp, which after digestion with 
Rsa 1 (recognition sequence GT'AC) gives the following band sizes 
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Table 4,4 showing the number of possible cuts and the sizes of the 
fragments resolved after the digestion of LI amplicon with Rsa 1 for 
different HPV types. The bold values indicate the distinguishing 
bands. 
Type No. of cuts Fragment sizes 
HPV6 3 72,67, 149 and 159 
HPV 11 3 72,216,26 and 135 
HPV 16 2 72,70 and 310 
HPV 18 4 72,38,85, 125 and 135 
HPV 33 3 72, 39, 236 and 102 
RFLP of the PCR products of all the HPV positive samples was 
done using 1 Unit of Rsa 1 (New England Biolab; Catalog No. 167 L) 
with NEB reaction buffer, and incubating at 37^C for 1 hour. After 
digestion the products were resolved on 8% Polyacrylamide non 
denaturing gel with TEE buffer, after 30 minutes of staining with 
ethidium bromide, the products were visualized under UV/gel 
documentation system (BioRad) using the software Quantity One. The 
bands show the types of HPV present including their co-infections. 
Analysis of mutant CYP2D6 alleles by Polymerase Chain 
Reaction 
40-60ng of DNA was taken as template and standard polymerase 
chain reaction was carried out in a 25|iL reaction volume, with 20pmol 
of primers. An initial strand separation step was carried out at 94''C (4 
min), and 35 cycles of: denaturation at 94"C for 30 sec, primer annealing 
at 60 C for 1 min. and polymerization at 72"C for 1 minute, and final 
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polymerization for 7 minutes at 72"C to complete elongation of all 
amplified strands. 1 Unit of Taq DNA Polymerase (Roche, Applied 
Biosysteins), 2.5mM MgC12 and lOO^M dNTPs {New England Biolab) 
were used in the reaction and the amplified products were resolved on 
10% non-denaturing Polyacry!amide/TBE gel. The bands were 
visualized after ethidium bromide staining under gel documentation 
system (BioRad). The high annealing temperature is required in order 
that the pfprimers used annealed only to CYP2D6 sequences and not to 
the hi^ly homologous CYP2D7 or CYP2D8P gene. 
Primer pairs CYP 1 (Exon 3: 5'- GCCTTCGCCAACCACTCCG - 3'), 
CYP 2(Intron 4:5'- AAATCCTGCTCTTCCGAGGC -3') 
and CYP 3 (Exon 5: 5'-GATGAGCTGCTAACTGAGCcC-3'), 
CYP 4 (Intron 5:5'-CCGAGAGCATACTCGGGAC - 3') 
were used to amplify regions of CYP2D6 gene over the mutations to be 
identified. Amplification with CYPl and CYP2 generates a 334bp 
fragment which, as a consequence of G to A transition at the junction of 
intron 3/ exon 4, is resistant to digestion with the restriction enzyme 
BstNl. primer CYP3 contains a one base pair mismatch to the CYP2D6 
sequence (shown in lower case) which makes the 268bp PCR fragment 
produced from individuals with the exon 5 mutation sensitive to 
digestion with the restriction enzyme Hpa II at the site of the base pair 
deletion. The other Hpa II site present in all individuals. Amplification 
conditions for each assay were as previously descried. 
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All restriction enzyme digests were carried out overnight using 
25nL of PCR mixture and lUnit of restriction enzyme in IX restriction 
buffer concentration. For Polyacrylamide gel electrophoresis the 
restriction enzyme digests were mixed with an appropriate running dye 
(BPB). A. diagrammatic representation of the expected banding patterns 
of amplified DNA is described in chapter 8. The digested products were 
resolved on 10% non-denaturing Polyacrylamide/TBE gel and 
visualization of the bands was done by ethidium bromide staining. 
Expression of erbB-2/Her-2 neu, P-catenin by 
immunohistochemistry 
Paraffin-embedded specimens of 83 cervical carcinomas cases 
examined microscopically, were obtained on Poly-L-Lysine coated 
slides. Cellular localization and expression of HER-2/neu and P-catenin 
was investigated by immunohistochemistry in all samples. 
erbB-2 (cellular localization cell membrane) is a receptor tyrosine kinase 
of the erbB family, p-catenin is a structural component of the E-cadherin 
mediated cell-cell adhesion system as well as signaling molecule of the 
Wnt/wingless pathway. 
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Coating slides with Poly -L-Lysine 
Poly -L-Lysine is an adhesive solution used in adhering tissue sections in 
glass slides, particularly useful with immunohistochemical techniques. 
The Poly -L-Lysine solution Sigma (Cat # P8920) was diluted 1:10 with 
deionized water prior to coating slides. 
The Microscope slides were washed with SDS and then dipped in 
1%HC1 prepared in 70% alcohol for 5' and dried to make the slides 
grease free before coating with Poly-L-Lysine and dipped in diluted 
Poly -L-Lysine solution for 5' at 18-26°C. The slides were then 
incubated at 60"C for one hour or 18-26°C overnight. The coated slides 
can then be stored at 4°C. 
Immunohistochemical staining procedure 
Deparaffinizadon 
1. The slides were dipped in Xylene for 10 minutes (3 changes) 
2. Then 5-10 dips were given in acetone 
3. 5-10 dips in 95% ethanol 80% ethanol and 70% ethanol 
4. The slides were kept in slowly running tap water for 15 minutes 
5. Microwave antigen retrieval technique was applied, i.e. the 
slides were boiled resting flat with sections facing up in lOmM 
citrate buffer for 30 minutes using microwavable glass container, 
then allowed to cool to room temperature and the slides were 
washed briefly with Tris-HCl buffer (twice). 
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6. To block the endogenous peroxidase the slides were immersed 
in coplin jar containing 96mL methanol and 4mL hydrogen 
peroxide for 25-30 minutes at room temperature. Endogenous 
peroxidase blocking solution must be prepared fresh, 
immediately before use. 
7. The slides were then washed in two changes of Tris HCl buffer 
for a total of around 20 minutes. Tapping off excess buffer the 
slides were wiped around the specimen with filter paper. 
8. The slides were kept in moist chamber and the primary 
antibody was applied covering the entire specimen. 
9. The slides were incubated at 4°C overnight in the humid 
chamber. 
10. After removing from the moist chamber the slides were washed 
in two changes of Tris HCl at the intervals of 10 minutes. 
11. Biotinylated secondary antibody was applied and incubated at 
room temperature for one hour. 
12. Again with two changes of Tris HCl the slides were washed at 
the interval of 10 minutes. 
13. Peroxidase conjugated streptavidin was applied and kept at 
room temperature for one hour. (It is used in a labeled 
streptavidin-biotin immunoenzymatic antigen detection system. 
This technique involves the sequential incubation of the specimen 
with unconjugated primary antibody specific to the target antigen, 
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a biotinylated secondary antibody that acts with the primary 
antibody, enzyme labelled streptavidin and substrate-chromogen). 
14. Slides were washed in two changes of Tris HCl buffer for 20 
minutes. 
15. DAB solution was prepared (immediately before use) and applied 
controlling the intensity under microscope using known positive 
control as guide. 3-3'Diaminobenzidine (DAB) is a widely used 
chromogen for immunohistochemical staining and 
immunoblotting. In the presence of peroxidase enzyme, DAB 
produces a brown precipitate that is insoluble in alcohol. This 
product is available in two component form DAB chromogen and 
DAB substrate. The standard working dilution is 40|iL (0.9mg) 
of DAB chromogen per ImL of DAB substrate. Once the two 
components are combined the reagent can be used for upto six 
hours.Combine 1-2 drops (40-100|iL) of DAB chromogen with 
each ImL of DAB substrate and apply mixture to the tissue 
section. Incubate for 5-15 minutes. 
16. Immersing the slide in distilled water stopped the DAB reaction 
and then it was washed thoroughly (with distilled water). 
17. The slides were then counterstained lightly with Harris' 
hematoxylin and dried thoroughly at room temperature. 
18. Then it was mounted with coverslip using DPX, a mounting 
medium and labeled appropriately. 
19. The slides were then observed under microscopes with positive 
and negative controls that were run during every batch of 
staining. 
20. Positive control = Appropriate tissue sections known to express a 
particular antigen. 
Negative control = Eliminate the step of primary antibody 
application rest remaining unaltered. 
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5. MICROSATELLITE INSTABILITY 
Introduction 
Microsatellite instability (MSI) is characterized by small 
deletions or expansions within short tandem repeats in tumor DNA as 
compared with matching normal DNA. Most polymorphisms occur in 
the 97% of the non-coding junk DNA of the human genome, variations 
therein are functionally inconsequential and hence well tolerated during 
evolution. Much of this noncoding DNA consists of highly repetitive 
DNA segments, one such class in humans consists of simple tandem 
repeats (STRs). Such repeats of 2-3 nucleotide segments, known as 
microsatellite DNA are unique to each individual. All of the proteins 
coding regions account for only about 3% of the human genome. Most 
non-coding regions of DNA may be located within genes (introns) or in 
between the genes. Since these regions do not code for any functional 
protein, variations in these regions are well tolerated during evolution 
allowing tremendous genetic diversity to develop in these regions. Clues 
to the mechanism underlying the molecular basis of tumor microsatellite 
instability emerged from the study of the effects of mutations within the 
mismatch repair proteins were localized and cloned and their role in 
HNPCC was examined. Greater than 80% of HNPCC tumors 
demonstrated microsatellite instability (Aaltonen et ai, 1994). 30% of 
families with HNPCC have germline mutations in liMSH2, while 
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another 30% in liMLHl (Wijnen et ai, 1996). The presence of MSI has 
been reported in a variety of malignancies. Colorectal cancer was the 
first type of human malignancy in which MSI was described (Aaltonen 
et al., 1993; Thibodeau et al., 1993; lonov et al.,1993). The reported 
genomic instabilities involved mono-di and tri-nucleotide repeats and 
occurred in hereditary as well as sporadic cancer. Tumor microsatellite 
instability can be detected in a PCR based assay by comparing tumor 
DNA to that derived from normal tissue of the same patient. Alterations 
of length of simple repetitive genomic sequences (microsatellite 
instability) characterize a distinct mechanism of carcinogenesis. MSI 
analysis has become an attractive method for both diagnostic and 
tumoribiological purposes (Dietmer et al., 1997). Instabilities in the 
microsatellite region of tumor DNA have been observed when compared 
with the normal allele of same patient showing either an expansion or 
contraction on one or both alleles in some tumors. Variations in such 
microsatellite regions are generated by errors in DNA replication. Since, 
microsatellite instability is one of the defects 'mismatch repair' is 
supposed to prevent, indicates a defective mismatch repair system. 
In December 1997, the National Cancer Institute sponsored a 
workshop on "Microsatellite Instability and RER Phenotypes in Cancer 
Detection and Familial Predisposition" and recommended the Bethesda 
Guidelines developed in 1996 to assist in selection of tumors for MSI 
analysis. Over the past five years the scope of MSI has been expanded to 
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encompass a unique form of genetic instability broadly involved in the 
genesis of cancer ( Boland et al., 1998). 
Materials and Methods 
Materials and Methods used in the study have been described in Chapter 
4 in detail, briefly described as follows: 
Tissue Samples: Tumor biopsy specimens and corresponding peripheral 
blood samples (2-3mL) were obtained after appropriate consent was 
granted from patients who attended the cancer clinic. Clinically the 
majority of the tumors belonged to stage II or III, 77 tumors had 
moderate to well differentiated histology and 6 tumors were of poorly 
differentiated type. 
Method: DNA was prepared from blood and biopsy samples by 
standard phenol chloroform methods (Sambrook et al., 1989). 40-60ng 
of DNA was taken as template for the PCR. 
Table 5.1 Primer used in the analysis of microsatellite instability 
Name Chr Repeat Motifs Primer sequence Tm (°C') 
BAT 25 4q TTTT.T.TTTT(T)7.A(T)26 TCG CCT CCA AGA ATG TAA GT 58 
TCT GCA TTT TAA CTA TGG CTC 
BAT 26 2p (T)5 (A)26 TGA CTA CTT TTG ACT TCA GCC 58 
AAC CAT TCA ACA TTT TTA ACC 
D2S123 2pi6 (CA),jTA(CA)i5(T/GA)7 AAA CAG GAT GCC GCC TGC CTT TA 60 
GGA CTT TCC ACC TAT GGG AC 
APC 5q21/22 (CA)26 ACT CAC TCT AGT GAT AAA TCG" 55 
(D5S346) GC AGA TAA GAC AGT ATT ACT AGT T 
Mfd15CA 17q11.2-12 (TA)7....(CA)24 GGA AGA ATC AAA TAG ACA AT 52 
(DI7S250) GCT GGC CAT ATA TAT ATT TAA ACC , 
75 Microsatellite Instahility 
Polymerase Chain Reaction 
A standard Polymerase chain reaction was carried out in a 25[iL 
reaction volume containing 30-50ng of DNA as template, 20pmol of 
primers. One primer was end-labeled with [y "P] ATP using O.IM DTT 
and incubating at 37°C for one hour. The amplification reactions were 
carried out for 35 cycles at annealing temperatures ranging from 52°-
56*'C using 1 Unit of Taq DNA Polymerase {Roche, Applied 
Biosystems), 2.5mM MgC12 and 200fiM dNTPs {New England Biolab). 
The amplification was first checked on 2% agarose then finally resolved 
on 6% denaturing Polyacrylamide/ Urea gel. After autoradiography 
analysis of microsatellite instability was done. 
MSI Analysis 
MSI was characterized by small deletions or expansions within 
short tandem repeats in tumor DNA as compared with matching normal 
DNA (Fig. 5.1). Two common band patterns were observed, either a 
novel discrete band in tumor DNA not observed in the corresponding 
normal DNA or as a marked alteration of repeat length, often 
heterogeneous in nature and appeared as a ladder. The tumors with MSI 
were divided into two groups: the first is characterized by MSI-H (MSI 
exhibited by two or more markers) and MSI-L (MSI exhibited by one 
marker) and a third group lacking instability (when none of the markers 
exhibit instability) was MSS 
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In the present study, reference panel of the five markers 
recommended by the Bethesda Consensus Conference reference panel, 
were used for the first time for MSI analysis on 83 invasive squamous 
cell carcinoma of uterine cervix. Using this reference panel MSI-H 
tumors are defined as having instability in two or more markers, 
whereas, MSI-L tumors are defined as having instability in one marker. 
Microsatellite Index for the five markers [Instability observed by the 
primers/number of markers used] and RMA for individual primers were 
also calculated. [RMA = Number of cases with microsatellite instability/ 
total number of cases]. 
N 
90802.2 
Fig. 5.1 Photograph of MSI, showing increase in the repeat units in the 
tumor DNA (T) (indicated by arrows), compared with the matched 
constitutional normal DNA (N) from the same patient. 
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Results 
Eighty-three squamous cell carcinoma of uterine cervix were 
examined. Microsatellite instability [MA Index 1.0] was observed with 
all the five markers. Thirty-two cases were MSI-L, whereas, twelve 
cases showed high instability (with two or more m.arkers). Thirty-nine 
cases did not show instability with any of the five markers and were 
therefore considered MSS. BAT25 showed maximum instability 
(22.9%) followed by D2S123, D17S250 and BAT 26 (20.4%, 13.25% 
and 9.6% respectively). D5S346 showed instability in only three cases. 
Representative photographs of microsatellite instability with different 
markers are illustrated in figure 5.3 and the results are summarized in 
table 5.2 Details of the patients and their respective status of MSI are 
presented in chart I. Majority of the carcinoma were moderately to well 
differentiated type. 
Table 5.2. Showing MSI in invasive cancer (MA Index = 1) 
Primers 
BAT 25 
BAT 26 
D2S123 
D5S346 
D17S250 
Cases 
83 
83 
83 
83 
83 
MSI 
19/83 
8/83 
17/83 
3/83 
11/83 
MSI 
22.9 
9.6 
20.4 
3.6 
13.2 
RMA 
0.22 
0.09 
0.20 
0.03 
0.13 
LOH 
(%) 
0 
0 
0 
4.3(2/46) 
3.6(2/55) 
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Figure 5.2 Representative photographs showing DNA amplified by five different markers 
used for MSI analysis and resolved on 2% agarose gels with (|>X174 Hae III digested 
marker. Polymorphic microsateilite markers are designated below each block. 
200902.2 161001.1 181002.1 
N N N 
BAT 25 D5S346 D2S123 
270902.4 270902.3 
N N 
BAT 26 D17S250 
Figure 5.3 Representative autoradiograms of denaturing polyacrylamide 
gels demonstrating microsatellite instability (mono and di-nucleotide) 
using Bethesda conference reference panel of five markers [T =DNA from 
Tumor tissue; N= constitutional DNA from blood leukocytes of the same 
patient). 
Discussion 
Assessment of microsatellite instability (MSI) has become an 
important tool in tumor molecular pathology. Microsatellite instability 
(MSI) and microsatellite stability (MSS) appear to characterize two 
different pathways of carcinogenesis (Perucho,1996). Several studies 
have already shown that particular loci are prone to instability in 
different cancers; comparison between studies was difficult because of 
the selection of markers. In the present study we used the Bethesda 
Conference reference panel of five primers for the first time in cervical 
cancer. (A)n tracts located in the intron of c-kit oncogene showed 
maximum (22.9%) instability, followed by the dinucleotide (CA)n 
repeat loci D2S123 (20.4%). However, BAT-26, in intron 5 of hMSH2 
gene also showed little (9.6%) instability. However, D5S346 showed 
3.6% instability, which is significantly low. 13.2% instability was 
reported at D17S250. Our study supports the results obtained by 
Dietmer et al, 1997 in colorectal cancer, for which the above panel of 
markers was first recommended. Smce, particular repeat loci are prone 
to instability in different cancers, Dietmer et al 1997 reported high MSI 
in the (A) n tracts located in the intron of c-kit oncogene (BAT-25) 
confirming the susceptibility of mononucleotide repeats to instability. 
Abnormality of the mismatch repair system has been reported in many 
sporadic cancers. Genetic instability was found to be 38% in gastric 
cancers ( Han et al, 1993). 
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The role of MSI in invasive cervical cancer is still controversial. 
Chu et al (1999) and Rodriguez et al (1998) reported that incidence if 
MSI was as low as 5.3% and 5.6% respectively, indicating that a defect 
of mismatch repair system is not involved in cervical carcinogenesis. On 
the contrary, Wistuba et al, 1997 reported that MSI was detected in 35% 
invasive cervical carcinoma. Nishimura et al (2000) reported 22.9% MSI 
in invasive cervical cancer. Mitra et al., (1995) observed instability in 
5pter region in 40% of CIS and 13% of invasive carcinomas. In the 
present study, MSI was present in at least one of the five loci examined 
(MSI-L) in 32 of 83 (38.5%) cervical carcinomas and in 12 (14%) cases. 
MSI was present in two or more loci (MSI-H) (chart 1). In a similar 
study of 100 cervical carcinomas, Chung et al, (2001), using a separate 
panel of five different polymorphic markers (D3S1263, D4S402, 
D4S415, Dl 1S136 and Dl 1S912) observed 25%) MSI-L and 5% MSI-H. 
MSI was first described in colorectal cancer (Aaltonen et al, 
1993; Thibadeau et al, 1993; lonov et al,1993). It was reported in both 
HNPCC as well as sporadic colorectal cancer. Subsequently MSI was 
described in endometrial (Risinger et al., 1993), pancreatic and gastric 
(Han et al., 1993), and urinary bladder cancer (Gonzalez et al., 1993). 
The mechanism through which MSI contributes to tumorigenesis is 
unknown. However, it is now widely accepted that MSI assessment 
should be added as a distinct criterion to refine the diagnosis of HNPCC. 
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The present study indicates that a panel of mono and di nucleotide 
repeat loci that have initially been recommended for HNPCC (Boland et 
al., 1998), can be used for the assessment of MSI in cervical 
carcinogenesis which may prove useful from a clinical diagnostic point 
of view. 
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6. LOSS OF HETEROZYGOSITY 
Introduction 
Loss of heterozygosity (LOH) refers to the observation of single 
allele at particular genetic locus or loci in benign or cancerous, or 
precancerous lesion, arising in an individual who is heterozygous for the 
same locus or loci in its normal tissue. LOH has been reported in several 
tumors of human origin (Yokota et al., 1989; Vogelstein et al., 1988; 
Wagata et al., 1991; Meitzer et al., 1987; Simon et al., 1991; Khosla et 
al., 1991; Fey et al, 1989; Vogelstein et al., 1989; Kovacs et al., 1988; 
Lee et al., 1990). Frequent LOH at a given chromosomal locus implies 
the existence of a tumor suppressor gene that is important in the 
pathogenesis of the particular cancer under study. LOH is believed to 
represent inactivation of one allele of a tumor suppressor gene by 
chromosomal or subchromosomal deletion. Frequent LOH have been 
detected on 3p and 5p (Kohno et al 1993; Mitra et al., 1994; 
Mullokandov et al 1996 and Karlsen et al 1994). Several TSGs have 
been reported to be located at 3p. Whereas, 5p (D5S406) showed high 
incidence of LOH (66.7%) in cervical cancer, suggesting the presence of 
candidate tumor suppressor gene (Mitra et al., 1994a). To elucidate the 
role of LOH at 3p and 5p regions in cervical cancer, we evaluated 83 
cases__of squamous cell carcinoma of uterine cervix. Clinically the 
majority of the tumors belonged to stage II or III, 77 tumors had 
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moderate to well differentiated histology and 6 tumors were of poorly 
di fferentiated type. 
Materials and Methods 
Materials and Methods used in the study have been described in detail in 
Chapter 4. Briefly described as follows. 
Tissue Samples: Tumor biopsy specimens and corresponding peripheral 
blood samples (2-3mL) were obtained after appropriate consent was 
granted from patients who attended the cancer clinic. 
Method: DNA was prepared from blood and biopsy samples by 
standard phenol chloroform methods (Sambrook et al., 1989). 40-60ng 
of DNA was taken as template for the PCR. 
Table 6.1 Primer details for LOH analysis 
MARKERS AMPLIMER AMPLICON SIZE 
D3S1234 5'-CCTGTGAGACAAAGCAAGAC-3' 
5'-GAC ATT AGG CAC AGG GCT AA-3' 
D3S1300 5'-AGC TCA CAT TCT AGT CAG CCT-3' 
5'-GCC AAT TCC CCA GAT G 
D3S1313 5'-CCCCTTGGAAAATCACTG-3' 
5'-CCA TGA ATA AGC CTT GCC-3' 
D5S20S 5'-ACCTGA GTC TTC ATC AAT AC-3' 
5'-TCC AG A ATC ATC CAT GTT GT-3' 
D5S406 5'-CCT GCC AAT ACT TCA AGA AA-3' 
5'-GGG ATG CTA ACT GCT GAC TA-3' 
lllbp 
236bp 
233bp 
186bp 
185bp 
85 Loss of liclerozygositx 
Polymerase chain reaction 
Standard Polymerase chain reaction was carried out in a 25|iL reaction 
volume containing 30-50ng of DNA as template, 20pmol of primers 
(table 6.1). One primer was end-labeled with [y-'^ P] ATP using O.IM 
DTT and incubating at 37°C for one hour. The amplification reactions 
were carried out for 35 cycles at annealing temperatures ranging from 
52*'-56°C using 1 Unit of Taq DNA Polymerase (Roche, Applied 
Biosystems), 2.5mM MgC12 and 200^M dNTPs (New England Biolab). 
The PCR products were denatured in sequencing stop buffer and 
subjected to electrophoresis in 6% denaturing Poly aery lamide gels, and 
the dried gels were autoradiographed for 6-18 hrs. 
LOH Analysis 
To evaluate LOH in cen'ical cancer, a panel of five markers was used 
covering the following chromosomal regions 3pl4.I-14.2 (D3S1234, 
D3S1300, D3S1313) and 5pl5.1-15.2 (D5S208 and D5S406). Markers 
that identified two distinguishable alleles of different sizes but similar 
intensity in the lane having constitutional normal DNA were termed 
"informative" (heterozygous). Markers that gave a single major band in 
the normal DNA were termed "non-informative" (homozygous). 
Complete absence of upper or lower allele compared with constitutional 
alleles was considered evidence for LOH (see fig 6.1). FRL (FRL =the 
number of patients with LOH in that region / the number of patients 
86 "^.v.v of heterozygosity 
informative in that region) was also calculated. LOH was considered 
significant if the frequency was above 25%. 
N 
60902.1 
Fig 6.1 Representative photograph of LOH, showing complete loss of the 
upper allele in the tumor DNA (T) (indicated by arrow), compared with 
the matched constitutional normal DNA (N) from the same patient. 
Results 
Paired tumor/normal DNA samples from 83 SCC patients were 
examined for the loss of heterozygosity at five polymorphic markers 
mapped to chromosomal arms 3p and 5p (fig. 6.3). Frequency of LOH 
was high at chromosome 5p as compared to 3p, however, the difference 
was not significant. Highest frequency of LOH (42.6%) was observed at 
D5S208 followed by D5S406 (32%). 30.2% LOH was observed at 
D3S1234 followed by D3S1300 (27.6%) (table 6.2). Using LI 
consensus primers MY09/11 in PCR amplification we found 73/83 
(87.9%) of SCC to display HPV (also see chart 2). To identify high-risk 
types (HPV 16 and 18) PCR was done by type specific primers. 48/83 
8 7 /^ o.v.v of heterozyg()\ li\' 
(57.8%) were HPV 16 positive. None of the cases showed positivity by 
HPV type 18 primers. The remaining 35 cases were positive for LI, 
therefore, represent HPV types, some of which may be other high-risk 
types. Neither HPV positivity nor presence of HPV types correlated with 
allelic deletions. 
Table 6.2: Showing LOH in invasive cancer 
Primers 
D3S1234 
D3S1300 
D3S1313 
D5S208 
D5S406 
No. Of 
Cases 
83 
83 
83 
83 
83 
Informative LOH 
53 
47 
73 
54 
50 
.4%) 
/l6/53f\ 
1 13/47 \ 
7/73 1 
I 23/54 
\ 16/50/ 
LOH 
30.2 
27.6 
09.6 
42.6 
32.0 
FRL 
0.30 
0.27 
0.09 
0.42 
0.32 
'^CKX'-^ O T CH- e^<J^^ 
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Figure 6.2 Representative photographs showing DNA amplified by five different markers 
used for LOH analysis and resolved on 2% agarose gels with (|>X174 Hae III digested 
marker. 
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N 
D3S1300 
291102.2 
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Figure 6.3 Representative autoradiograms of denaturing polyacryiamide 
gels demonstrating the allelic losses at chromosomal arms 3p and 5p 
indicated by arrows [T =DNA from Tumor tissue; N= constitutional DNA 
from blood leukocytes of the same patient]. 
Discussion 
In recent studies of cytogenetics and allelotypes, many 
observations of allelic losses at specific chromosomal loci in a variety of 
human cancers have implicated the presence of TSGs on some 
chromosomes. In the previous study by Mitra et al., (1994a), LOH of 
>25% was observed at sites on eleven chromosomal arms including 3p 
(35%) and 5p (53%) in squamous cell carcinoma of uterine cervix. 
In the present study of 83 invasive cervical cancer cases 
maximum frequency of LOH (42.6%) was observed at D5S208 (5pl5.1-
15.3) followed by D5S406 (32%) mapped to 5pl5.1-15.2 Three 
polymorphic markers (D3S1234, D3S1300 and D3S1313) mapped to 
chromosome 3pl4.2 region were used in the study. 3pl4.2 have been 
reported to be frequently involved in many cancers of human origin 
including that of cervix. In particular deletions at 3pl4.2 (FHIT gene 
region) are very frequent in lung cancer (Sozzi et al., 1996), breast 
cancer (Negrini et al., 1996), head and neck cancer (Virgilio et al., 
1996), stomach and esophageal cancer (Ohta et al., 1996), pancreatic 
cancer (Simon et al., 1998) and cervical cancer (Greenspan et al., 1997). 
FHIT gene covering more than 1Mb is composed of 10 exons. The most 
common fragile site of human chromosome FRA3B also, maps within 
the FHIT gene. It has been speculated that fragile sites observed in the 
human genome correspond to chromosomal regions frequently involved 
in rearrangements in human cancers. A wide range 35% to 100% of 
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allelic imbalance frequencies at 3p loci has been reported in cervical 
carcinomas (Yokota et al., 1989; Chung et al., 1992; Jones and 
Nakamura 1992; Kohno et al., 1993; Karlsen et al., 1994; Wong et al., 
1997; Chu et al., 1998; Guo et al., 1998; Kersemaekers et al., 1998a,b). 
Helland et al, 2000 in his study of 79 primary cervical carcinomas, 
using 16 markers reported 63% allelic imbalance at one or more 3p loci. 
The most frequently altered loci were D3S1234 (30.2%) within intron 5 
of the FHIT gene followed by D3S1300 loci (27.6%). Allelotype 
instability at 3pl4.2 suggests inactivation of the FHIT gene, which maps 
to this chromosomal band (Larson et al., 1997; Kohno et al., 1993; Ku et 
al., 1997 and Chu et al, 1998). Mitra et al., 1994a reported high 
frequency (53%) of LOH at D5S208 loci that maps to 5pl5.1 region. In 
another study of recurrent cervical dysplasia (Lin et al., 2000), LOH in 
recurrent cervical dysplasia was reported to be significantly higher 
(53%) as compared to non-recurrent group (33%)). LOH at 5p was the 
novel site reported by Mitra et al.. (1994a) in cervical carcinoma. In the 
present study, maximum frequency of LOH (42.6%) was observed at 
"shtomosome 5p^supporting the previous results obtained by Mitia et al., 
(1994a), suggesting the possibility of a candidate tumor suppressor gene 
involved in cervical carcinogenesis. Thus, our result confirms a high 
frequency of allelic imbalances at chromosome arm 3p and 5p indicating 
the possible existence of one or more tumor suppressor genes involved 
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in cervical carcinogenesis. Our result also indicates the involvement of 
FHIT gene in cervical cancer. 
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7. HUMAN PAPILLOMAVIRUSES 
Introduction 
Human papillomaviruses form icosahedral non-enveloped 
particles with a diameter of approximately SSMII. They-contain a double 
c<s\x^ ^ f lS - ^^^'^ 
stranded, circular and covalently closed DNA/genomeCoTTSOO-SOOObp. 
The virus capsid is composed of 72 capsomeres, which are arranged on 
an icosahedral surface lattice. Papillomaviruses have been placed as a 
subfamily (Shah and Howley, 1992) together with polyomaviruses in the 
family Papovaviridae. The circular DNA genome of papillomaviruses 
can be divided into three segments. The long control region (LCR), also 
called upstream regulatory region (URR) represents about 10% of the 
genome. The early (E) and late (L) genes are coded by about 50 and 
40% of genome respectively. From both biological and epidemiological 
standpoints there are compelling evidences, which conclude that human 
<^\ ' papillomaviruses are carcinogenic in humans (lARC Working Group, 
\ 
1995; Hildesheim et al.,(1994). Till date about 100 types of HPVs have 
been isolated and characterized. HPV DNA. More than 70 types of HPV ^ cLo-^^^i 
types have been characterized so far on the basis of differences in their '^ 
DNAjequences (Favre et al., 1989a,b,c and d; Heilman et al., 1980; /o^ 
Danos et al., 1982; Kremsdorf et al., 1983, 1984; Gismann et al., 1977; il-TU/u, 
Durst et al., 1983., Boshart et al., 1984; Cole 1986; Beaudenon et al., n^^^^ 
1986; Lorincz et al., 1987, 1989; Muller et al., 1987, Nuovo et al., 1988 ^ 
94 Human papillomavirus 
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etc.). Type specific prevalence is presented for the eighteen most 
common HPV types as identified by Clifford et al 2003; Lechner et al., 
1992 in meta-analysis of HPV types in invasive cervical cancers are: 
HPV types 6, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 70, 73 
and 82 in order of descending prevalence for each subgroup analysis. 
Two third of invasive cervical cancer cases included in the meta-
analysis were associated with HPV 16 (51.0%) or 18 (16.2%) infection. 
Nubia Munoz et al 2003 in their epidemiologic classification of human 
papillomavirus types grouped fifteen HPVs as high-risk types (16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82); three as probable 
high-risk types (26, 53 and 660) and 12 were classified as low-risk types 
(6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108). HPVs can induce 
immortalization in primary cultures of human and rodent cells. In human 
cells, immortalization is restricted to high-risk viruses, whereas in rodent 
cells, low-risk HPV types also possess weak immortalization potential. 
Extensive viral carcinogenesis studies the world over point to human 
papillomavirus virus as an important factor in cervical carcinogenesis. 
Of the many HPV types, types 16 and 18 are documented as high-risk 
HPV associated with genital neoplasia. Although a cause and effect 
relationship between HPV and cervical cancer is yet to be proven, over 
80% of cervical cancers today are associated with HPV infection. 
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Materials and Methods 
HPV detection was done by Polymerase chain reaction using 
MYQ2/ii. consensus primers. Detection of HPV types was done using 
type specific primers. DNA for PCR was isolated from cervical swabs 
from the females using Ayer's spatula and transferred to the vials 
containing phosphate buffer saline. The DNA was isolated from the 
exfoliated cervical cells. DNA extraction method involved incubation of 
cell nuclei in higher concentration of Proteinase-K at 65 C for 
2.'3hrsifollowing prolonged incubation at higher temperature, the 
enzyme is auto inactivated and the DNA isolated can be used directly 
for analysis without further purification (Gopalkrishna et al., 1992) (also 
see fig 7.1). 0.5-lfiL of DNA was used as template for PCR. 
Polymerase Chain Reaction 
p-globin primers PC04 and GH20 (Saiki et al, 1988), which 
produces a 268bp PCR product (fig 7.2), were used as an internal 
amplification control. All the samples proved positive for P-globin 
amplification were considered for HPV analysis. DNA was amplified 
using MY09/11 consensus primers (Manos., et al., 1989) (figure 7.3), in 
thermal cycler The amplification reactions were carried out for 35 cycles 
at annealing temperatures ranging from 56" C to 58*^  C using 1 Unit of 
Taq DNA Polymerase (Roche, Applied Biosystems), 2.5mM MgC12 and 
200).iM dNTPs (New England Biolab). Positive and negative controls 
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were also taken with every round of amplification. The PCR products 
were resolved on 2% agarose, stained with ethidium bromide and 
visualized under transilluminator or Gel Documentation system 
(BioRad). All the positive samples were further subjected to HPV typing 
with type specific primers for HPV types 6. 11, 16 and 18 (table 7.1; 
also see fig 7.4) or by RFLP of LI amplicon (MY09/11) using Rsa 1 
(Naqvi et al., 2004). 
Table 7.1 Primers used in HPV analysis 
Primer Primer Sequence (amplimer) Amplicon (bp) 
5'-CAACTTCATCCACGTTCACC-3' 268 
5 '-GAAGAGCCAAGGACAGGTAC-3' 
5'-CGTCCM*ARR*GGAW*ACTGATC-3' -450 
5'- GCMCAGGGWCATAAY*AATGG - 3 ' 
5'-TAGTGGGCCTATGGCTCGTC-3' 280 
5'- TCCATTAGCCTCCACGGGTG -3 ' 
5'- GGAATACATGCGCCATGTGG-3' 360 
5'- CGAGCAGACGTCCGTCCTCG-3' 
5'-AAGGCCAACTAAATGTCAC-3' 217 
5'- CTGCTTTTATACTAACCGG -3' 
5'- ACCTTAATGAAAAACCACGA -3' 100 
5'- CGTCGTTGGAGTCGTTCCTG -3 ' 
*Note: M= A/C; R = A/G; W = A/T: Y ==C/T 
Detection of HPV using DHCA H 
Twenty-seven LI positive cases, taken randomly, were also 
screened by the Digene HPV test using Hybrid Capture -II technology, 
which is a signal amplified hybridization antibody capture microplate 
assay that utilizes chemiluminiscent detection. Specimens containing the 
PC04 
GH20 
MY09 / 
MYll 
HPV 
Type 6 
HPV ^ 
Type 11 
HPV « 
Type 16 
HPV 
Type 18 
(F) 
(R) 
(F) 
(R) 
(F) 
(R) 
(F) 
(R) 
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target DNA hybridize with a specific HPV RNA probe cocktail. The 
resultant RNA: DNA hybrids are captured onto the surface of a 
microplate well coated with antibodies specific for RNA: DNA hybrids. 
Immobilized hybrids are then reacted with alkaline phosphatase 
conjugated antibodies specific for RNA: DNA hybrids and detected with 
a chemiluminiscent substrate, several alkaline phosphatase molecules 
are conjugated to each antibody. Multiple conjugated antibodies bind to 
each captured hybrids resulting in substantial signal amplification. As 
the substrate is cleaved by the bound alkaline phosphatase, light is 
emitted which is measured. It is a simple technique that could be readily 
automated for large-scale use if required. Detailed methodology is 
discussed in chapter 4. 
Results 
All samples proved positive for (5-globin amplification (Saiki et 
al.. 1988), the internal amplification control, and were therefore 
considered suitable for HPV analysis. HPV DNA was detected in 73/83 
(88%) of the patients with cervical cancer using MY09/11 consensus 
primers of LI region of HPV genome (Manos et al., 1989). Clinically 
^S^ majority of the tumors belonged to stage II or III, 77 tumors had 
moderate to well differentiated histology and 6 tumors were of poorly 
differentiated type with median age 50 years. Further genotyping, using 
type specific primers for HPV types 6, 11, 16 and 18 (see table 7.1) 
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revealed that HPV type 16 was predominantly present 48/83 (58%), 
followed by type 6, 45/83 (54%) and type II, 17/83 (20.4%), HPV type 
18 was not detected in any of the samples. However, HPV type 16 was 
present exclusively in 20/83 (24%) cases, which was same for HPV type 
6 (24%). WOiereas, HPV 11 was present exclusively in 2/83 (2.4%) 
cases. Co-infection of HPV type 6 and 16 was present in 23/83 (28%) of 
cases followed by multiple infection of HPV 6 and 11 (12%). 
Incidence of HPV types 6 and 16 and their co-infection with respect 
to age 
HPV type 16 was detected in 19/48 (39%) of women of age group 45-50 
years, with prevalence declining rapidly to 6/48 (12.5%) in 65 + years. 
Similarly, HPV type 6 showed a peak (35.5%) between age group 45-54 
years and declining after 65 years (4.4%) (see graph 7.1). Interestingly 
co-infection of HPV types 6 and 16 showed the peak at the same age 
group. 
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HPV6 
HPV16 
Co-inf. 6/16 
25-34 35-44 45-54 55-64 65-74 75-84 
Age (in years) 
Graph 7.1 Human papillomavirus types 6, 16 and their co-infection with 
respect to age 
18/27 (67%) of the MY09/11 positive cases were found to be positive 
for high-risk (HR-HPV) by DHCA. Further typing of HR-HPV positive 
samples with type specific primers for HPV types 16 and 18 revealed 
that 14/18 (80%) were HPV type 16 positive while HPV type 18 was not 
detected in any sample, mdicating the presence of few different HR-
HPV types (other than types 16 and 18) in rest of the 20% samples. 
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M 
Figure 7.1 Representative photograph showing DNA resolved on 1% 
agarose gel [M = X Hind III digested marker] 
1 2 3 4 5 6 7 M 
268bp 
Figure 7.2 Representative photograph showing DNA amplified using 
beta globin primers (used as internal amplification control) resolved on 
2% agarose gel [M = <j)X174 Hae III digested marker] 
M l 2 3 4 5 6 7 8 9 1011 12 
~450bp 
Figure 7.3 Representative photograph showing HPV positive (lanes 
3,4,5&7-12) and HPV negative (lane 6) cases, ampUfied using MY09/11 
consensus primers resolved on 2% agarose gel with positive (l^ne 1) and 
negative (lane 2) controls [M = <|iX174 Hae III digested marker] 
M 
280bp 
360bp 
B 
217bp 
F'igure 7.4 Representative photographs showing human papillomavirus 
type 6, 11 and 16 positive cases (A to C respectively) resolved on 2% 
agarose gels. Lanes 2 in B and C, lane 1 in A are positive controls and 
lanes 1 in B and C and lane 2 in A are negative controls. [M = <|>X174 Hae 
III digested marker] 
Discussion 
In the present study, we investigated the presence of HPV types 
6, 11, 16, 18 and their co-infections in cervical cancer patients. 88% 
(73/83) were positive for HPV by MY09/11 consensus primers which 
detects a wide spectram of both oncogenic and non-oncogenic human 
papillomavirus types. 27 samples from the MY09/11 positive cases were 
taken randomly for detection of HR-HPV types using DHCA-II kit 
showed 67% (18/27) positivity for HR-HPV types, of which, 80% 
(14/18) were HPV-16 (by PCR using type specific primers). However 
no HPV type 18 was detected in any of the samples. Since high-risk 
probe was used for the detection of HPVs by DHCA and genotyping 
was done by the type specific primers for HPV types 16 and 18, results 
suggest that HPV 16 was predominantly present among majority (80%) 
of the high risk types and while other high-risk types constitute only 
20%) (4/18) of high-risk positive samples. 
All the 73 samples positive for HPV by LI consensus primers 
(MY09/11) were subjected to further genotyping by type specific 
primers for the types 6/11/16/18 which are the most prevalent HPV 
types commonly associated with cervical abnormalities like warts 
(Schwarz et al, 1983), papillomas (Gissmann et al, 1982) and certain 
cancers including cancer of the uterine cervix (Bosch et al, 1995, 
Beaudenon et al 1986, Cole et al 1986). The high-risk viruses, such as 
HPV-16 (Favre et al, 1989; Seedorf et al, 1985), HPV 18 (Cole ST et al, 
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1987) and HPV 33 (Beaudenon et al, 1986; Cole et al 1986), and few 
other are associated with CIN and cervical cancer. HPV 16, 18, 33 and 
45 accounts for more than 90% of the high-risk types. Cervical 
intraepithelial neoplasia and cervical cancer both are strongly associated 
with persistence presence of some types of human papillomavirus. Over 
90% of the cervical carcinoma have been shown to contain some high-
risk HPV types (Nieminen et al, 1991). HPV 16 is considered to be 
prototype among malignant HPVs and HPV 11 is considered to be 
benign prototype (Vousden, 1993). HPV 16 has been found to be the 
most prevalent HPV types associated with cervical carcinoma. Earlier 
studies reported HPV- 16 infection in more than 80% of cancers of 
uterine cervix (Das et al., 1992). In the study of HPV prevalence in 
different countries have found the HPV-16 prevalence to be 33-50% in 
African countries; 34-59% in South America; 31-59% in South East 
Asia; 54-76.5% in Europe; 76.5% in Germany and overall percentage of 
HPV-16 in cervical cancer was 49.9% worldwide. Munoz et al., (2003) 
found HPV-16 to be present in 54.6% of cancers and HPV type 18 was 
present in 66% cases of adenocarcinoma. In the present study HPV 16 
was found to be present in 48/83 (58%) of cancer cases. However, we 
observed a considerable number (54%)) of HPV type 6 in cancer 
patients. HPV type 6 exclusively, was present in 20% of the cancer 
cases suggesting the possible involvement of LR-HPV types in the 
pathogenesis of the disease. Since, there is no clear line of demarcation 
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between HR and LR-HPV types. The studies show that the LR-HPV 
tj'pcs have the capability to transactivate cells. Foster and coworkers 
(1994) argue that there is no linear sequence that convincingly 
distinguishes the high risk from low-risk HPV E6 proteins (Foster, et al., 
1994). Further, binding ability of high-risk HPV's E7 for pRB complex 
is 10 folds higher than that of LR-HPV (Huibregste, et al., 1993). This 
difference results apparently from a single amino-acid modification at 
the position 21 (Heck, et al., 1992) affecting its oncogenicity. 
In the present study HPV typell, which is mostly associated 
with warts, was present in 20.4% of cases. Both HPV types 6 and 16 
showed peak in the age group 45-54 years and a second peak in 55-64 
years of age group, which showed a declining trend after 65+ (see graph 
7.1). Similar trend was observed with the co-infection of HPV types 6 
and 16. Since, infection of multiple HPV DNA types is a risk factor for 
cervical intraepithelial neoplasia (Liaw et al., 1995), detection of LR-
HPV types along with high-risk types is also of considerable importance 
both for diagnostic and research point of view. Serological evidences 
indicate protection by HPV type 6 infection against HPV type 16 
cervical carcinogenesis (Sillins et al., 1999), whereas in co-infections 
the E6 protein of low-risk HPV (type 6) augments the ability of E7 of 
HPV type 16 or E7 of HPV type 6 coupled with E6 of type 16 increases 
the potency and ability to immortalize cells (Halbert et al., 1992). HPV 
type 6 was also present exclusively in 20% of the cancers, suggesting its 
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possible involvement in the process of carcinogenesis. These studies 
suggest the detection of low-risk HPV types and their co-infections 
along with HR-HPVs to be important for understanding the 
pathogenesis of the disease and the biological behavior of HPVs during 
cervical carcinogenesis. 
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8. Cytochrome P450 2D6 Polymorphism 
Introduction 
Among other environmental factors tobacco smoking is an 
important and frequent cause of cervical cancer. Data of cancer registry 
shows a positive correlation between cervical cancer and tobacco related 
cancers (Winkelstein, 1977). Tobacco smoke contains many potential 
carcinogens including polycyclic aromatic hydrocarbons, N-
nitrosamines, aromatic amines, aldehydes and halomethanes. The 
importance of tobacco derived compounds as local carcinogens is shown 
by the findings that nicotine and cotinine are concentrated in cervical 
mucus which can be mutagenic (Winkelstein, 1990; Gram et al., 1992; 
Burger et al., 1993), and DNA from cervical epithelial cells of smokers 
contains adducts of the type expected from reaction with polycyclic 
aromatic hydrocarbons and aromatic amines (Simons et al., 1993). This 
may explain the biological plausibility of the association between 
smoking and cervical cancer. In addition an increased risk of cervical 
neoplasia and its precursors was associated with duration, intensity and 
early age of initiation of smoking (Harris 1980; Brinton, 1986). 
The superfamily of cytochromes P450 (CYPs) consists of 
microsomal hemoproteins that catalyze the oxidative, peroxidative and 
reductive metabolism of a wide variety of endogenous and exogenous 
compounds. This superfamily is divided into families and subfamilies 
according to homologies in their nucleic acid sequences (Nelson et al., 
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1996). Cytochrome P450s constitute superfamily of enzymes crucial for 
the oxidative, peroxidative and reductive metabolism of a diverse group 
of compounds, including endobiotics, such as steroids, bile acids, fatty 
acids, prostaglandins and leukotrienes and xenobiotics including most of 
the therapeutic drugs and environmental pollutants (Nelson et al., 1996; 
Bertz and Granneman, 1997). Drug metabolism has classically been 
dixided into "Phase I" (flinctionalization) and "Phase 11" (conjugation) 
reactions. Phase I enzymes often introduce a ftinctional group, such as 
hydroxyl, into the substrate; Phase II enzymes then use this fiinctional 
group as a "handle" for conjugation with such moieties as glutathione, 
glucuronic acid, sulphate, glucose or cysteine, yielding a very 
hydrophilic product that can easily be excreted (Nebert et al 1990). 
Cytochrome P450 comprise probably more than 95% of all known 
Phase I enzymes, and they are important in the oxidative metabolism of 
numerous endogenous compounds such as steroids, fatty acids, 
prostaglandins, leucotrienes, and biogenic amines. Many of these 
enzymes also metabolize a wide range of foreign chemicals including 
drugs, environmental pollutants and natural plant products. P450 
mediated reactions often lead to the formation of toxic metabolites, 
some of which may be active in tumor initiation and/or promotion 
(Nebert et al 1990; Meyer et al.,1990; Guengerich, 1990). 
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Eukaryotic cyp enzymes are membrane bound mostly localized to the 
endoplasmic reticulum, but some CYPs are also present in 
mitochondrial inner membranes. In order to function, cytochrome P450s 
require an electron transfer chain. In the endoplasmic reticulum this 
source is NADPH-cytochrome P450 reductase, previously called 
NADPH - cytochrome c reductase (Omura 1999). In mitochondria, 
electrons are transferred from NADPH by redoxin reductase to redoxin 
and then to CYP (Gonzalez, 1990). Despite their occasionally minimal 
sequence similarity, all CYPs have a similar structural fold with a highly 
conserve core (Graham and Peterson, 1999). 
The expression of CYP enzymes varies between individuals due 
to genetic and environmental factors and some diseases. These factors 
produce inter-individual variation in the rate and metabolic pathways of 
xenobiotics. One example of genetic factors influencing the inter-
individual variation is the polymorphic expression of at least CYP2A6, 
CYP2C9, CYP2C19 and CYP2D6 among the population. The frequency 
of poor metabolizers (PMs) varies between races and ethnic groups. 
Some dietary compound, cigarette smoking, alcohol and drugs may 
cause induction or diminution of the expression of certain CYPs 
(Pelkonen and Breimer, 1994; Pelkonen et al., 1998). The human 
genome includes only one functional gene inCYP2D subfamily, namely 
CYP2D6 (Nelson et al, 1996). Cigarette smoking is a risk factor, 
suggesting polymorphism at loci that encode carcinogen-metabolizing 
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enzyme such as cytochrome P450 (CYP2D6) and glutathione S 
transferase (GSTTl, GSTMl) may determine susceptibility to cervical 
cancer. Pharmacogenetics is the study of unusual drug responses that 
have an heritable basis (Nebert et al., 1990). Responses can be 
immediate (Rash, hypotension), sub-acute (lupoid hepatitis, peripheral 
neuropathy), or delayed (cancer). Genetic makeup of the person 
dramatically influences the individual susceptibility to the adverse 
health effects of environmental agents. 
Extensive metabolizers and Poor metabolizers: 
The cytochrome P450 enzyme debrisoquine 4 hydroxylase 
(CYP2D6) metabolizes many drugs and carcinogens. The debrisoquine 
polymorphism, which is one of the most extensively studied of the P450 
polymorphisms, was first discovered by R L Smith and colleagues in 
studies of patients taking debrisoquine, a beta adrenergic blocking agent 
prescribed for the treatment of hypertension. (Idle et al., 1979). Most 
individuals receiving the drug excrete in their urine large amounts of 
hydroxylated debrisoquine metabolites, and they are termed "extensive 
metabolizers" (EM phenotype). About 5-10% of the Caucasian 
population excrete the drug virtually unchanged, and they are termed 
"poor metabolizers"(PM phenotype) (Idle et al., 1979). The link 
between squamous cell carcinoma of uterine cervix and cigarette smoke, 
which contains carcinogenic substrates for phase I cytochrome P450 
(CYP) detoxifying enzyme suggests susceptibility to this cancer may be 
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linked to allelic variation at this locus. CYP2D6 is a promising 
candidate as the PM and wild type, EM genotypes are associated with 
different risks of several cancers (Wolf et. al., 1992; Idle et. al., 1992). 
Materials and Methods 
Blood samples (5ml) were obtained from cases and control from 
the cancer clinic and gynecological out patient department after taking 
proper consent from the patients. Enzyme genotypes were determined 
using the Polymerase chain reaction (PCR) and restriction enzyme 
digestion of leukocyte DNA. As part of the medical survey all subjects 
were interviewed to obtain their smoking history. Smoking history was 
summarized as total amount of cigarettes/ bidis consumed during the 
lifetime up until the time of inter\'iew. The group comprised of females 
who smoked atleast 10 cigarettes/ bidis per day or those who have 
quitted smoking but have been smokers for two to three years in the 
past. The control group consisted of 77 females who attended 
gynecological out patient department having normal cervical histology 
(mean age 39.8 yrs) and the cases comprised of 61 mild/moderate 
dysplasia (mean age 33.2), 48 severe dysplasia (mean age 37.8) and 85 
cases of squamous cell carcinoma (mean age 50.3) of uterine cervix. 
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DNA extraction from blood 
DNA was extracted from the peripheral blood using standard 
phenol chloroform extraction method (Sambrook et al., 1989) described 
in detail in chapter 4. 
Analysis of mutant CYP2D6 aUeies by Polymerase Chain Reaction 
40-60ng of DNA was taken as template and standard polymerase 
chain reaction was carried out in a 25(iL reaction volume, with 20pmol 
of primers. An initial strand separation step was carried out at 94*^ C (4 
min), and 35 cycles of: denaturation at 94°C for 30 sec, primer annealing 
at 60°C for 1 min. and polymerization at 72°C for 1 minute, and final 
polymerization for 7 minutes at 72°C to complete elongation of all 
amplified strands. 1 Unit of Taq DNA Polymerase {Roche, Applied 
Biosystems), 2.5mM MgC12 and 200nM dNTPs {New England Biolab) 
were used in the reaction and the amplified products were resolved on 
10% non-denaturing Polyacrylamide/TBE gel. The bands were 
visualized after ethidium bromide staining under gel documentation 
system (BioRad). The high annealing temperature is required in order 
that the ptorimers used annealed only to CYP2D6 sequences and not to 
the highly homologous CYP2D7 or CYP2D8P gene. 
Primer pairs CYP 1 (Exon 3: 5'- GCCTTCGCCAACCACTCCG - 3'), 
CYP 2 (Intron 4: 5 - AAATCCTGCTCTTCCGAGGC - 3) 
and CYP 3 (Exon 5:5' - GATGAGCTGCTAACTGAGCcC-3'), 
CYP 4 (Intron 5: 5' - CCGAGAGCATACTCGGGAC - 3) 
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were used to amplify regions of CYP2D6 gene over the mutations to be 
identified. Amplification with CYPl and CYP2 generates a 334bp 
fragment (fig 8.3A) which, as a consequence of G to A transition at the 
junction of intron 3/ exon 4, is resistant to digestion with the restriction 
enzyme BstNl, and in individuals containing dbl sequence digests 
334bp fragment into fragments of 105bp and 230bp with BstNl (Gough 
et al., 1990). Primer CYP3 contains a one base pair mismatch to the 
CYP2D6 sequence (shown in lower case) which makes the 268bp PCR 
fragment (fig 8.3B) produced from individuals with the exon 5 mutation 
sensitive to digestion with the restriction enzyme Hpa II at the site of the 
base pair deletion. The other Hpa II site present in all individuals. 
Amplification conditions for each assay were as previously descried. 
All restriction enzyme digests were carried out overnight using 25|iL of 
PCR mixture and lUnit of restriction enzyme in IX restriction buffer 
concentration. For Polyacrylamide gel electrophoresis the restriction 
enzyme digests were mixed with an appropriate running dye (BPB). 
A diagrammatic representation of the expected banding patterns of 
amplified DNA following separation of restriction fragments by 
polyacrylamide gel electrophoresis through a 10% non-denaturing 
Polyacrylamide/TBE gel is given in figures 8.1 and 8.2. 
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Analysis of the G to A transition 
334bp 
lOSbp 230b 
.p.-
Intron 3 I iniron j i 
BstNl 
Intron 4 
D 
HOMOZYGOTE HETEROZYGOTE 
H HEM 
HOMOZYGOTE 
PM 
334bp 
230bp 
lOSbp 
Fig. 8.1 Predicted banding patterns of digested products {Bst Nl) of 
CYP 1 and CYP 2 ampHcon. 
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Analysis of the base pair deletion 
268bp 
20bp 168bp 80bp 
• " « * -
Intron 5 
Hpa l l H p a l l 
Predicted banding patterns 
HOMOZYGOTE HETEROZYGOTE 
H HEM 
HOMOZYGOTE 
PM 
188bp 
I68bp 
80bp 
Fig. 8.2 Predicted banding patterns of digested products {Hpa II) of 
CYP 3 and CYP 4 amplicon. 
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Results 
In the present study the base pair deletion in exon 5 was not 
identified in any of the cases and majority of cases were found to be 
homozygous extensive metabolizers (EM). Therefor^ the analysis was 
done on data obtained using intron3/exon4 primers (CYP1&CYP2) 
followed by Bst NI digestion (fig 8.4). Among 77 normal controls, 41 
(53.2%) were homozygous extensive metabolizers (EM), 33 (42.9%) 
were heterozygous extensive metabolizers (HEM) and 3 (3.9%) were 
poor metabolizers (PM). Similarly, in 61 mild/moderate dysplasia cases 
35 (57.4%) were EM, 23(37.7%) were HEM and 3(4.9%) were PM. In 
48 severe dysplasia cases 29 (60.4%) were EM, 17 (35.4%)) were HEM 
and only 2 (4.2%) were PM. In 85 cases of squamous cell carcinoma, 60 
(70.6%) were EM, 19 (22.4%) were HEM and 6 (7.0%) were PM. (also 
see table 8.1) 
The genotype frequencies at the CYP2D6 gene locus investigated 
in this study showed differences between cases and controls suggesting 
that this gene may be involved in susceptibility to cancer of uterine 
cervix. RFLP analysis of the CYP2D6 gene revealed a non-significant 
increase in the number of homozygous extensive metabolizers (EM) 
among the cancer patients as compared to normal controls (70.6% vs. 
52.3%) (see table 8.1). 
Smokers in the category of homozygous extensive metabolizers 
(EM) in squamous cell carcinoma were significantly high (p<0.05) as 
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compared to non-smokers. Whereas, no such correlation was observed 
in normal / precancerous cases, (see table 8.2) 
Table 8.1 Incidence of genotypes CYP2D6 among different grades of 
cervical cancer 
Genotypes Normal 
(%) 
Mild/Mod. 
Dysplasia 
(%) 
Severe 
Dysplasia 
(%) 
Sq. cell 
carcinoma 
i%) 
EM 
HEM 
PM 
41/77 
(53.2) 
33/77 
(42.9) 
3/77 
(3.9) 
35/61 
(57.4) 
23/61 
(37.7) 
3/61 
(4.9) 
29/48 
(60.4) 
17/48 
(35.4) 
2/48 
(4.2) 
60/85 
(70.6) 
19/85 
(22.4) 
6/85 
(7.0) 
r = 7.545, p> 0.05, df= 6 
Table. 8.2 Showing cases among extensive metabolizers 
Category Normal 
Smokers 22 
Non smokers 19 
Mild/Mod 
Dysplasia 
21 
14 
Severe 
Dysplasia 
24 
5 
Sq. cell 
carcinoma 
51 
9 
r = 14.79, p<0.05 
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M 
334bD 
M 
268bp • 
Figure 8.3 Representative photographs showing DNA amplified using primers CYP1 & 
2 (A, 334bp), CYP 3 & 4 (B, 268bp), resolved on 2% agarose gel with <|>X 174 (Hae ffl 
digested marker) 
M HEM EM PM EM EM HEM 
334bp 
230bp 
105bp 
Figure 8.4 Representative photograph showing digested products of 334bp amplicons from 
exon 3 to intron 4 (CYP 1 & 2, Bst Nl) resolved on 10% non denaturing polyacryiamide 
gel. [M = <|>X174 Hae III digested marker; EM = homozygote extensive metabolizer; HEM 
= heterozygote extensive metabolizer and PM = poor metabolizer] 
. < 
o^ 
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Discussion 
The CYP2D6 polymorphisms have been associated with an 
increase risk for smoking related cancers such as lung, bladder and head 
and neck cancer (Nakachi et al., 1993; Kihara et al., 1994; Trinza et al., 
1995; Park ei ai., 1997; Mc Williams ct al, 1996; Bell et a!., 199?; 
Muscat et al., 1996). Cigarette smoking is a risk factor for cervical 
neoplasia (Winkelstein, 1990). In the present study of 77 normal and 
194 cases comprising 61 mild/moderate dysplasia, 48 severe dysplasia 
and 85 squamous cell carcinoma, a significant association between 
smoking and CYP2D6 EM genotype in cancer cases was observed. 
However, no significant difference was observed in precancers. 
Cytochrome P450 activity is polymorphic and has also been 
linked to lung cancer risk (Ayesh et al., 1984; Caporaso et al., 1990). 
CYP2D6 hydroxylates xenobiotics such as debrisoquine, and a tobacco 
specific N-nitrosamine (Gonzalez et al., 1990) and an individual's 
polymorphic phenotype is inherited as an autosomal recessive manner. 
There are two possible explanations for the association of 
smoking with cervical neoplasia. Firstly, chemical carcinogens in 
tobacco smoke might directly induce cervical carcinogenesis; secondly, 
cigarette smoking may produce a local immunologic defect. Smoking is 
associated with a significant decrease in the concentration of antigen 
presenting Langerhans' cell in the normal cervical epithelium (Barton et 
al., 1988). In the present study we described that the susceptibility to 
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squamous cell carcinoma is influenced by polymorphisms at CYP2D6. 
Our data suggests that CYP2D6 and smoking is a high-risk combination, 
which categorizes women susceptible to squamous cell carcinoma. 
Smce, several genotypes have been associated with cancer risk (Idle et 
al, 1992; Wolf et al.. 1992: Nakachi et al., 1993). These include the 
CYP2D6 poor metabolizer (PM) genotype that results from several gene 
inactivating mutations (Gough et al., 1990; Wolf et al., 1992). 
Significantly, the PM genotype may also enhance risk, thus, studies in 
leukemia and malignant melanoma show increased frequency of mutant 
alleles implicating impaired detoxification of an unidentified chemicals 
(Wolf et al., 1992). A significant influence of CYP2D6 and 
susceptibility to cervical intraepithelial neoplasia was observed in 
women who smoked (Warwick et al., 1994). 
The method used in the present study for genotype analysis 
of the CYP2D6 polymorphism allowed us to identify the wild type 
homozygous extensive metabolizers (EM), the heterozygous extensive 
metabolizers (HEM) and poor metabolizers (PM) unequivocally. Our 
results indicate an increase in the number of homozygous EM in cervical 
carcinoma patients relative to the controls. Warwick et ai., (1994) in the 
study of cervical intraepithelial neoplasia and CYP2D6 polymorphism 
suggested that CYP2D6 EM smokers have increased susceptibility to high 
grade CIN but are less likely to progress to squamous cell carcinoma, 
whereas, our results support the study of Simons et al., (1993) showing 
smokers to have increased susceptibility to cervical cancer. 
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9, Expression of erbB-2 and Beta catenin in cervical cancer 
Introduction 
Activation of various oncogenes has been reported to be involved 
in the development of several human cancers More than twenty such 
oncogenes have been detected in different human cancers, acting on the 
similar pathway of cell proliferation. These genes were first identified 
from oncogenic RNA viruses called retroviruses. These oncogenes are 
named after the viral strain from which they were isolated: e.g. rel, src, 
myb, erb-K erb-B, fps, yes, ros, mos, ras, abl, fes, fins and sis. Recently, 
amplification of cellular proto-oncogenes has been found to be 
associated with tumor progression (Bishop et al., 1991) e.g. MYCN in 
neuroblastomas (Brodeur et al., 1984), small cell lung cancer (Wong et 
al. 1986) and various other tumor types; and erbB-2 (HER-2/nue) in 
breast (Slamon et al., 1987; Skalova et al.2003) ovarian (Slamon et al., 
1989; Tyson et al., 1991; Hou et al., 1996), gastric (Houldsworth et al., 
1990; Al-Kasspooles et al., 1993) and bladder carcinomas (Coombs et. 
al., 1991) suggesting that this gene may play a role in tumorigenesis 
(Bishop et al., 1991). Expression of oncogenes, including ras, myc and 
erbB-2 has been reported in a high proportion of cholangiocarcinomas. 
The oncogene erbB-2 located on chromosome 17q has been reported to 
be frequently amplified and overexpressed in many adenocarcinomas 
and carcinoma of breast (Slamon et al., 1989), stomach (Yokota et al., 
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1988), renal (Freeman et a!., 1989) and ovary (Slamon et al., 1989; 
Tyson, et a!., 1991; Hou et al., 1996). The erbB-2 oncogene has been 
found to be a truncated version of the gene coding for epidermal growth 
factor receptor. The tyrosine kinase domain in the viral erbB-2 oncogene 
is intact but its catalytic activity is increased because of a shorter extra 
cellular domain. However, expression of genes may occur by various 
pathways like gene mutation, amplification etc. 
In a comprehensive study Mitra et al., (1994b) studied 22 proto-
oncogenes for amplification in 50 primary untreated squamous cell 
carcinoma of uterine cervix belonging to clinical stages II and III and 
histologically all moderately to well differentiated, high amplification of 
erbB-2 was observed. Further, Sharma et al., (1999) reported frequent 
amplification of erbB-2 (HER-2/neu) oncogene in cervical carcinoma 
using non-fluorescence in-situ hybridization technique on paraffin 
sections. Overexpression of erbB-2 protein is associated with 
amplification of erbB-2 gene and frequently occurred in cer\'ical 
adenocarcinomas of patients with poor prognosis (Kihana et al., 1994). 
Human epidermal growth factor recepior-2 (HER-2/neu; erbB-2) 
belongs to a family of four transmembrane receptor tyrosine kinases 
involved in signal transduction pathways that regulate cell growth and 
proliferation. Amplification or overexpression of HER-2/neu occurs in 
about 30% of human breast and ovarian cancers and is associated with a 
poor clinical outcome, including short survival time and short time to 
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relapse. Recent advances in our understanding of HER-2/neu signaling 
pathways have greatly increased our knowledge of breast cancer 
tumorigenesis and have provided new targets for treating breast and 
ovarian tumors that overexpress HER-2/neu. Although controversial still 
many studies support that HER-2/neu overexpression leads to a high 
degree of malignancy and may predict a poor prognosis and shorter 
survival of the patients. The erbB-2 (HER-2/neu) oncogene protein is 
found over-expressed in 20-30% of all breast cancers. However, <20% 
of tumors with high erbB-2 levels show objective response to the anti-
erbB-2 targeted therapeutic, Trastuzumab (Herceptin). Herceptin is the 
first therapy for breast cancer that targets an oncogene product. Thus, 
the ways in which erbB-2 stimulates progression and maintenance of 
tumor growth is highly complex and incompletely understood^ The 
recombinant humanized anti-erbB-2/HER-2/neu monoclonal antibody 
Herceptin (Trastuzumab) has been shown to significantly enhance the 
tumoricidal effects of antitumor drugs such as paclitaxel (Taxol) in 
patients with erbB-2 overexpressing breast cancers. Several studies 
suggest that Herceptin enhances the antitumor effects of Taxol. 
Herceptin pretreatment renders erbB-2 overexpressing breast cancers 
more susceptible to Taxol-induced cell death, which may have important 
clinical therapeutic implications. 
It has been further revealed that beta-catenin, a central 
component of the cadherin adhesion system, binds to both the 
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cytoplasmic domain of cadiierin and the amino-terminal domain of a-
catenin during cell adhesion, mediates the interactions of the cadherin 
catenin complex with the erbB-2 gene product and epidermal growth 
factor receptor (Hoschuetzky et al., 1994; Ochiai A., et al., 1994; Kanai 
et al., 1995). E-cadherin is suggested to be the major cell adhesion 
molecule in the mammary gland, in the cytoplasm E-cadherin is linked 
to beta-catenin and alpha-catenin, which mediate the connection of the 
cytoskeleton. Further, in invasive ductal carcinomas using immuno-
histochemistry, disruption of this cell adhesion system by erbB-2 
oncoprotein through beta-catenin phosphorylation was observed (Nagae 
et al., 2002). These results suggest that the E-cadherin-mediated cell 
adhesion system is frequently lost in invasive ductal-type breast cancers 
by random loss of E-cadherin/catenins or erbB-2 overexpression, and 
that the preservation of this system correlates with well-differentiated 
morphological features. 
Ougolkov et al., (2000) in early gastric cancer reported 12 out of 14 
cases with erbB-2 overexpression also showing altered beta-catenin 
expression, suggesting that both molecules are involved in the 
development of a certain set of differentiated early gastric cancers 
(EGCs). However no such information is available in cervical cancer. 
To understand the extent of involvement of erbB-2 and beta 
catenin in the development of cervical cancer the study has been planned 
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to know the state of expression of erbB-2 and beta catenin in different 
stages of cancerous lesions of uterine cervix. 
The accumulation of cytoplasmic P-catenin is reported to result 
from the genetic mutation of APC and Axin (Ikeda et al., 1998) or that 
of p-catenin itself (Munemitsu et al., 1995) Thus overexpression of beta-
catenin in the cytoplasm or nucleus is often found in cancers of various 
organs, including the large intestine (Takayama et al., 1998), 
endometrium, ovaries (Davies et al., 1998), esophagus (Yutaka Kimura 
et al., 1999), thyroid (Huang et al., 1998), soft tissue (Alman et al., 
1997) and liver (Nhieu et al.,1999). Therefore the localization (cell 
membrane, nuclei or cytoplasm) of P-catenin is of considerable 
importance. P-catenin (95kDa) is considered to mediate interaction 
between E-cadherin and a-catenin as P-catenin binds with both the 
cytoplasmic domain of E-cadherin and a-catenin. P-catenin has two 
distinct roles in E-cadherin mediated cell adhesion and carcinogenesis 
through APC gene mutation. One occurs at cell adhesion sites where 
cadherins become linked to the actin based cytoskeleton, the other 
occurs in the cytoplasm and nuclei and are thought to regulate cell 
transformation. 
In order to evaluate the role of erbB-2 and P-catenin in the 
development of cervical cancer, we studied expression of both 
cytoplasmic and membranous P-catenin in the cancerous lesions of 
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uterine cervix in relation to HPV infection, which is considered to have 
strong association with this cancer. 
Materials and Methods 
In the present study fifty cervical cancer cases (including 28 
squamous cell carcinoma and 22 adenocarcinoma) were examined. 
Lesions were graded histologically according to the World Health 
Organization classification (Watanabe et al., 1990). Paraffin sections 
(5}i thick) were obtained on Poly-L-Lysine coated slides. Cellular 
localization and expression of erbB-2 (HER-2/neu) and P-catenin was 
investigated by immunohistochemistry. 3'Diaminobenzidine (DAB) was 
used as chromogen for staining. Primary antibodies, biotinylated 
secondary antibody and peroxidase-conjugated streptavidin were 
obtained from Neomarker [LSAB Kit, (Ready to use)]. 
Level of expression of erbB-2 protein was classified as follows: 
Negative (-): the cells were not stained at all or the cytoplasm of less 
than half the cells was weakly and diffusely stained; weakly positive (+): 
the cytoplasm of at least half of the cells was weakly and diffusely 
stained; and strongly positive {++)'• the cell membrane was definitely 
stained in all or a substantial portion of the cancer cells (greater than 
20%). 
Evaluation of immunostaining for the expression of beta catenin 
was done by comparing the intensity of staining in the normal epithelial 
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cells and the tumor cells. If the intensity in tumor cells was the same as 
in normal epithelial cells or cancer cells express f3-catenin on the cell-
cell boundaries same as normal epithelial cells, the tumor cells were 
evaluated as preserved expression (+) (also see charts 3 & 4). Cases in 
which the intensity of staining was homogenously weak or variable, or 
the tumor cells showed diffuse or obscured staining in the cytoplasm, 
the cancerous tissue was evaluated as reduced expression (±) (see charts 
3 & 4) (Takayama et al., 1996). Assessment of the staining was carried 
out using light microscopy and was confirmed by at least two 
independent observers with no knowledge of histological grade and 
patients history. Two observers scored staining independently and a high 
level of concordance (95%) was achieved. Chi-square test and Fisher 
exact test were used as per requirement. 
Results 
Fifty cases, (including 28 squamous cell carcinoma, 22 
adenocarcinoma) and eleven controls (females with chronic cervicitis), 
were investigated immunohistochemically to see the expression of erbB-
2 protein. The squamous cell carcinoma cases included 3 poorly 
differentiated, 13 moderately differentiated and 12 well differentiated 
squamous cell carcinoma. One out of eleven controls showed erbB-2 
expression whereas, erbB-2 expression was significantly high (p<0.05) 
in squamous cell carcinoma (Figures 9.2, 9.3 and 9.4) and was found to 
be 32.1% (9/28); of which, 66.6% (6/9) were strongly positive (++) for 
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erbB2 expression and in 33.3% (3/9) erbB-2 expression was weakly 
positive (+) (see chart 3). Strong correlation (p<0.05) between erbB-2 
expression and human papillomavirus type 16 infection was observed in 
squamous cell carcinoma, 88.9% (8/9) of the cases showing erbB-2 
expression (+/++) were positive for HPV type 16, whereas, erbB-2 
expression in HPV 16 negative cases was 11.1%. Further, 33.3% (4/12) 
of well differentiated squamous cell carcinoma showed erbB-2 
expression, of which all (100%) were positive for HPV type 16, 
similarly 38.4% (5/13) of moderately differentiated squamous cell 
carcinoma showed erbB-2 expression of which 80% (4/5) were HPV 
type 16 positive, whereas there was no erbB-2 expression among the 
poorly differentiated squamous cell carcinomas, however, all were HPV 
positive but none was positive for HPV type 16. Among 22 
adenocarcinoma (Figures 9.6 and 9.7) of uterine cervix and 7 controls, 
expression of erbB-2 oncogene was found to be 31.8% {1111) in 
adenocarcinoma (chart 4), whereas, none of the controls showed erbB-2 
expression. 
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Table 9.1 Showing erbB-2 and P-catenin expression in squamous cell carcinoma 
and adenocarcinoma of the uterine cervix 
Histology erbB-1 beta catenin 
(-) (+) (++) + ± 
Poorly diff. 3/3 0/3 0/3 3/3 0/3 
sec 
Squamous cell 
Carcinoma Moderately 8/13 2/13 3/13 7/13 6/13 
(SCC) diff. s e c 
(n=28) 
Well diff. 8/12 1/12 3/12 4/12 8/12 
SCC 
Adenocarcinoma 15/22 5/22 2/22 15/22 7/22 
(n=22) 
Expression of P-catenin was immunohistochemically investigated 
in fifty cases, including 28 squamous cell carcinoma (13 moderately 
differentiated, 12 well differentiated and 3 poorly differentiated 
carcinoma) and 22 adenocarcinoma, and eleven controls (females with 
chronic cervicitis). The membranous staining observed in healthy 
specimens was used as control (Fig. 9.8A). Out of the 28 squamous cell 
carcinoma of uterine cervix, 50% (14/28) were evaluated as beta-catenin 
preserved and 50% were evaluated as reduced expression. In the tumors 
with preserved ^-catenin expression, cells expressed ^-catenin on the 
cell-cell boundaries same as normal epithelial cells (Fig 9.8A). On the 
other hand in tumors with reduced beta-catenin expression, cells showed 
obscure or diffused staining on the membrane and increased cytoplasmic 
or nuclear staining (Fig 9.8B). In moderately differentiated squamous 
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cell carcinoma reduced beta catenin expression was observed in 46% 
(6/13) cases, while in well differentiated squamous cell carcinoma 
reduced beta catenin expression was observed in 66.6% (8/12) cases. 
However, none of the poorly differentiated squamous cell carcinoma 
showed reduced expression of beta-catenin. Further, reduced beta 
catenin expression was found to be high among HPV type 16 positive 
cases. Five out of eight (62.5%) of well-differentiated tumors with 
reduced beta-catenin expression were HPV 16 positive, similarly 3/6 
(50%) of moderately differentiated tumors with reduced beta-catenin 
expression were positive for HPV type 16. Further, erbB-2 expression 
among cases with reduced beta-catenin expression was significantly 
higher (p<0.05) as compared to that in preserved beta-catenin 
expression. Out of 14 cases showing reduced beta-catenin expression, 
7(50%) were erbB-2 positive whereas, only 2/14 (14.3%)) tumors with 
preserved ^-catenin expression were erbB-2 positive. Thus, in squamous 
cell carcinoma, erbB-2 expression in cases with reduced beta catenin 
expression was significantly higher (p<0.05) as compared to those with 
preserved beta catenin expression. However, no such correlation 
between beta catenin and erbB-2 overexpression was observed in 
adenocarcinoma. 
130 Expression of Oncogenes 
Analysis of Her-2 neu expression by immunohistochemistry performed 
on formalin fixed, paraffm embedded sections of cervical lesions 
displaying various levels of aggressiveness 
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Fig. Negative control (showing absence of immunoreactivity 
of Her-2 neu due to elimination of primary antibody) 
Fig Poorly differentiated squamous cell carcinoma 
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Fig Moderately differentiated squamous cell carcinoma 
Fig Well differentiated squamous cell carcinoma 
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Fig. Slides showing Her-2 neu expression by immunohistochemistry 
performed on sections of adenocarcinoma of uterine cervix 
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Fig. Slides showing Her-2 neu expression by immunohistochemistry 
performed on sections of adenocarcinoma of uterine cervix 
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Figure 9.8 Representative photographs, A and B: immunoreactivity of beta 
catenin in normal cells (control) showing membranous staining whereas C and 
D: showing predominantly cytoplasmic and nuclear staining with loss of 
membranous expression of beta catenin (images B and D are under higher 
magnification). 
Discussion 
The present study of 50 cervical carcinoma (including 28 
squamous cell carcinoma and 22 adenocarcinoma) employing 
immunohistochemistry showed evidence of frequent erbB-2 expression. 
Of the 28 squamous cell carcinoma, 32.1% (9/28), showed erbB-2 
expression, the expression level varied from + (3) to ++ (6). Whereas, in 
22 adenocarcinoma 31.8% (7/22) showed erbB-2 expression and the 
expression level varied from + (5) to ++ (2). Overexpression of erbB-2 
protein mostly was reported to be associated with erbB-2 gene 
amplification (Slamon et al, 1987, 1989; Tsuda et al., 1989, 1990; 
Kihana et al., 1994; Mitra et al., 1994b, 1999). It has also been noted for 
breast and ovarian. (Slamon et al., 1989; Tsuda et al., 1990). In the 
present study 7/22 (31.8%) of adenocarcinoma revealed erbB-2 
expression. erbB-2 (HER-2/neu) oncogene that encodes a 185 kDa 
receptor tyrosine kinase, which is homologous to human epidermal 
growth factor receptor (EGFR), have been reported to be overexpressed 
in adenocarcinomas (Kihana et al, 1994), intraepithelial neoplasia and 
invasive cancer of the uterine cervix (Pinion et al, 1991; Mitra et al., 
1994b; Soh et al., 2002). In our previous study, expression of erbB-2/ 
HER-2 neu was found to be insignificant (8.6%) in cervical dysplasia 
[unpublished data], suggesting that expression of erbB-2 oncogene is a 
late event in the process of cervical carcinogenesis. Overexpression of 
the HER-2/neu enhances the malignancy and metastatic potential of 
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cancer cells and induces the resistance to chemotherapeutic agents 
provides a scientific basis for the poor clinical outcome associated with 
HER2/neu overexpressing cancers and overexpression of HER2/neu 
gene correlates with the relapse and survival rates associated with many 
human cancers, including breast and ovarian cancers. In a previous 
study of 22 protooncogenes, Mitra et al (1994b), showed that erbB-2 
(HER-2/neu) oncogene was frequently amplified in SCC of uterine 
cervix. We, in the present study, screened the two high-risk HPV types 
(type 16 and 18), a significant association (p<0.05) between HPV type 
16 infections and erbB-2 overexpression was observed, as compared to 
erbB-2 negative cases (see Chart 3). 88.8% of the cases showing erbB-2 
expression were positive for particular HPV type (type 16). Further, a 
strong correlation (p<0.05) between HPV type 16 infecfion and erbB-2 
overexpression was observed in higher-grade lesions. HPV type 16 was 
present in 80% of the moderately differentiated squamous cell 
carcinoma with erbB-2 expression and 25% in erbB-2 negative tumors. 
Similarly, HPV type 16 was present in all the cases of well-
differentiated squamous cell carcinoma with erbB-2 expression as 
compared to erbB-2 negative tumors (25%). 
In the present study, non-cancerous epithelium expressed (5-
catenin on cell-cell boundaries without exception, whereas, 50% (14/28) 
of the cancers had reduced beta-catenin expression. 6/13 (46.5%) of the 
moderately differentiated squamous cell carcinoma and 8/12 (66.6%) of 
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well differentiated squamous cell carcinoma showed reduced beta-
catenin expression, of which, 50% of the moderately and 62.5% of well 
differentiated tumors were positive for HPV type 16. The reduction in 
immunoreactivities of the cancer cells might be acquired through 
malignant transformation. Strong correlation with 3-catenin expression 
and histological grade has been observed in colorectal cancer, however, 
no such correlation was observed in esophageal or gastric cancer 
(Takayama et al., 1996). Utsunomiya et al., (2001) also observed 
overexpression of p-catenin in the cytoplasm and nucleus and reduced 
expression on cell-cell boundaries in colon cancers. Since it was 
revealed that P-catenin is involved not only in the cadherin cell adhesion 
system but also in the growth signal pathway. Beta-catenin binds with 
the APC tumor suppressor gene product in the cytoplasm, and this 
complex does not include cadherin (Rubinfeld et al., 1995). The APC 
gene has been found to be mutated in 80% of colorectal cancers 
(Miyoshi et al., 1992) and most mutations occurred at beta-catenin 
binding site. The function of APC as tumor suppressor gene might bind 
and limit the cytosolic beta-catenin. ^-catenin in this status binds to 
Tcf/Lef transcription factors. Soluble beta-catenin plays an important 
role as a signal transducer that binds and activates the Tcf/Lef 
transcription factors (Korinek et al., 1997). P-Catenin/Tcf has been 
widely regarded as the major pathway for carcinogenesis. In association 
with Tcf, it is translocated to nucleus where it is thought to promote 
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transcription of genes involved in differentiation and proliferation 
(Peifer, 1997). Several studies have shown overexpression of P-catenin 
in human cancers (Takayama et al., 1998; Davies et al., 1998; Yutaka et 
al., 1999; Huang et al, 1998; Alman et al, 1997; Nhieu et al., 1999). 
Our results indicate the relationship between beta catenin expression and 
histological grade. Reduced beta catenin expression was more frequently 
observed in well-differentiated carcinoma as compared to poorly 
differentiated squamous cell carcinoma. 
Furthermore, in the present study erbB-2 expression in tumors with 
reduced beta-catenin expression was found to be significantly higher 
50%(7/14) as compared to preserved beta-catenin expression 14.2% 
(2/14) (p<0.05). Recently, it has been revealed that beta-catenin 
mediates the interactions of the cadherin catenin complex with the erbB-
2 gene product and epidermal growth factor receptor (Hoschuetzky et 
al., 1994; Ochiai et al., 1994; Kanai et al., 1995). Since E-cadherin is 
suggested to be the major cell adhesion molecule in the mammary gland, 
in the cytoplasm E-cadherin is linked to beta-catenin and alpha-catenin 
which mediate the connection of the cytoskeleton, Nagae et al., (2002), 
in invasive ductal carcinomas using immunohistochemistry, observed, 
erbB-2 oncoprotein causing disruption of this cell adhesion system 
through beta-catenin phosphorylation. These results suggest that the E-
cadherin-mediated cell adhesion system is frequently lost in invasive 
ductal-type breast cancers by random loss of E-cadherin/catenins or 
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erbB-2 overexpression, and that the preservation of this system 
correlates with well-differentiated morphological features. Ougolkov et 
al., (2000) in early gastric cancer reported 12 out of 14 cases with erbB-
2 overexpression also showing altered beta-catenin expression, 
suggesting that both molecules are involved in the development of a 
certain set of differentiated EGCs. Takata et al., (1999) in his study of 
31 tumor samples of extramammary Paget's disease reported erbB-2 
overexpression but observed no activation of beta-Catenin gene possibly 
because the pathogenesis of this skin cancer could be different from 
other common epithelial malignancies. 
Therefore it is presumed that along with human papillomavirus 
infection other genetic changes are involved in the process of cervical 
carcinogenesis which appear to act either in conjunction with HPV or 
independently. 
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Concfiislon 
GENERAL CONCLUSION 
Cancer of the uterine cervix is the second most common cancer 
among women worldwide. Epidemiologic studies reveal multiple 
etiologic factors responsible for the development of cancer, these 
include infection with ^certain___oncogenic types of human 
papillomaviruses (HPV), socio-economic factors like, multiparity, 
multiple sexual partners etc. Extensive viral carcinogenesis studies 
world over poin^_to_jTuman papillomavirus virus as an important 
etiologic factor in cervical carcinogenesis. Of the many HPV types, 
types 16 and 18 are documented as high-risk HPV associated with 
genital neoplasia. Although a cause and effect relationship between 
HPV and cervical cancer is yet to be proven, over 80% of cervical 
cancers today are associated with HPV infection. HPV type 16, which is 
considered to be high-risk type for the pathogenesis of cervical cancer, 
.was present in 42%_o£_cervical cancer (Squamous cell carcinoma), 
whereas HPV type 6 (LR-HPV) was present in 75% j n squamous cell 
carcinoma (SCC). Co-infection of HPV type 6 and 16 was also present 
in a considerable number of cases (28%) in squamous cell carcinoma; 
studies indicate infection of multiple DNA types to be a risk factor for 
cervical intraepithelial neoplasia (Liaw et al., 1995). E6 of HPV type 6 
augments the capability of E7 of HPV type 16 and E7 of type 6 
promotes the potential of HPV type 16 in immortalizing normal cell 
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(Halbert et al., 1992). However, several serologic evidences suggest the 
interaction of different HPV types. Both HPV types 6 and 16 have 
antagonistic interference in the respect that HPV type 6 provides 
immunity against HPV 16 infection These studies suggest that the 
detection of low-risk HPV types and their co-infection along with HR-
HPVs to be important for understanding the pathogenesis of the disease 
and the biological behavior of HPVs during the process of cervical 
carcinogenesis. 
Further, studies indicate that infection of HPV alone is not 
sufficient for transforming a normal cell into malignant one, indicating 
involvement of additional genetic alterations in the progression of 
cervical cancer, either independently or in conjunction with other 
etiological factors including HPV infection. Allelic loss and deletion 
mapping using microsatellite markers and the detection of homozygous 
deletions represented until now the most powerful method to localize 
potential tumor suppressor genes. The recurrent genetic alterations can 
take several forms such as point mutation, viral DNA integration or 
LOH. Currently, the consistent observation of LOH for markers at a 
specific location in a series of tumors of a particular histological type is 
considered to be a marker for loss of function of one or more tumor 
suppressor genes in the marked genomic region. Frequent LOH at a 
given locus implies the existence of a candidate tumor suppressor gene 
that is important in the pathogenesis of the particular cancer under study. 
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LOH is being detected with increasing frequency in a wide variety of 
human tumors. Therefore the identification of recurrent chromosomal 
locations is important for the understanding of the biology of cancer. 
The genetic alterations in cervical cancer might be either a consequence 
of biological selection for specific chromosome locations containing 
integrated HPV DNA or result from other alterations that are recurrently 
effected in this tumor. 
On the other hand mutations in DNA mismatch repair genes 
result in the accumulation of mutations. The cell with a defect in any of 
these genes will invariably progress to develop cancer (Kinzler and 
Vogelstein, 1998). Assessment of microsatellite instability (MSI) has 
become an important tool in tumor molecular pathology. In the present 
study we used the Bethesda Conference reference panel of five primers 
for the first time in cervical cancer. (A)n tracts located in the intron of c-
kit oncogene showed maximum (22.9%) instability, followed by the 
dinucleotide (CA)n repeat loci D2S123 (20.4%). However, BAT-26, in 
intron 5 of liMSHl gene also showed little (9.6%) instability. However, 
D5S346 showed 3.6% instability, which is significantly low. 13.2% 
instability was reported at D17S250. Our study supports the results 
obtained by Dietmaier et al, 1997 in human non-polyposis colorectal 
cancer (HNPCC), for which the above panel of markers was first 
recommended. Since, particular repeat loci are prone to instability in 
different cancers, Dietmaier et al 1997 reported high MSI in the (A)n 
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tracts located in the intron of c-kit oncogene (BAT-25) confirming the 
susceptibility of mononucleotide repeats to instability. The present study 
indicates that a panel of mono and di nucleotide repeat loci that have 
initially been recommended for HNPCC (Boland et al., 1997), can be 
used for the assessment of MSI in cervical carcinogenesis which may 
prove useful from a clinical diagnostic point of view. 
In the present study five different polymorphic markers mapped 
to chromosomal arms 3p and 5p were used to detect LOH. Markers were 
selected for their reported high LOH rate in other cancers and cervical 
cancer (Ku et al., 1977; Yokota et al., 1989; Jones and Nakamura, 1992; 
Kohno et al., 1993; Karlsen et al, 1994; Mitra et al., 1994a; 
MuUokandov et al, 1996; Larson, 1997; Chu et al., 1998). Of the 83 
squamous cell carcinoma, maximum frequency of LOH (42.6%) was 
observed at D5S208 (5pl5.1-15.3) followed by D5S406 (32%) mapped 
to 5pl5.1-15.2. Of the three polymorphic markers mapped to 
chromosome 3pl4.2 (D3S1234, D3S1300 and D3S1313) the most 
frequently altered loci were D3S1234 (30.2%) within intron 5 of the 
FHIT gene followed by D3S1300 loci (27.6%). AUelotype instability at 
3pl4.2 suggests inactivation of the FHIT gene, which maps to this 
chromosomal band (Larson et al., 1997; Kohno et al., 1993; Ku et al., 
1997 and Chu et al., 1998). Our result confirms a high frequency of 
allelic imbalances at chromosome arm 3p and 5p indicating the possible 
existence of candidate tumor suppressor genes involved in cervical 
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carcinogenesis. Our result also indicates the involvement of FHIT gene 
in cervical cancer. 
LOH and MSI were found to be two independent events 
occurring during the process of cervical carcinogenesis 
Involvement of various oncogenes has been reported in several 
human cancers. It has recently been reported that erbB-2 oncogene is 
overexpressed in adenocarcinomas of uterine cervix (Kihana., et al., 
1994) and in CIN and invasive cancer of the cervix (Mitra et al., 1994b; 
Soh et al., 2002). Oncogene erbB-2 (Her-2/neu), which has been 
reported to be overexpressed in adenocarcinomas of uterine cervix and 
squamous cell carcinomas of uterine cervix, was studied on 50 cervical 
cancer cases (including 28 squamous cell carcinoma and 22 
adenocarcinoma) employing immunohistochemistry. The results showed 
evidence of frequent erbB-2 expression. Overexpression of the Her-
2/neii enhances the malignancy and metastatic potential of cancer cells 
and induces the resistance to chemotherapeutic agents. Further a 
significant association between HPV type 16 infections and erbB2 
overexpression in different histologic types of SCC was observed. 
Reduced (i-catenin expression at the cell membrane is associated 
with cancer progression. Overexpression of beta-catenin in the 
cytoplasm or nucleus is often found in cancers of various organs, 
including the large intestine (Takayama et al., 1998), endometrium, 
ovaries (Davies et al., 1998), esophagus (Yutaka Kimura et al., 1999), 
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thyroid (Huang et al., 1998), soft tissue (Alman et al., 1997) and liver 
(Nhieu et al.,1999). Therefore the localization (cell membrane, nuclei or 
cytoplasm) of p-catenin is of considerable importance. Our results show 
the relationship between beta catenin expression and histological grade. 
Reduced beta catenin expression was more frequently observed in well-
differentiated carcinoma as compared to poorly differentiated squamous 
cell carcinoma. In order to investigate the cause of increased 
cytoplasmic staining of /^catenin in well differentiated squamous cell 
carcinoma, it is suggested to analyze the P-catenin gene (CTNNBl) 
using PCR-SSCP analysis. Exon 3 of j3-catenin gene with nuclear 
overexpression has already been investigated and was found that 
mutations in CTNNBl can increase free cytoplasmic ft-catenin in colon 
cancers (Morin et al., 1997). Reduced beta-catenin expression was 
observed in 46.5% of moderately differentiated squamous cell 
carcinoma and 66.6% of well differentiated squamous cell carcinoma, of 
which, 50% of the moderately and 62.5% of well differentiated tumors 
were positive for HPV type 16. It is likely that accumulation of /}-
catenin in cytoplasm starts in late stage and could pass into the nucleus 
(nuclear translocation) and interact with transcription factors causing 
progression to cancer. 
Cigarette smoking is a risk factor for cervical neoplasia. 
Cytochrome P450s that constitute superfamily of enzymes crucial for 
the oxidative, peroxidative and reductive metabolism of a diverse group 
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of compounds like endobiotics, xenobiotics that include most of the 
therapeutic drugs and environmental pollutants (Nelson et al., 1996; 
Bertz and Granneman, 1997). Nicotine and cotinine have been found to 
be concentrated in cervical mucus which can be mutagenic 
(Winkelstein, 1990; Gram et al., 1992; Burger et al., 1993), and DNA 
from cervical epithelial cells of smokers contains adducts of the type 
expected from reaction with polycyclic aromatic hydrocarbons and 
aromatic amines (Simons et al., 1993). This may explain the biological 
plausibility of the association between smoking and cervical cancer. The 
expression of CYP enzymes varies between individuals due to genetic 
and environmental factors and some diseases. Most individuals 
receiving certain drug like debrisoquine, a beta adrenergic blocking 
agent prescribed for the treatment of hypertension, excrete large 
amounts of hydroxylated debrisoquine metabolites in their urine, and 
they are termed "extensive metabolizers" (EM phenotype) whereas 
individuals that excrete the drug virtually unchanged are termed "poor 
metabolizers"(PM phenotype) (Idle et al., 1979). In the present study of 
77 normal and 194 cases comprising 61 mild/moderate dysplasia, 48 
severe dysplasia and 85 squamous cell carcinoma, a significant 
influence of CYP2D6 and susceptibility to cervical cancer was observed 
in women who smoked. 
The analysis of the data indicates the involvement of various 
genetic alterations in the development of cervical cancer. LOH at 3p and 
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5p was found to be frequent in these cancers. 32.1 percent of cervical 
cancer cases show high expression of erbB-2 however; higher 
expression of erbB-2 was seen more frequent in tumors having HPV-16 
infection. Reduced expression of beta catenin was found to be more in 
well differentiated cervical cancers. The data indicates further study on a 
larger cohort of cervical cancer for a comprehensive view. 
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Chart 3 showing expression of erbB-2 and beta catenin in 
squamous ceii carcinoma of uterine cervix 
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Chart 4 showing expression of erbB-2 and beta catenin in adenocarcinoma 
of uterine cervix 
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Abstrdcl 
Detection ot human papillomavirus (HPV) types 6, I I , 16, 18, and 33 including co-infections among females attending gynaecological 
outpatient department and cancer clinics, was done by restriction fragment length polymorphism (using Rsa-1), of approximately 450 bp 
amplicon. obtained by the amplification of the LI region of HPV genome with consensus pnmers MY09/11 [Cancer Cells 7 (1989) 209] The 
results were turther tested with HPV typs specific pnmers [J Med Virol 29 (1989) 20] The technique was found to be low-cost and less 
lime consuming The advantage of Rsa 1 over other enzymes was that it detects the five most prevalent HPV types commonly associated with 
warts, cervical dysplasia, and cancer 
<^  2003 Elsevier B V All nghts reserved 
Kc\-\iords HPV, RFLP. Rsa I. Cervical dysplasia, Cancer 
1. Method 
(i) DNA extraction = 3 h 
(11) Polymerase chain reaction for detection of HPV intec-
iion by MY()9/11 primers = 2h 
(III) Electrophoresis = 45mm 
(IV) Preparation of polyacrylamide gel = 1 h 
(v) RE digestion — 1 h 
(VI) Electrophoresis on polyacrylamide gel = 2 5h 
(vii) Staining with ethidium bromide = 25min Total time 
in detection = 11 h 
Human papillomaviruses (HPV) are small non-enveloped 
tumorigenic double stranded DNA viruses of about 
8kbp More than 100 HPV types have been identified 
and characterized on the basis of DNA sequences Hu-
man papillomaviruses cause warts (Schwarz et al, 1983), 
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papillomas (Gissmann et al , 1982) and certain cancers in-
cluding cancer of the utenne cervix (Bosch et al, 1995, 
Beaudenon et al , 1986, Cole and Streeck, 1986) Cervi-
cal intraepithelial neoplasia and cervical cancer both are 
strongly associated v/ith persistence presence of some types 
of human papillomavirus Over 90% of the cervical car-
cinoma have been shown to contain some high-risk HPV 
types (Nieminen et al, 1991) The genital HPVs are clas-
sified into two groups high and low-nsk based on whether 
or not the lesions with which they are associated are at sig-
nificant risk for malignant progression The low-nsk HPVs 
such as HPV6 and 11 are generally associated with gen-
ital warts (condyloma accuminata and flat genital warts), 
lesions that only rarely progress to cervical cancer The 
high-risk viruses, such as HPV16 (Favre et al , 1989, Seedorf 
et al , 1985), HPV18 (Cole and Danos, 1987) and HPV33 
(Beaudenon et al, 1987, Cole and Streeck, 1986), and few 
other are associated with carcinoma in situ and cervical 
cancer HPV 16, 18, 33, and 45 account for more than 90% 
of the high-risk types The MY09/MY11 primer set me-
diated PCR (MY-PCR) (Hildesheim et al . 1994, Manos 
et al , 1989) and the GP5 -I- GP6 -(- pnmer set mediated 
PCR (GP -f PCR) (de Roda Husman et al, 1997, Jacobs 
SH Naqvi cl al /Journalof IhvlogiLalMethods 117(2004) 91-95 
CI dl, 1999) are the most frequently used amplification 
systems tor the detection of HPV DNA in clinical samples 
and genotyping by type specific primers (Van den Brule 
ct al, 1989) There was differential amplification sensitiv-
ity of Hl'V types between the two systems MY-primer set 
was found to be inefficient for HPV type 35 detection but 
was proved to be more sensitive than GP + PCR pnmer 
set in the amplification of muUiplc HPV DNA types within 
a given sample (Qu et al., 1997). According to a recent 
meta-analysis (Clifford et al., 2003), it was found that HPV 
prevalence vary little between geographical regions. The 
most common high-risk HPV types in cervical squamous 
cell carcinoma was HPV 16 whereas, HPV 18 was predom-
inant in adenocarcinomas and adenosquamous carcinomas 
followed by HPV 16. The MY09/11 primer set has been 
used predominantly in epidemiologic studies in north and 
south America and Asia (Bosch et al., 1995; Liaw et al., 
1995) whereas the GP5 -I- GP6 has been used pnmanly in 
Europe (de Rod Husman et al., 1995). Furthermore, vari-
ous studies indicated fi^equent co-infections of HPV 16 and 
HPV6, suggesting interaction between different HPV types 
in multiple infections. HPV 16 and 6 appeared to have an-
tagonistic interference in cervical carcinogenesis. Serologi-
cal evidences indicate protection by HPV type 6 infection 
against HPV type 16 cervical carcmogenesis (Sillins et al., 
1999). whereas in co-infections the E6 protein of low-risk 
HPV type 6 augments the ability of E7 of HPV type 16 or 
E7 of HPV type 6 coupled with E6 of type 16 increases 
the potency and ability to immortalize cells (Halbert et al., 
1992) These studies suggest the detection of low-nsk HPV 
types and their co-infections along with HR-HPVs to be 
important for understanding the pathogenesis of the dis-
ease and the biological behavior of HPVs during cervical 
carcinogenesis. Infection of multiple HPV DNA types is a 
risk factor for cervical intraepithelial neoplasia (Liaw et al., 
1995) These observations demand for an early detection 
ol virus types, especially those associated with cervical 
dysplasia and cancers, with an easy, cost-effective and sim-
ple diagnostic procedure. We, developed a new rapid and 
cost-effective PCR-RFLP technique, using restriction di-
gestion with Rsa 1, of the amplified products of LI region 
(by MY09/11 consensus primers). It detects five different 
HPV types and their co-infections simultaneously (Table 1), 
commonly associated with warts, precancerous, and can-
cerous lesions. Cervical scrapes fi^om the women, attending 
the outpatient department of Gynaecology, were obtained 
after taking their proper consent. Scrapes were taken by 
scraping the ectocervix or the surface of the portio with 
Ayer's spatula and put in 5 ml of 1 x PBS (phosphate buffer 
saline) The samples were transported to the laboratory at 
4 ''C and stored at -20 °C till further processing. The DNA 
isolation from the exfoliated cervical cells involves basi-
cally two steps' first washing the pellet twice with tris-tnton 
buffer (TTB) and PK digestion in tris-EDTA buffer (TEB) 
(Gopalkrislma et al, 1992), total time required in DNA 
isolation was 3h. Cervical scrapes were agitated along 
with the wooden spatula, and poured in 1 5 ml tubes after 
removing the spatula. Then the tubes were cenlrifuged at 
2000 rpm for 2 nun at 4°C. The pellet was rcwashed with 
chilled 1 X PBS and cold cenlnfugation was done for 2 min 
at 2000 rpm The pellet was washed twice in 1 ml chilled 
TTB (lOmM Tris-HCl pH 8.0), lOmM MgCb, 300mM 
Sucrose and 0.8% Triton-X 100). The pellet was collected 
and rewashed in 0.5 ml cold TE buffer (10 MM Tris-HCl 
(pH 8.0), lOmM EDTA and lOmM NaCl). Finally, the 
pellet was resuspended in 200 (JLI TE buffer supplimented 
with Proteinase K (PK = 1.25 rng/'ml) and incubated ai 
65 °C for 2.5 h. The tubes were shaken vigorously every 
half hour in order to allow uniform analysis of the pellet 
till the solution became transparent. PK inactivation was 
done by boiling at 95 °C for 10 mm. P-Globin pnmers 
PC04 (5'-CAACTTCATCCACGTTCACC-3') and GH20 
(5'-GAAGAGCCAAGGACAGGTAC-3') (Saiki et al, 
1988), which produces a 268 bp PCR product, were used 
as an internal amplification control. Precautions were taken 
to avoid cross contamination of samples and the ampli-
fied products. The samples were then screened for the 
presence of HPV usmg proper controls. The detection of 
HPV was done by PCR amplification of the LI region of 
HPV genome using degenerate primers, MY09/11 (Manos 
et al., 1989) (Fig. 1). PCR using MY09/11 pnmers have 
been proved to be a valid tool for the detection of a wide 
spectrum of genital HPVs (Gravitt et al., 1998) The ampli-
fication was done using Taq DNA polymerase (0 6 U/25 JJLI, 
Catalog No. MME 5J), 10 x buffer with 2.5 MgCb and 
dNTPs 200 PLM/25 pil (UK Biolab; Catalog No. N0442S), 
with initial denaturation of 95 °C for 4 mm followed by 
35 cycles of 94, 56, and 72 °C each for 30 s and a final 
extension of 72° for 7min. Eight microliters of the sam-
ple was loaded for electrophoresis on 2% agarose (Sigma; 
Catalog No. A9539), stained with ethidium bromide, for 
the screening of HPV positive cases (Fig 1) RFLP of the 
PCR products of all the HPV positive samples was done 
using ID of Rsa 1 (UK Biolab; Catalog No 167 L) with 
NEB reaction buffer, and incubating at 37 °C for 1 h After 
digestion the products were resolved on 8% polyacrylamide 
non-denaturing gel with TBE buffer, after 30 mm of stain-
ing with ethidium bromide, the products were visualized 
under UV/gel documentation system (Bio Rad) usmg the 
software quantity one. The bands show the types of HPV 
present including their co-infections (Fig 2) 
The degenerate pnmers MY09/11 used for amplifying LI 
region, accepts certain degree of mismatch between pnmers 
and target DNA, accomplished by reducing the stnngency 
of primer annealing, there being always a difference of few 
bases in the amplicon for different HPV types, which are not 
distinguishable in lower concentration of agarose gels The 
product (amplicon) sizes amplified by MY09/11 pnmers for 
HPV type 6 was 447 bp; HPV 11-449 bp, HPV 16-452 bp, 
HPV18-455bp, and for HPV33 was 449 bp, which after 
digestion with Rsa 1 (recognition sequence GT'AC) gives 
the following band sizes (also see Fig 2) 
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Slum s llie luiinher of possible cuts and the size of the fnigmcnls resolved 
.illor llic (tigcslioii of LI ainplicon with Rsa 1 for difTerenl III'V types 
Table 2 
Primers used for PCR 
lype No or cuts Fragment Mie 
l!l'\f. 
III'VIl 
HI'N 16 
lll'\ IX 
lll>\ n 
3 
3 
2 
4 
3 
72, 67. 149, 159 
72, 2lfi. 26, 135 
72, "0 \\n 
72, « , x<, 125, 135 
72, 39, 2H, l«I 
1 l\c Ivild values mdicale the distinguishing bands 
lo confirm the results obtained by RFLP, all positive 
c.iscs were amplified using type specific primers (Table 2). 
I 2 ^1 DNA was used for amplification with type specific 
primers, temperature profile for the amplification was same 
lor each type, initial denaturation 95 °C for 5min, followed 
bv ^s cycles (95T for 30s, 56''C for 30s, and 72°C for 
^Os) and a final extension at 72 °C for 7min. The products 
,M I 
Fig 2 Rsii I digest of Ll amplicon resolved on 8% PAGE showing HPV 
types 6, 11, 16, IX, and 33 in lanes 1-5, respectively (M, <t)X174 (Hae 
III digested) marker) 
HPV type Primer sequence 
Type 6 ( F ) 
Type 11 (F) 
(R) 
Type 16 (F) 
(R) 
Type 18 (F) 
(R) 
Type 33 (F) 
(R) 
5 -TAGTGGGCCTATGGCTCGTC-3 
5'-TCCATTAGCCTCCACGGGTG-l' 
5'-GGAATACATGCGCCATGTGG-3 
5'-CGAGCAGACGTCCGTCCTCG-3 
5'-AAGGCCAACTAAATGTCAC-3 
5 -CTGCTTTTATACTAACCGG-3 
5 •-ACCTTAATGAAAAACCACGA-3 
5'-CGTCGTTGGAGTCGTTCCTG-3 
5'-ATGATAGATGATGTAACGCC-3' 
5'-GCACACTCCATGCGTATCAG-3 
were resolved on 2% agarose after ethidium bromide stain-
ing (Fig. 3A-E). 
Amplimer details for type specific PCR and 3-globin 
taken fi"om published papers previously and were obtained 
through Microsynth. 
Comparing the two techniques, RFLP with restriction en-
zyme Rsa 1 and PCR with type specific primers, we found 
that RFLP using Rsa-1 can detect co-infections simultane-
ously and more consistently than individual typing with type 
specific primers and was cost-efiective as it saves the to-
tal cost of second PCR for HPV typing with type specific 
primers (Aadnan et al., 1990). Use of nested PCR with de-
generate pnmers have been described by various workers 
to be extremely sensitive means of detecting a wide range 
of HPV types (Broker et al., 2001; Harwood et al.. 1999, 
Pizzighella et al, 1995). RFLP of the inner nested PCR prod-
uct of MY09/11 primers using Bst Ell and a double digest 
of Pst 1 and BgU (Patti et al., 2002) detected 10 high-risk 
anogenital HPV types. Both the methods were able to de-
tect broad range of HPV types. Most of the PCR-RFL? 
studies show either use of multiple restriction enzymes with 
two rounds of amplification. Whereas, method described m 
this paper, was found to be precise, with only one round of 
ampification, followed by RFLP using a restriction enzyme, 
detected the five most prevalent HPV types commonly asso-
ciated with cervical abnormalities and cancer. In conclusion, 
this method is less cumbersome and user-friendly for the 
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1 ij! ^ Sliouiiig HPV types 18, 16, 11, 6, and 33 (A-E respectively) amplified using type specific pnmer, resolved on 2% agarose with i>X 174 (Hae III 
digested) marker with positive controls (lanes 1 in A, C, and D and lane 2 in B and E) and negative controls (lanes 2 in A, C, and D, lane 1 m B and E) 
detection of IIPV DNA from cervical swabs, both at clinical 
.iiul research level 
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